UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)



þ☑			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2017~~

2020



☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36569



LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)



~~Delaware~~

~~35-2318913~~

Delaware

35-2318913

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

331 Treble Cove Road ~~North Billerica, MA~~

01862

North Billerica,

(Address of principal executive offices)

(Zip Code)



(978)			671-8001
(Registrant’s telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	LNTH	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes þ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☑

Accelerated filer

☐

~~Large accelerated filer~~

☐

~~Accelerated filer~~

☐

Non-accelerated filer

þ ~~(Do not check if a smaller reporting company)~~

☐

Smaller reporting company

☐

Emerging Growth Company

þ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. þ☐

Table of Contents

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act) Yes ☐ No þ☑

The registrant had ~~37,505,996~~66,813,380 shares of common stock, $0.01 par value, outstanding as of ~~October 31, 2017.~~

July 24, 2020.

~~LANTHEUS HOLDINGS, INC.~~

~~TABLE OF CONTENTS~~

Table of Contents

LANTHEUS HOLDINGS, INC.

TABLE OF CONTENTS


					Page
PART I. FINANCIAL INFORMATION

Item 1.			Financial Statements (Unaudited)

	Condensed Consolidated Balance Sheets ~~as of September 30, 2017 and December 31, 2016~~			1

	Condensed Consolidated Statements of Operations ~~for the Three and Nine Months Ended September 30, 2017 and 2016~~			2

	Condensed Consolidated Statements of Comprehensive Income ~~for the Three and Nine Months Ended September 30, 2017 and 2016~~			3
			Condensed Consolidated Statements of Changes in Stockholders’ Equity		4
			Condensed Consolidated Statements of Cash Flows ~~for the Nine Months Ended September 30, 2017 and 2016~~		45

	Notes to Condensed Consolidated Financial Statements			57

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations			1524

Item 3.	Quantitative and Qualitative Disclosures About Market Risk			2944

Item 4.	Controls and Procedures			2944

PART II. OTHER INFORMATION

Item 1.			Legal Proceedings		3046
Item 1A.			Risk Factors		48
~~Item 1A.~~			~~Risk Factors~~	30

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds			3256

Item 3.	Defaults Upon Senior Securities			3256

Item 4.	Mine Safety Disclosures			3256
Item 5.			Other Information		56
Item 5.6.			~~Other Information~~Exhibits		3257

~~Item 6.~~SIGNATURES	~~Exhibits~~			3358

~~SIGNATURES~~		34

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Lantheus Holdings, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except par value)


	September 30, 2017			December 31, 2016				June 30, 2020		December 31, 2019
Assets							Assets
Current assets							Current assets
Cash and cash equivalents	$	68,077		$	51,178		Cash and cash equivalents	$	90,309	$	92,919
Accounts receivable, net	41,713			36,818			Accounts receivable, net	46,883		43,529
Inventory	23,032			17,640			Inventory	35,334		29,180
Other current assets	3,789			5,183			Other current assets	8,630		7,283
Total current assets	136,611			110,819			Total current assets	181,156		172,911
Property, plant & equipment, net	94,516			94,187
Property, plant and equipment, net							Property, plant and equipment, net	122,903		116,497
Intangibles, net	12,645			15,118			Intangibles, net	389,512		7,336
Goodwill	15,714			15,714			Goodwill	57,765		15,714
Deferred tax assets, net							Deferred tax assets, net	67,441		71,834
Other long-term assets	21,535			20,060			Other long-term assets	60,918		21,627
Total assets	$	281,021		$	255,898		Total assets	$	879,695	$	405,919
Liabilities and Stockholders’ Deficit
Liabilities and stockholders’ equity							Liabilities and stockholders’ equity
Current liabilities							Current liabilities
Current portion of long-term debt	$	2,750		$	3,650
Revolving line of credit	—			—
Current portion of long-term debt and other borrowings							Current portion of long-term debt and other borrowings	$	17,143	$	10,143

Accounts payable	18,756			18,940			Accounts payable	16,301		18,608
Accrued expenses and other liabilities	24,581			21,249			Accrued expenses and other liabilities	42,892		37,360
Total current liabilities	46,087			43,839			Total current liabilities	76,336		66,111
Asset retirement obligations	10,151			9,370			Asset retirement obligations	13,602		12,883
Long-term debt, net	265,523			274,460
Long-term debt, net and other borrowings							Long-term debt, net and other borrowings	210,010		183,927
Other long-term liabilities	37,176			34,745			Other long-term liabilities	64,164		28,397
Total liabilities	358,937			362,414			Total liabilities	364,112		291,318
Commitments and contingencies (See Note 12)
Stockholders’ deficit
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	—			—
Common stock ($0.01 par value, 250,000 shares authorized; 37,498 and 36,756 shares issued and outstanding, respectively)	375			367
Commitments and contingencies (See Note 17)							Commitments and contingencies (See Note 17)
Stockholders’ equity							Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; 0 shares issued and outstanding)							Preferred stock ($0.01 par value, 25,000 shares authorized; 0 shares issued and outstanding)	—		—
Common stock ($0.01 par value, 250,000 shares authorized; 66,808 and 39,251 shares issued and outstanding, respectively)							Common stock ($0.01 par value, 250,000 shares authorized; 66,808 and 39,251 shares issued and outstanding, respectively)	668		393
Additional paid-in capital	228,934			226,462			Additional paid-in capital	657,669		251,641
Accumulated deficit	(306,139		)	(332,398		)	Accumulated deficit	(140,148)		(136,473)
Accumulated other comprehensive loss	(1,086		)	(947		)	Accumulated other comprehensive loss	(2,606)		(960)
Total stockholders’ deficit	(77,916		)	(106,516		)
Total liabilities and stockholders’ deficit	$	281,021		$	255,898
Total stockholders’ equity							Total stockholders’ equity	515,583		114,601
Total liabilities and stockholders’ equity							Total liabilities and stockholders’ equity	$	879,695	$	405,919

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Lantheus Holdings, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)


	Three Months Ended September 30,						Nine Months Ended September 30,							Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016				2020		2019		2020		2019
Revenues	$	79,941		$	73,063		$	250,137		$	227,503		Revenues	$	66,010	$	85,705	$	156,714	$	172,215
Cost of goods sold	41,414			39,382			125,901			124,370			Cost of goods sold	40,162		41,132		92,864		83,558
Gross profit	38,527			33,681			124,236			103,133			Gross profit	25,848		44,573		63,850		88,657
Operating expenses													Operating expenses
Sales and marketing	10,075			8,706			31,892			27,856			Sales and marketing	6,305		10,948		16,435		21,345
General and administrative	12,076			10,091			35,549			28,842			General and administrative	20,670		13,293		37,369		25,882
Research and development	3,554			2,849			14,149			8,493			Research and development	4,418		5,795		8,466		10,724
Total operating expenses	25,705			21,646			81,590			65,191			Total operating expenses	31,393		30,036		62,270		57,951
Gain on sales of assets	—			(560		)	—			(6,505		)
Operating income	12,822			12,595			42,646			44,447
Operating (loss) income													Operating (loss) income	(5,545)		14,537		1,580		30,706
Interest expense	4,442			6,792			14,147			20,799			Interest expense	1,914		4,543		3,860		9,135
Debt retirement costs	—			1,415			—			1,415
Loss on extinguishment of debt	—			—			2,161			—			Loss on extinguishment of debt	—		3,196		—		3,196
Other (income) expense	(908		)	148			(2,037		)	(317		)
Income before income taxes	9,288			4,240			28,375			22,550
Provision for income taxes	762			20			2,116			657
Net income	$	8,526		$	4,220		$	26,259		$	21,893
Net income per common share outstanding:
Other income													Other income	(756)		(1,312)		(1,106)		(2,499)
(Loss) income before income taxes													(Loss) income before income taxes	(6,703)		8,110		(1,174)		20,874
Income tax expense													Income tax expense	309		1,698		2,501		4,513
Net (loss) income													Net (loss) income	$	(7,012)	$	6,412	$	(3,675)	$	16,361
Net (loss) income per common share:													Net (loss) income per common share:
Basic	$	0.23		$	0.14		$	0.71		$	0.71		Basic	$	(0.16)	$	0.16	$	(0.09)	$	0.42
Diluted	$	0.22		$	0.13		$	0.67		$	0.71		Diluted	$	(0.16)	$	0.16	$	(0.09)	$	0.41
Weighted-average common shares outstanding:													Weighted-average common shares outstanding:
Basic	37,393			31,221			37,174			30,658			Basic	43,135		38,972		41,284		38,789
Diluted	39,121			32,402			38,971			31,049			Diluted	43,135		40,239		41,284		40,064

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Lantheus Holdings, Inc.

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

(in thousands)


												Three Months Ended June 30,						Six Months Ended June 30,
	Three Months Ended September 30,					Nine Months Ended September 30,						2020		2019		2020		2019
Net (loss) income											Net (loss) income	$	(7,012)	$	6,412	$	(3,675)	$	16,361
Other comprehensive (loss) income:											Other comprehensive (loss) income:
	2017			2016		2017			2016
Net income	$	8,526		$	4,220	$	26,259		$	21,893
Other comprehensive (loss) income:
Reclassification adjustment for gains on sales of assets included in net income	—			435		—			435
Foreign currency translation	(115		)	234		(139		)	490		Foreign currency translation	252		88		(194)		144
Unrealized loss on cash flow hedges, net of tax											Unrealized loss on cash flow hedges, net of tax	(464)		—		(1,452)		—
Total other comprehensive (loss) income	(115		)	669		(139		)	925		Total other comprehensive (loss) income	(212)		88		(1,646)		144
Total comprehensive income	$	8,411		$	4,889	$	26,120		$	22,818
Comprehensive (loss) income											Comprehensive (loss) income	$	(7,224)	$	6,500	$	(5,321)	$	16,505

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Lantheus Holdings, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

(in thousands)


	Six Months Ended June 30, 2020
	Common Stock					Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity
	Shares	Amount
Balance, January 1, 2020	39,251	$	393	$	251,641	$	(136,473)	$	(960)	$	114,601
Net income	—	—		—		3,337		—		3,337

Other comprehensive loss	—	—		—		—		(1,434)		(1,434)
Stock option exercises and employee stock plan purchases	33	—		366		—		—		366
Vesting of restricted stock awards and units	563	6		(6)		—		—		—
Shares withheld to cover taxes	(97)	(1)		(1,546)		—		—		(1,547)
Stock-based compensation	—	—		3,075		—		—		3,075
Balance, March 31, 2020	39,750	$	398	$	253,530	$	(133,136)	$	(2,394)	$	118,398
Net loss	—	—		—		(7,012)		—		(7,012)

Other comprehensive loss	—	—		—		—		(212)		(212)
Stock option exercises and employee stock plan purchases	7	—		50		—		—		50
Vesting of restricted stock awards and units	242	2		(2)		—		—		—
Shares withheld to cover taxes	(36)	(1)		(484)		—		—		(485)
Issuance of common stock, net of $3,776 issuance costs	26,845	269		394,065		—		—		394,334
Fair value of replacement options related to pre-acquisition services	—	—		7,125		—		—		7,125
Stock-based compensation	—	—		3,385		—		—		3,385
Balance, June 30, 2020	66,808	$	668	$	657,669	$	(140,148)	$	(2,606)	$	515,583


	Six Months Ended June 30, 2019
	Common Stock					Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity
	Shares	Amount
Balance, January 1, 2019	38,466	$	385	$	239,865	$	(168,140)	$	(1,108)	$	71,002
Net income	—	—		—		9,949		—		9,949

Other comprehensive income	—	—		—		—		56		56
Stock option exercises and employee stock plan purchases	37	—		606		—		—		606
Vesting of restricted stock awards and units	365	4		(4)		—		—		—
Shares withheld to cover taxes	(50)	(1)		(1,119)		—		—		(1,120)
Stock-based compensation	—	—		2,720		—		—		2,720
Balance, March 31, 2019	38,818	$	388	$	242,068	$	(158,191)	$	(1,052)	$	83,213
Net income	—	—		—		6,412		—		6,412

Other comprehensive income	—	—		—		—		88		88
Stock option exercises and employee stock plan purchases	9	—		120		—		—		120
Vesting of restricted stock awards and units	253	3		(3)		—		—		—
Shares withheld to cover taxes	(37)	(1)		(943)		—		—		(944)
Stock-based compensation	—	—		3,358		—		—		3,358
Balance, June 30, 2019	39,043	$	390	$	244,600	$	(151,779)	$	(964)	$	92,247

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Lantheus Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)


	Six Months Ended June 30,
	2020		2019
Operating activities
Net (loss) income	$	(3,675)	$	16,361
Adjustments to reconcile net (loss) income to net cash flows from operating activities:
Depreciation, amortization and accretion	7,764		6,577
Impairment of long-lived assets	7,275		—
Amortization of debt related costs	338		639
Loss on extinguishment of debt	—		3,196

Provision for bad debt	206		57
Provision for excess and obsolete inventory	1,531		977
Stock-based compensation	6,460		6,078



Deferred taxes	1,067		2,387
Long-term income tax receivable	(1,109)		(1,604)
Long-term income tax payable and other long-term liabilities	1,409		2,036
Other	408		(10)
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable	2,087		(1,755)
Inventory	(6,777)		(365)
Other current assets	1,742		(118)
Accounts payable	(3,452)		2,881

Accrued expenses and other liabilities	(8,022)		(5,816)
Net cash provided by operating activities	7,252		31,521
Investing activities
Capital expenditures	(4,953)		(13,984)
Lending on bridge loan	(10,000)		—
Cash acquired in acquisition of business	17,562		—
Net cash provided by (used in) investing activities	2,609		(13,984)
Financing activities
Proceeds from issuance of long-term debt	—		199,461
Payments on long-term debt and other borrowings	(7,032)		(270,247)
Equity issuance costs	(345)		—

Deferred financing costs	(1,225)		(2,034)

Proceeds from stock option exercises	50		444
Proceeds from issuance of common stock	366		282
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(2,032)		(2,064)
Net cash used in financing activities	(10,218)		(74,158)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash	(112)		105
Net decrease in cash, cash equivalents and restricted cash	(469)		(56,516)
Cash, cash equivalents and restricted cash, beginning of period	92,919		113,401
Cash, cash equivalents and restricted cash, end of period	$	92,450	$	56,885

Table of Contents

Nine Months Ended
September 30,
2017 2016
Operating activities
Net income $ 26,259
$ 21,893
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion 15,019
12,664
Amortization of debt related costs 1,031
1,235
Provision for excess and obsolete inventory 1,002
982
Stock-based compensation 3,764
1,869
Gain on sales of assets —
(6,505 )
Loss on extinguishment of debt and debt retirement costs 2,161
1,415
Other 1,404
(254 )
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable (4,609 ) 1,071
Inventory (6,361 ) (1,658 )
Other current assets 54
(1,032 )
Accounts payable (270 ) 2,684
Accrued expenses and other liabilities 2,237
2,497
Net cash provided by operating activities 41,691
36,861
Investing activities
Proceeds from sales of assets 1,234
10,541
Capital expenditures (11,589 ) (4,976 )
Other —
74
Net cash (used in) provided by investing activities (10,355 ) 5,639
Financing activities
Payments on long-term debt (285,979 ) (57,790 )
Proceeds from issuance of long-term debt 274,313
—
Proceeds from issuance of common stock 187
41,600
Payments for public offering costs —
(1,266 )
Proceeds from stock option exercises 1,210
61
Payments for minimum statutory tax withholding related to net share settlement of equity awards (2,681 ) (552 )
Deferred financing costs (1,576 ) (11 )
Other (74 ) —
Net cash used in financing activities (14,600 ) (17,958 )
Effect of foreign exchange rates on cash and cash equivalents 163
57
Net increase in cash and cash equivalents 16,899
24,599
Cash and cash equivalents, beginning of period 51,178
28,596
Cash and cash equivalents, end of period $ 68,077
$ 53,195
Lantheus Holdings, Inc.

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)

(in thousands)


	Six Months Ended June 30,
	2020		2019
Reconciliation to amounts within the condensed consolidated balance sheets
Cash and cash equivalents	$	90,309	$	56,885
Restricted cash included in other long-term assets	2,141		—
Cash, cash equivalents and restricted cash at end of period	$	92,450	$	56,885

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Lantheus Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note Regarding Company References and Trademarks

Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries, references to “Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries, and references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Holdings. Solely for convenience, the Company refers to trademarks, service marks and trade names without the ™, ^{TM, SM} and ^® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names.

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of ~~Lantheus~~ Holdings ~~Inc.~~ and its direct and indirect wholly-owned subsidiaries, including Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”) for the period from June 19 through June 30, 2020 (see “Acquisition of Progenics” below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 are not necessarily indicative of the results that may be expected for the year ended December 31, ~~2017~~2020 or any future period.

The condensed consolidated balance sheet at December 31, ~~2016~~2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, ~~2016~~2019 filed with the Securities Exchange Commission (“SEC”) on February ~~23, 2017. Certain immaterial amounts~~25, 2020.

Acquisition of Progenics

On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the previously announced acquisition of Progenics, by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Merger”).

In accordance with the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen targeted imaging agent designed to visualize prostate cancer currently a late stage clinical candidate (“PyL”). Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PyL in 2022 and 2023 in excess of $100 million and $150 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Transaction, exceed 19.9% (which we estimate could be approximately $100 million) of the total consideration the Company pays in the ~~prior period~~Progenics Transaction. No fractional shares of Holdings common stock have been ~~reclassified~~or will be issued in the Merger, and Progenics’ former stockholders have received or will receive cash in lieu of any fractional shares of Holdings common stock.

In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to ~~conform~~$4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a “Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Lantheus Stock Option converted on an exchange ratio determined based on the average of the volume weighted average price per share of common stock of Progenics and Lantheus Holdings prior to the ~~current period financial statement presentation.~~Effective Time, which exchange ratio was 0.31.

~~Manufacturing Concentrations~~

Table of Contents

As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders. Holdings also assumed 34,000 in-the-money Progenics stock options and 6,507,342 out-of-the-money Progenics stock options, each converted into Lantheus Stock Options as noted above. In addition, Lantheus assumed Progenics equity plans, which, on an as-converted basis, increased the number of Lantheus shares available for issuance by an aggregate of 4,211,290 shares prior to converting the stock options noted above, subject to certain limitations as to eligibility for issuance.

Please refer to Note 8, “Business Combinations”, for further details on the acquisition.

COVID-19

On March 11, 2020, the World Health Organization declared the novel coronavirus (“COVID-19”) a pandemic. The global spread of COVID-19 has created significant volatility, uncertainty and economic disruption. Governments in affected regions have implemented, and may continue to implement, safety precautions which include quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures as they deem necessary. Many organizations and individuals, including the Company and its employees, have taken additional steps to avoid or reduce infection, including having non-essential employees work from home and limiting travel. These measures have disrupted normal business operations both in and outside of affected areas and have had significant negative impacts on businesses and economies worldwide. It is not clear when businesses or economies will return to their pre-COVID-19 operating status or productivity.

The Company ~~currently relies on Jubilant HollisterStier (“JHS”) as its sole source manufacturer~~experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of ~~DEFINITY, Neurolite, Cardiolite~~2020 and ~~evacuation vials for TechneLite. The Company has on-going development~~through the date of this filing, including the impact of stay-at-home mandates and ~~technology transfer activities for~~advisories, and a ~~next generation DEFINITY product with Samsung BioLogics (“SBL”) located~~decline in ~~Songdo, South Korea, approximately 20 miles southwest~~the volume of ~~Seoul, but can give no assurances as to when those technology transfer activities will be completed~~procedures and ~~when~~treatments using the Company’s products. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all of its discretionary expenses. Beginning in the first quarter of 2020, the Company implemented certain cost reduction initiatives, including, among other things, reducing travel and promotional expenses, reducing the Company’s work week from 5 days to 4, reducing salaries by between 20% and 75%, and implementing a hiring freeze through the balance of 2020. In the latter half of June, the Company restored its work week back to 5 days and restored most salaries back to 100% (other than executive team members whose salaries were restored in early July and directors whose compensation will ~~begin to receive supply~~remain at reduced levels for the balance of ~~a next generation DEFINITY product from SBL. In addition, those activities could be adversely affected by~~the calendar year).

The severity of the on-going ~~political and military tensions~~impact of the COVID-19 pandemic on the ~~Korean peninsula.~~Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the extent and severity of the impact on the Company's customers and suppliers, all of which are uncertain and cannot be predicted. While the impact of COVID-19 on the Company’s results of operations and cash flows has been, and is expected to continue to be, material, given the continually evolving nature of the pandemic, the Company is currently unable to accurately predict the impact of COVID-19 on its overall 2020 operations and financial results or cash flows for the foreseeable future and whether the impact of COVID-19 could lead to potential future impairments.

2. Summary of Significant Accounting Policies

~~Collaboration and License Agreement~~Derivative Instruments

The Company uses interest rate swaps to reduce the variability in cash flows associated with ~~GE Healthcare Limited~~

~~On April 25, 2017,~~a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company ~~announced that~~must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it ~~entered into a definitive, exclusive Collaboration and License Agreement (the “License Agreement”) with GE Healthcare Limited (“GE Healthcare”) for~~remains highly effective throughout the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational positron emission tomography myocardial perfusion imaging agent that may improve the diagnosis of coronary artery disease. Under the License Agreement, GE Healthcare will complete the worldwide development of flurpiridaz F 18, pursue worldwide regulatory approvals and, if successful, lead a worldwide launch and commercializationlife of the ~~agent, with LMI collaborating~~hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.

Business Combinations

The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on ~~both~~the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired in-process research and development (“IPR&D”) is recognized at fair value and ~~commercialization through a joint steering committee. LMI~~initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an ~~option~~alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to ~~co-promote~~goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.

During the ~~agent~~measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the

Table of Contents

measurement period, all adjustments are recorded in the ~~U.S. GE Healthcare’s development plan will~~condensed consolidated statements of operations as operating expenses or income.

Contingent Consideration Liabilities

The estimated fair value of contingent consideration liabilities, initially ~~focus~~measured and recorded on ~~obtaining~~the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations.

The estimated fair value is determined based on probability adjusted discounted cash flow and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval ~~for flurpiridaz F 18~~of the development projects and subsequent commercial success.

Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the ~~U.S., Japan, Europe and Canada.~~

~~Under the terms of the License Agreement, the Company received an up-front payment of $5.0 million. In addition, the Company is eligible~~probabilities as to receive, from GE Healthcare, up to $60 million in regulatory and sales-based milestones and tiered double-digit royalties on U.S. sales and mid-single digit royalties on sales outside the U.S. Because the Company concluded there was only one significant deliverable under the License Agreement, consisting of the license of the product which occurred upon the signing of the License Agreement, the Company recognized $5.0 million associated with entering into the license as revenue during the nine months ended September 30, 2017. In addition, because the Company concluded that the regulatory and sales-based milestones are solely dependent on GE Healthcare’s performance and there are no continuing performance obligations from the Company, all development and sales milestones under the License Agreement are considered non-substantive. As of September 30, 2017, the Company has not recognized revenue for those milestones under the License Agreement and will recognize such revenue in the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.

Intangible and Long-Lived Assets

The Company’s IPR&D represents intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the ~~milestones are achieved. Similarly,~~technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&D acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will ~~recognize royalty revenues in~~determine the ~~periods~~useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the ~~sale~~associated IPR&D intangible asset. IPR&D assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in our condensed consolidated statements of ~~the related products, provided that the reported sales are reliably measurable, collectability is reasonably assured and the Company has no further performance obligations.~~operations.

Recent Accounting Pronouncements

~~The following table provides a description of recent accounting pronouncements that may have a material effect on the Company’s condensed consolidated financial statements:~~

Standard

Description

~~Description~~

Effective Date

for Company

Effect on the Condensed Consolidated Financial Statements

Recently Issued Accounting Standards Not Yet Adopted

~~ASU 2017-09,~~ ~~Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting~~

This ASU clarifies when to account for a change to the terms or conditions of a share–based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, vesting conditions or classification of the award (as equity or liability) changes as a result of the change in terms or conditions.

The new guidance will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 for all entities. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued or made available for issuance.

~~January 1, 2018~~

~~The Company does not expect that the adoption of this standard will have a material impact on the Company’s condensed consolidated financial statements.~~

~~ASU 2014-09,~~ ~~Revenue from Contracts with Customers (Topic 606) and related additional amendments ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, ASU 2017-05, ASU 2017-10~~

This ASU and related amendments affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization’s contracts with customers. In August 2015, the Financial Accounting Standards Board issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year.

~~The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods:~~

~~• A full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or~~

~~• A modified retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).~~

~~January 1, 2018~~

The Company has established an implementation team which includes third-party specialists to assist in the evaluation and implementation of the new standard. The Company has completed its assessment of the impact of the standards on its contract portfolio by reviewing the Company’s current accounting policies and practices and identifying potential differences that would result from applying the requirements of the new standard to its revenue contracts. The Company has categorized its customers into multiple customer types and assessed significant customer arrangements within those customer types. The Company is currently in the process of formalizing its conclusion. At this time, the Company does not anticipate a significant impact to its revenue upon adoption of the new standard. The Company, in part due to the limited anticipated impact, will utilize the modified retrospective approach of adopting the ASU. In addition, during 2017 the Company has begun to identify and implement, if necessary, appropriate changes to its business processes, systems and controls to support recognition and disclosure under the new standard.

~~Standard~~

~~Description~~

~~Effective Date~~

~~for Company~~

~~Effect on the Condensed Consolidated Financial Statements~~

Accounting Standards Adopted During the ~~Nine~~Six Months Ended ~~September~~June 30, ~~2017~~2020

ASU 2020-04, “Reference Rate Reform (Topic 848)”

This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting.

~~ASU 2016-09,~~ ~~Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting~~

~~ASU 2016-09 simplifies several aspects of the stock compensation guidance in Topic 718 and other related guidance providing the following amendments:~~

~~• Accounting for income taxes upon vesting or exercise of share-based payments and related EPS effects~~

~~• Classification of excess tax benefits on the statement of cash flows~~

~~• Accounting for forfeitures~~

~~• Liability classification exception for statutory tax withholding requirements~~

~~• Cash flow presentation of employee taxes paid when an employer withholds shares for tax-withholding purposes~~

~~• Elimination of the indefinite deferral in Topic 718~~

~~For public business entities, the amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.~~

January 1, ~~2017~~2020

The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)”

This ASU requires financial instruments measured at amortized cost and accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts that affect the collectability of the reported amount.

January 1, 2020

The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Table of Contents

3. Revenue from Contracts with Customers

The following table summarizes revenue by revenue source and reportable segment as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
Major Products/Service Lines by Segment (in thousands)	2020		2019		2020		2019
U.S.
Product revenue, net⁽¹⁾	$	56,657	$	75,190	$	135,402	$	150,624
License and royalty revenues	742		—		742		—
Total U.S. revenues	57,399		75,190		136,144		150,624
International
Product revenue, net⁽¹⁾	8,270		9,987		19,738		20,536
License and royalty revenues	341		528		832		1,055
Total International revenues	8,611		10,515		$	20,570	$	21,591
Total revenues	$	66,010	$	85,705	$	156,714	$	172,215

(1)The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the

same revenue recognition policies and judgments for all of its principal products.

The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

4. Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

•Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

•Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.

~~At September 30, 2017 and December 31, 2016, the~~The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money ~~market funds.~~market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps are determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 12, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the acquisition of Progenics at fair value based on inputs that are not observable in the market. Please refer to Note 8, “Business Combinations”, for further details on the acquisition.

Table of Contents

The ~~table~~tables below ~~presents~~present information about the Company’s assets and ~~liabilitie~~sliabilities measured at fair value on a recurring basis:


	June 30, 2020
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Assets:
Money market	$	49,662	$	49,662	$	—	$	—
Contingent receivable	10,100		—		—		10,100
Total assets	$	59,762	$	49,662	$	—	$	10,100
Liabilities:
Interest rate swaps	$	1,953	$	—	$	1,953	$	—
Contingent consideration liabilities⁽¹⁾	16,300		—		—		16,300
Total liabilities	$	18,253	$	—	$	1,953	$	16,300


	December 31, 2019
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Assets:
Money market	$	39,530	$	39,530	$	—	$	—
Total assets	$	39,530	$	39,530	$	—	$	—

(1)Includes purchase consideration of $3.7 million related to CVRs and $12.6 million of assumed contingent consideration liabilities.

During the three and six months ended June 30, 2020, there were no transfers into or out of Level 3.

As part of the acquisition of Progenics, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc., related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.

As part of the acquisition of Progenics, the Company issued CVRs and recorded the fair value as part of consideration transferred. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013. These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets for Azedra and 1095 and a $5.0 million 1095 commercialization milestone. The Company considers the contingent consideration liabilities a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.

Significant changes in any of the probabilities of success or the probabilities as to the periods in which milestones will be achieved would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations.

The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at June 30, 2020.

Table of Contents

Total Fair
Value
Level 1 Level 2 Level 3
September 30, 2017 (in thousands)
Money market funds $ 6,565
$ 6,565
$ —
$ —
$ 6,565
$ 6,565
$ —
$ —
December 31, 2016
Money market funds $ 3,565
$ 3,565
$ —
$ —
$ 3,565
$ 3,565
$ —
$ —


(in thousands)	Fair Value at June 30, 2020		Valuation Technique	Unobservable Input	Assumption
Contingent receivable:
Regulatory milestone	$	3,100	Probability adjusted discounted cash flow model	Period of expected milestone achievement	2021
				Probability of success	90	%
				Discount rate	23	%
Royalties	7,000		Probability adjusted discounted cash flow model
				Probability of success	13% - 77%
				Discount rate	23	%
Total	$	10,100


(in thousands)	Fair Value at June 30, 2020		Valuation Technique	Unobservable Input	Assumption
Contingent consideration liability:
Net sales targets - PyL (CVRs)	$	3,700	Monte-Carlo simulation	Period of expected milestone achievement	2022 - 2023

				Discount rate	24	%

1095 commercialization milestone	2,200		Probability adjusted discounted cash flow model	Period of expected milestone achievement	2026
				Probability of success	45	%
				Discount rate	0.48	%





Net sales targets - AZEDRA and 1095	10,400		Monte-Carlo simulation	Probability of success	40% - 100%
				Discount rate	23% - 24%
Total	$	16,300

4.For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated (in thousands):


	Financial Assets		Financial Liabilities
(in thousands)	Six Months Ended June 30, 2020		Six Months Ended June 30, 2020
Fair value, beginning of period	$	—	$	—
Progenics acquisition	10,100		16,300


Fair value, end of period	$	10,100	$	16,300

Changes in unrealized gains (losses) included in earnings	$	—	$	—

5. Income Taxes

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full year, ~~in addition to~~adjusted for any discrete events which ~~impact~~are recorded in the ~~interim period.~~period they occur. The Company’s effective tax rate in fiscal 2020 differs from the U.S. federal statutory rate of 21% principally due to the ~~change in valuation allowance~~impact of state taxes, non-deductible transaction costs, and the ~~rate impact~~accrual of interest on uncertain tax positions. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax provision was $0.8 million and $20,000 for the three months ended September 30, 2017 and 2016, respectively, and $2.1 million and $0.7 million for the nine months ended September 30, 2017 and 2016, respectively.expense is presented below:


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands)	2020		2019		2020		2019
Income tax expense	$	309	$	1,698	$	2,501	$	4,513

Table of Contents

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. ~~Evidence~~The Company has recorded valuation allowances of $3.0 million against the ~~Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance against its domestic~~ net deferred tax assets ~~beginning in 2011, and in each year thereafter. The Company was profitable on~~of certain foreign subsidiaries, as well as a ~~cumulative basis for the three-year period ended September 30, 2017, but substantially all of that profitability was achieved during 2016 and the nine months ended September 30, 2017.~~

The Company continues to evaluate other negative evidence including customer concentration and contractual risk, DEFINITY supplier risk, the risk of Moly supply availability and cost, and certain product development risks, all of which provide for uncertainties around the Company’s future level of profitability. Based on its review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability sufficient to outweigh the objectively verifiable negative evidence, and has recorded a full valuation allowance of $0.7 million against ~~its domestic~~ net state deferred tax assets ~~at September 30, 2017. The Company will continue~~due to ~~assess~~ the ~~level~~potential expiration of ~~the valuation allowance required. If a sufficient weight of positive evidence exists in future periods~~certain state tax losses and tax credits prior to support a release of some or all of the valuation allowance recorded against domestic deferred tax assets, such a release would likely have a material impact on the Company’s results of operations in that future period.utilization.

In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS ~~related~~under which BMS agreed to ~~certain~~indemnify the Company for any payments made to settle those uncertain tax ~~obligations arising prior~~positions with the taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the ~~acquisition~~Company of future indemnification payments, net of actual tax benefits received, to be paid on behalf of the Company ~~for which the Company has the primary legal obligation.~~by BMS. The tax indemnification receivable is ~~recognized~~recorded within other long-term assets. ~~The changes in the tax indemnification asset are recognized within other income in the condensed consolidated statement of operations.~~

In accordance with the Company’s accounting policy, the change in the ~~contingent~~ tax liability, ~~and~~ penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within ~~the~~income tax ~~provision. Accordingly, as~~expense. As these reserves change, adjustments are included in ~~the~~income tax ~~provision~~expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMSBMS continues to be considered recoverable by the Company, there iswill be no ~~net~~ effect on ~~earnings related to these liabilities~~net income and no net cash ~~outflows.~~outflows related to these liabilities.

On June 19, 2020, the Company acquired the stock of Progenics Pharmaceuticals, Inc. in a transaction that is expected to qualify as a tax-deferred reorganization under Section 368 of the Internal Revenue Code of 1986, as amended. The transaction resulted in an ownership change of Progenics under Section 382 and a limitation on the utilization of Progenics’ pre-transaction tax attributes. All pre-transaction research credits and Orphan drug credits have been removed from the balance sheet, and the gross carrying value of the tax loss carryforwards reduced to their realizable value on the opening balance sheet, in accordance with the Section 382 limitation. Significant deferred tax liabilities arising from the purchase accounting basis step-up in identified intangibles were also recorded as part of the purchase accounting, resulting in a small net overall deferred tax liability for Progenics after the application of purchase accounting.

6. Inventory

Inventory consisted of the following:


(in thousands)	June 30, 2020		December 31, 2019
Raw materials	$	15,629	$	11,417
Work in process	12,991		9,450
Finished goods	6,714		8,313
Total inventory	$	35,334	$	29,180

(in thousands) September 30,
2017
December 31,
2016
Raw materials $ 10,699
$ 9,658
Work in process 5,571
3,965
Finished goods 6,762
4,017
Total inventory $ 23,032
$ 17,640

As of September 30, 2017 and December 31, 2016, the Company had $1.2 million of inventory classified within other long-term assets, which represent raw materials not expected to be used by the Company during the next twelve months.

6.7. Property, Plant &and Equipment, Net

Property, plant &and equipment, net, consisted of the following:


(in thousands)	September 30, 2017			December 31, 2016			(in thousands)	June 30, 2020		December 31, 2019
Land	$	14,950		$	14,950		Land	$	13,450	$	13,450
Buildings	74,864			70,628			Buildings	69,643		75,654
Machinery, equipment and fixtures	69,549			65,407			Machinery, equipment and fixtures	88,728		87,763
Computer software	18,463			18,482			Computer software	20,931		20,739
Construction in progress	10,068			7,224			Construction in progress	15,535		10,546
	187,894			176,691				208,287		208,152
Less: accumulated depreciation and amortization	(93,378		)	(82,504		)	Less: accumulated depreciation and amortization	(85,384)		(91,655)
Total property, plant & equipment, net	$	94,516		$	94,187
Total property, plant and equipment, net							Total property, plant and equipment, net	$	122,903	$	116,497

Depreciation and amortization expense related to property, plant &and equipment, net, was $2.7 million and $2.5 million for the three months ended ~~September~~June 30, ~~2017~~2020 and ~~2016~~2019, respectively, and ~~$11.7~~$5.7 million and ~~$8.1~~$5.0 million for the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 and ~~2016,~~2019, respectively.

Table of Contents

7.The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the three months ended March 31, 2020, as a result of a decline in expected future cash flows and the effect of COVID-19 related to certain other nuclear legacy manufacturing assets in the U.S. segment, the Company determined certain impairment triggers had occurred. Accordingly, the Company performed an undiscounted cash flow analysis as of March 31, 2020. Based on the undiscounted cash flow analysis, the Company determined that the manufacturing assets had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair values of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a non-cash impairment of $7.3 million for the six months ended June 30, 2020 in cost of goods sold in the condensed consolidated statement of operations.

8. Business Combinations

On June 19, 2020, the Company completed the acquisition of Progenics, an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The acquisition combines the commercialization, supply chain and manufacturing expertise of the Company with the currently commercialized products and R&D pipeline of Progenics. Progenics brings several commercial products and a pipeline of product candidates that will further diversify the Company’s commercial and clinical development portfolios.

Under the terms of the Merger Agreement, the Company acquired all of the issued and outstanding shares of Progenics common stock for a purchase price of $419.0 million by means of an all-stock transaction, which includes Replacement Stock Options for precombination services as well as CVRs.

The CVRs were accounted for as contingent consideration, the fair value of which was determined using a Monte-Carlo simulation. Additionally, the fair value of replacement options related to pre-acquisition services was recorded as a component of consideration transferred. Finally, as a result of the acquisition, Lantheus effectively settled an existing bridge loan with Progenics at the recorded amount (principal and accrued interest) of $10.1 million, representing the effective settlement of a preexisting relationship. This effective settlement of the bridge loan was treated as a component of consideration transferred. The Company determined that the bridge loan was at market terms and no gain or loss was recorded upon settlement.

The acquisition date fair value of the consideration transferred in the acquisition consisted of the following:


(in thousands)	Amount
Issuance of common stock	$	398,110
Fair value of replacement options	7,125
Fair value of bridge loan settled at close	10,074
Fair value of contingent considerations (CVRs)	3,700
Total consideration transferred⁽¹⁾	$	419,009

(1)Non-cash investing and financing activities in the condensed consolidated statements of cash flows

The transaction was accounted for as a business combination which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The purchase price allocation is preliminary and is subject to change, including for the valuation and amortization of intangible assets, income taxes and related valuation allowances and certain assets and liabilities among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Any potential adjustments made could be material in relation to the preliminary values presented below.

The preliminary fair value of the assets acquired and liabilities assumed were as follows:

Table of Contents


(in thousands)	Amount
Cash and cash equivalents	$	15,421
Accounts receivable	5,787
Inventory	915
Other current assets	3,250
Property, plant and equipment	14,972
Identifiable intangible assets (weighted average useful life):
Currently marketed product (15 years)	142,100
Licenses (11.5 years)	87,500
Developed technology (9 years)	3,000
IPR&D	150,900

Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,207)
Other long-term liabilities	(30,778)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(3,717)
Goodwill	42,051
Total consideration transferred	$	419,009

Intangible assets acquired consist of currently marketed products, licenses, developed technology and IPR&D. The fair value of the acquired intangible assets was determined based on estimated future revenues, royalty rates and discount rates, among other variables and estimates. The acquired intangible assets subject to amortization were assigned useful lives based on the expected use of the assets and the regulatory and economic environment within which they are being used and are being amortized on a straight-line basis over the respective estimated useful lives. The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 24.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

As part of the acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics, related to a prior sale of certain intellectual property. The estimated fair value of the acquired contingent receivable of $10.1 million was determined by applying a probability adjusted discounted cash flow model based on estimated future expected payments and recorded in other long-term assets.

The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Progenics’ assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $42.1 million recognized in connection with the acquisition is not deductible for tax purposes and has not yet been assigned to operating segments.

The Company recognized $7.5 million and $8.9 million of acquisition-related costs, including legal, accounting, compensation arrangements and other related fees that were expensed when incurred in the three and six months ended June 30, 2020, respectively. These costs are recorded in general and administrative expenses in the condensed consolidated statements of operations.

Progenics Pro Forma Financial Information

Progenics has been included in the Company’s consolidated financial statements since the acquisition date. Progenics contributed revenues of $1.0 million and a net loss of $3.2 million to the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2020.

The following unaudited pro forma financial information presents the Company’s results as if the Progenics acquisition had occurred on January 1, 2019:

Table of Contents


	Six Months Ended June 30, 2020		Six Months Ended June 30, 2019
(in thousands)	Amount		Amount
Pro forma revenue	$	167,619	$	186,462
Pro forma net loss	18,115		42,901

The pro forma financial information for all periods presented adjusts for the effects of material business combination items, including amortization of acquired intangible assets, transaction-related costs, adjustments to interest expense related to the assumption of long-term debt, retention and severance bonuses and the corresponding income tax effects of each. These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the acquisition actually taken place on January 1, 2019. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the acquisition, including, but not limited to, revenue enhancements, cost savings or operating synergies that the combined company may achieve as a result of the acquisition.

9. Asset Retirement Obligations

The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and San Juan, Puerto Rico sites. As of June 30, 2020, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.9 million.

The following table provides a summary of the changes in the Company’s asset retirement obligations:


(in thousands)	Amount
Balance at January 1, 2020	$	12,883

Accretion expense	719
Balance at June 30, 2020	$	13,602

The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts production facility upon closure, although the Company does not intend to ~~clos~~eclose the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond.

10. Intangibles, Net

Intangibles, net, consisted of the following:


	June 30, 2020
(in thousands)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	Straight-Line	$	13,540	$	(10,683)	$	2,857
Customer relationships	Accelerated	98,903		(95,214)		3,689
Currently marketed product	Straight-Line	142,100		(289)		141,811
Licenses	Straight-Line	87,500		(235)		87,265
Developed technology	Straight-Line	3,000		(10)		2,990
IPR&D	N/A	150,900		—		150,900
Total		$	495,943	$	(106,431)	$	389,512


	December 31, 2019
(in thousands)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	Straight-Line	$	13,540	$	(10,407)	$	3,133
Customer relationships	Accelerated	99,019		(94,816)		4,203
Total		$	112,559	$	(105,223)	$	7,336

Table of Contents

The ~~fair value~~Company recorded amortization expense for its intangible assets of ~~a liability~~$0.9 million and $0.5 million for ~~asset retirement obligations is recognized in~~ the ~~period in which~~three months ended June 30, 2020 and 2019, respectively, and $1.3 million and $0.9 million for the ~~liability is incurred. As of September~~six months ended June 30, ~~2017,~~2020 and 2019, respectively.

The below table summarizes the ~~liability is measured at the present value of the obligation~~estimated aggregate amortization expense expected to be ~~incurred,~~recognized on the above intangible assets:


(in thousands)	Amount
2020	$	9,534
2021	18,813
2022	18,684
2023	18,074
2024	17,998
2025 and thereafter	155,509
Total	$	238,612

11. Long-Term Debt, Net, and Other Borrowings

As of approximately $26.9 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.

~~The following table provides a summary of the changes in the Company’s asset retirement obligations:~~

(in thousands) Amount
Balance at January 1, 2017 $ 9,370
Accretion expense 781
Balance at September 30, 2017 $ 10,151

~~8. Financing Arrangements~~

~~On March~~June 30, 2017, the Company refinanced its previous $365 million seven-year term loan agreement (the facility thereunder, the “2015 Term Facility”) with a new five-year $275 million term loan facility (the “2017 Term Facility” and the loans thereunder, the “Term Loans”). In addition, the Company replaced its previous $50.0 million five-year asset based loan facility (the “ABL Facility”) with a new $75.0 million five-year revolving credit facility (the “2017 Revolving Facility” and, together with the 2017 Term Facility, the “2017 Facility”). The terms of the 2017 Facility are set forth in that certain Amended and Restated Credit Agreement, dated as of March 30, 2017 (the “Credit Agreement”), by and among Holdings, the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. The 2017 Term Facility was issued net of a $0.7 million discount. The Company has the right to request an increase to the 2017 Term Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to $75.0 million, plus additional amounts, in certain circumstances.

The net proceeds of the 2017 Term Facility, together with approximately $15.3 million of cash on hand, were used to refinance in full the aggregate remaining principal amount of the loans outstanding under the 2015 Term Facility and pay related interest, transaction fees and expenses. No amounts were outstanding under the ABL Facility at that time. The Company accounted for the refinancing as both a debt extinguishment and debt modification by evaluating the refinancing on a creditor by creditor basis. The Company recorded a loss on extinguishment of debt of $2.2 million related to the write-off of unamortized debt issuance costs and incurred general and administrative expenses of $1.7 million related to third-party costs associated with the modified debt. In addition, the Company incurred and capitalized $1.6 million of new debt issuance costs related to the refinancing.

~~2017 Term Facility~~

~~The Term Loans under the 2017 Term Facility bear interest, with pricing based from time to time at~~2020, the Company’s ~~election at (i) LIBOR plus a spread~~maturities of 4.50% or (ii) the Base Rate (as defined in the Credit Agreement) plus a spread of 3.50%. Interest is payable (i) with respect to LIBOR Term Loans, at the end of each Interest Period (as defined in the Credit Agreement)principal obligations under its long-term debt and ~~(ii) with respect to Base Rate Term Loans, at the end of each quarter.~~ other borrowings are as follows:


(in thousands)	Amount
Remainder of 2020	$	8,607
2021	21,927
2022	30,643
2023	15,972
2024	148,750

Total principal outstanding	225,899
Unamortized debt premium	1,566
Unamortized debt issuance costs	(687)
Finance lease liabilities	375

Total	227,153
Less: current portion	(17,143)
Total long-term debt, net and other borrowings	$	210,010

At ~~September~~June 30, ~~2017,~~2020, the Company’s interest rate under the ~~2017~~2019 Term Facility was ~~5.7%~~3.4%.

On June 19, 2020, the Company amended its 2019 Credit Agreement (“the Amendment”) as a result of the impact of the COVID-19 pandemic on the business and operations of the Company and the near-term higher level of indebtedness resulting from the Company’s decision not to immediately repay the Progenics debt secured by the RELISTOR royalties following the Company’s acquisition of Progenics. The Company accounted for the Amendment as a debt modification and capitalized $1.2 million of associated costs.

The ~~Company is permitted~~Amendment provides for, among other things, modifications to ~~voluntarily prepay the Term Loans, in whole or in part.~~LMI’s financial maintenance covenants. The ~~2017 Term Facility requires the Company~~covenant related to ~~make mandatory prepayments of the outstanding Term Loans in certain circumstances. The 2017 Term Facility amortizes at 1.00% per year until its June 30, 2022 maturity date.~~

~~The Company’s maturities of principal obligations under the 2017 Term Facility are as follows as of September 30, 2017:~~

(in thousands) Amount
Remainder of 2017 $ 688
2018 2,750
2019 2,750
2020 2,750
2021 2,750
2022 261,937
Total principal outstanding 273,625
Unamortized debt discount (2,273 )
Unamortized debt issuance costs (3,079 )
Total 268,273
Less: current portion (2,750 )
Total long-term debt $ 265,523

~~2017 Revolving Facility~~

Under the terms of the 2017 Revolving Facility, the lenders thereunder agreed to extend credit to the Company from time to time until March 30, 2022 (the “Revolving Termination Date”) consisting of revolving loans (the “Revolving Loans” and, together with the Term Loans, the “Loans”) in an aggregate principal amount not to exceed $75.0 million (the “Revolving Commitment”) at any time outstanding. The 2017 Revolving Facility includes a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”). The Letters of Credit and the borrowings under the 2017 Revolving Facility are expected to be used for working capital and other general corporate purposes.

~~The Revolving Loans under the 2017 Revolving Facility bear interest, with pricing based from time to time at the Company’s election at (i) LIBOR plus a spread of 3.50% or (ii) the Base Rate~~Total Net Leverage Ratio (as defined in the Amended Credit Agreement) ~~plus a spread~~has been waived from the date of ~~2.50%.~~the Amendment through December 31, 2020. The ~~2017 Revolving Facility also includes an unused line fee, which is set at 0.375% while the Company’s secured~~maximum total net leverage ratio ~~(as defined in the Credit Agreement) is greater than 3.00 to 1.00~~ and ~~0.25% when the Company’s secured leverage ratio is less than or equal to 3.00 to 1.00.~~

The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans and Letters of Credit exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. As of September 30, 2017~~, there were no outstanding borrowings under the 2017 Revolving Facility.~~

~~2017 Facility Covenants~~

The 2017 Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The 2017 Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum consolidated leverageinterest coverage ratio permitted by the financial covenant is displayed in the table below:

~~2017 Facility Financial Covenant~~

Table of Contents


2020 Amended Credit Agreement
Period			Total Net Leverage Ratio
Q1 2021			5.50 to 1.00
Q2 2021			3.75 to 1.00
Thereafter			3.50 to 1.00

Period			Interest Coverage Ratio
Q2 2020 to Q1 2021			2.00 to 1.00
Thereafter			3.00 to 1.00

The Amendment also introduces a new financial covenant requiring Consolidated Liquidity (as defined in the Amended Credit Agreement) to be no less than $150.0 million. The Consolidated Liquidity covenant is tested on a continuing basis beginning on the date of the Amendment and ending on the date on which LMI delivers a compliance certificate for the fiscal quarter ending March 31, 2021.

For the period beginning on the date of the Amendment and ending on the Adjustment Date (as defined in the Amended Credit Agreement) for the fiscal quarter ending March 31, 2021, loans under the Amended Credit Agreement bear interest at LIBOR plus 3.25% or the Base Rate plus 2.25%. On and after the Adjustment Date for the fiscal quarter ending on March 31, 2021, loans bear interest at LIBOR plus a spread that ranges from 1.50% to 3.00% or the Base Rate plus a spread that ranges from 0.50% to 2.00%, in each case based on LMI’s Total Net Leverage Ratio.

The commitment fee applicable to the Revolving Facility is 0.50% until the Adjustment Date for the fiscal quarter ending March 31, 2021. On and after the Adjustment Date for the fiscal quarter ending on March 31, 2021, the commitment fee ranges from 0.15% to 0.40% based on LMI’s Total Net Leverage Ratio.

On June 19, 2020, as a result of the acquisition, the Company assumed Progenics outstanding debt as of such date in the amount of $40.2 million. Progenics, through a wholly-owned subsidiary MNTX Royalties Sub LLC (“MNTX Royalties”), entered into a $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. (“HCRP”) on November 4, 2016. Under the terms of the Royalty-Backed Loan, the lenders have no recourse to Progenics or any of its assets other than the right to receive royalty payments from the commercial sales of RELISTOR products owed under Progenics’ license agreement with Salix Pharmaceuticals, Inc., a wholly-owned subsidiary of Bausch Health Companies Inc. (“Bausch”). The RELISTOR royalty payments will be used to repay the principal and interest on the loan. The Royalty-Backed Loan bears interest at a per annum rate of 9.5% and matures on June 30, 2025. On June 22, 2020, HCRP waived the automatic acceleration of the Royalty-Backed Loan that otherwise would have been triggered by the consummation of the Progenics Transaction and MNTX Royalties agreed not to prepay the loan until after December 31, 2020.

Under the terms of the loan agreement, payments of interest and principal, if any, are made on the last day of each calendar quarter out of RELISTOR royalty payments received since the immediately-preceding payment date. On each payment date, 50% of RELISTOR royalty payments received since the immediately-preceding payment date in excess of accrued interest on the loan are used to repay the principal of the loan, with the balance retained by the Company. Starting on September 30, 2021, all of the RELISTOR royalties received since the immediately-preceding payment date will be used to repay the interest and outstanding principal balance until the balance is fully repaid.

12. Derivative Instruments

The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At June 30, 2020, accumulated other comprehensive loss included $0.6 million of pre-tax deferred losses that are expected to be reclassified to earnings during the next 12 months.

Table of Contents

The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheet:

(in thousands)

June 30, 2020

December 31, 2019

Derivatives type

Classification

~~Period~~

~~Consolidated~~

~~Leverage Ratio~~

~~Q3 2017 through Q1 2018~~

~~5.00 to 1.00~~

~~Q2 2018 through Q1 2019~~Liabilities:

~~4.75 to 1.00~~

~~Thereafter~~ Interest rate swap

~~4.50 to 1.00~~Accrued expenses and other liabilities

1,953

—

13. Accumulated Other Comprehensive Loss

The ~~2017 Facility contains usual~~components of Accumulated Other Comprehensive Loss, net of tax of $0.5 million and ~~customary restrictions on~~$0.0 million for the ~~ability~~six months ended June 30, 2020 and June 30, 2019, respectively, consisted of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.following:

Upon an event of default, the administrative agent under the Credit Agreement will have the right to declare the Loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced.


(in thousands)	Foreign currency translation		Unrealized loss on cash flow hedges		Accumulated other comprehensive loss
Balance at January 1, 2020	$	(960)	$	—	$	(960)
Other comprehensive loss before reclassifications	(194)		(1,528)		(1,722)
Amounts reclassified to earnings	—		76		76
Balance at June 30, 2020	$	(1,154)	$	(1,452)	$	(2,606)

Balance at January 1, 2019	$	(1,108)	$	—	$	(1,108)
Other comprehensive income before reclassifications	144		—		144
Amounts reclassified to earnings	—		—		—
Balance at June 30, 2019	$	(964)	$	—	$	(964)

The 2017 Facility is guaranteed by Holdings and Lantheus MI Real Estate, LLC (“LMI-RE”), and obligations under the 2017 Facility are generally secured by first priority liens over substantially all of the assets of each of LMI, Holdings and LMI-RE (subject to customary exclusions set forth in the transaction documents) owned as of March 30, 2017 or thereafter acquired.

9.14. Stock-Based Compensation

The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands)	2020		2019		2020		2019
Cost of goods sold	$	645	$	531	$	1,263	$	971
Sales and marketing	394		508		647		959
General and administrative	1,994		1,881		3,809		3,455
Research and development	352		438		741		693
Total stock-based compensation expense	$	3,385	$	3,358	$	6,460	$	6,078

Three Months Ended
September 30,
Nine Months Ended
September 30,
(in thousands) 2017 2016 2017 2016
Cost of goods sold $ 198
$ 120
$ 514
$ 259
Sales and marketing 183
123
474
251
General and administrative 1,089
487
2,315
1,065
Research and development 187
147
461
294
Total stock-based compensation expense $ 1,657
$ 877
$ 3,764
$ 1,869

Table of Contents

~~Increase in Shares Reserved Under the 2015 Equity Incentive Plan~~

At the Company’s annual meeting of stockholders, held on April 27, 2017 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the 2015 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 1,200,000 shares, to an aggregate of 5,755,277 shares.

~~Employee Stock Purchase Plan~~

At the Annual Meeting, the Company’s stockholders also approved the 2017 Employee Stock Purchase Plan (“2017 ESPP”), which authorized the issuance of up to 250,000 shares of common stock thereunder. Under the terms of the 2017 ESPP, eligible U.S. employees can elect to acquire shares of the Company’s common stock through periodic payroll deductions during a series of six month offering periods, which will generally begin in March and September of each year. Purchases under the 2017 ESPP are effected on the last business day of each offering period at a 15% discount to the closing price on that day. The 2017 ESPP was implemented, subject to stockholder approval, on March 10, 2017, and the first purchases thereunder were made on September 13, 2017.

~~10.~~15. Net (Loss) Income Per Common Share

~~Basic~~A summary of net (loss) income per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted-average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.presented below:


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands, except per share amounts)	2020		2019		2020		2019
Net (loss) income	$	(7,012)	$	6,412	$	(3,675)	$	16,361

Basic weighted-average common shares outstanding	43,135		38,972		41,284		38,789
Effect of dilutive stock options	—		98		—		80
Effect of dilutive restricted stock	—		1,169		—		1,195

Diluted weighted-average common shares outstanding	43,135		40,239		41,284		40,064

Basic (loss) income per common share	$	(0.16)	$	0.16	$	(0.09)	$	0.42
Diluted (loss) income per common share	$	(0.16)	$	0.16	$	(0.09)	$	0.41

Antidilutive securities excluded from diluted net income per common share	1,649		31		1,517		55

Three Months Ended
September 30,
Nine Months Ended
September 30,
(in thousands, except per share amounts) 2017 2016 2017 2016
Net income $ 8,526
$ 4,220
$ 26,259
$ 21,893
Basic weighted-average common shares outstanding 37,393
31,221
37,174
30,658
Effect of dilutive stock options 318
1,084
371
391
Effect of dilutive restricted stock awards 1,410
97
1,426
—
Diluted weighted-average common shares outstanding 39,121
32,402
38,971
31,049
Basic income per common share outstanding $ 0.23
$ 0.14
$ 0.71
$ 0.71
Diluted income per common share outstanding $ 0.22
$ 0.13
$ 0.67
$ 0.71

Antidilutive securities excluded from diluted income per common share 322
448
378
1,873

~~11.~~16. Other ~~(Income) Expense~~Income

Other ~~(income) expense~~income consisted of the following:


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands)	2020		2019		2020		2019
Foreign currency (losses) gains	$	94	$	47	$	(220)	$	89
Tax indemnification income, net	554		802		1,109		1,604
Interest income	105		276		214		559
Other	3		187		3		247
Total other income	$	756	$	1,312	$	1,106	$	2,499

17. Commitments and Contingencies

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017 2016 2017 2016
Foreign currency (gains) losses $ (414 ) $ 349
$ (554 ) $ 330
Tax indemnification income (489 ) (196 ) (1,469 ) (632 )
Other income (5 ) (5 ) (14 ) (15 )
Total other (income) expense $ (908 ) $ 148
$ (2,037 ) $ (317 )

~~12.~~ Legal Proceedings ~~and Contingencies~~

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the ~~Company.~~Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of ~~September~~June 30, ~~2017,~~2020, the Company ~~has no~~had the following material ongoing litigation in which the Company was a ~~party or any material ongoing regulatory or other proceedings~~party:

RELISTOR Subcutaneous Injection

Between November 19, 2015 and ~~had no knowledge~~September 18, 2017, Progenics, Salix, Valeant (now Bausch) and Wyeth filed multiple lawsuits against Mylan Pharmaceuticals and certain of ~~any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on~~ its ~~current business.~~

~~13. Related Party Transactions~~

~~Related party expenses consisted of the following:~~

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) Transaction Type 2017 2016 2017 2016
Avista Capital Partners, L.P. and its affiliates* Offering costs paid on behalf of Avista pursuant to registration rights agreement $ —
$ —
$ 326
$ —
INC Research Holdings, Inc. (“INC”)** Pharmacovigilance services —
293
—
647
VWR Scientific* Inventory supplies —
60
297
245
Total related party expenses $ —
$ 353
$ 623
$ 892

* During the quarter ended September 30, 2017, Avista Capital Partners, L.P., Avista Capital Partners (Offshore), L.P. and ACP-Lantern Co-Invest, LLCaffiliates (collectively, ~~“Avista”~~“Mylan”) ~~distributed approximately 6.3 million shares of common stock of the Company~~ in the ~~aggregate, representing~~United States District Court for the ~~remainder~~District of ~~their holdings~~New Jersey for infringement of certain U.S. patents based upon Mylan’s filing of multiple ANDAs seeking to obtain approval to market a generic version of RELISTOR subcutaneous injection before some or all of those patents expire. These actions were later consolidated into two separate actions in the ~~Company. The transactions were effected~~District of New Jersey.

Table of Contents

On May 1, 2018, in the lead action, the Court granted Plaintiffs’ motion for partial summary judgment as ~~distributions-in-kind of the Company’s common stock~~ to the ~~investors~~validity of a particular claim that Mylan had admitted it infringed. On May 23, 2018, the Court entered an order for final judgment in ~~those investment funds. As such, Avista~~favor of Plaintiffs and ~~VWR Scientific (an entity in which Avista had an interest) are no longer related parties.~~

** During the year ended December 31, 2016, investment funds affiliated with Avista disposed of shares of INC common stock held by them.against Mylan on that particular claim. As a result, ~~such investment funds~~trial on the merits in the lead action was adjourned, allowing trial, if necessary, to be consolidated with the lagging, second action. Fact discovery has concluded in the lagging case, but deadlines for expert discovery have not yet been set.

On May 25, 2018, Mylan filed a Notice of Appeal to the United States Court of Appeals for the Federal Circuit (“CAFC”). On April 8, 2020, the CAFC issued its decision reversing the Court’s grant of summary judgment and remanding for further proceedings. On June 22, 2020, Plaintiffs filed a petition for rehearing/rehearing en banc, and on July 24, 2020 that petition was denied.

RELISTOR Tablets - Actavis

Between December 6, 2016 and December 8, 2017, Progenics, Salix, Bausch, and Wyeth filed suit against Actavis, Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. (collectively, “Actavis”) in the United States District Court for the District of New Jersey for infringement of certain U.S. patents based upon Actavis’s filing of an ANDA seeking to obtain approval to market a generic version of RELISTOR tablets before some or all of those patents expire. The actions were ~~no longer~~later consolidated into a ~~principal owner~~single action in the District of ~~INC. Related party expenses included~~New Jersey.

On May 6-9, 2019, a bench trial was held, and on July 17, 2019, the Court issued an Order finding the asserted claims of a certain U.S. patent valid and infringed. The Court additionally ordered that the effective date of any approval of Actavis’s ANDA may not be earlier than the expiration date of that patent. Actavis filed an appeal of the Court’s decision with the CAFC on August 13, 2019. The matter is currently pending on appeal at the CAFC and merits briefing is underway. Actavis’s opening brief was filed February 6, 2020. The deadline for Plaintiffs to file their responsive brief is currently September 15, 2020.

On June 13, 2019, Progenics, Salix, Bausch, and Wyeth filed another suit against Actavis in the United States District Court for the District of New Jersey for infringement of a separate, and at that time, recently granted U.S. patent based upon Actavis’s filing of an ANDA seeking to obtain approval to market a generic version of RELISTOR tablets before this patent expires. Litigation in this ~~table represent expenses~~action is underway, and fact discovery has not yet begun.

RELISTOR European Opposition Proceedings

In addition to the above described ANDA notifications, in October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone. Notices of opposition were filed separately by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the opposition division provided notice that the three European patents would be revoked. Each of these matters are on appeal with the European Patent Office. Oral proceedings are set to occur on September 22, 2020, November 17, 2020 and November 18, 2020. For each of the above-described RELISTOR proceedings, Progenics and Bausch continue to cooperate closely to vigorously defend and enforce RELISTOR intellectual property rights. Pursuant to the RELISTOR license agreement between Progenics and Bausch, Bausch has the first right to enforce the intellectual property rights at issue and is responsible for the costs of such enforcement. Because the outcome of litigation is uncertain and in these RELISTOR proceedings the Company does not control the enforcement of the intellectual property rights at issue, no assurance can be given as to how or when any of these RELISTOR proceedings will ultimately be resolved.

German PSMA-617 Litigation

On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court of Mannheim in Germany. In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University in its own name. On February 27, 2019, Endocyte, Inc., a wholly owned subsidiary of Novartis AG, filed a motion to intervene in the German litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings.

On November 27, 2018, MIP requested that the European Patent Office (“EPO”) stay the examination of a certain European Patent (EP) and related Divisional Applications, pending a decision from the German District Court on MIP’s Complaint. On December 10, 2018, the EPO granted MIP’s request and stayed the examination of the patent and patent applications effective November 27, 2018. MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) in the corresponding US patent applications. MIP’s filing with the USPTO takes the position that, in light of the collaboration and contracts between MIP and the University, MIP is the co-owner of these pending U.S. patent applications. On March 6, 2020, MIP filed with the USPTO a notice stating that the Power of Attorney in certain pending US patent applications was signed by less than all applicants or owners of the applications.

Table of Contents

On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the Court as security in the event of an unfavorable final decision on the merits of the dispute. The Court held the first oral hearing in the case on August 6, 2019. The Court considered procedural matters and granted the parties the right to make further submissions. A further oral hearing occurred July 23, 2020, during which the Court heard live testimony from several witnesses.

Progenics is vigorously enforcing its rights in this German proceeding. Because Progenics is the plaintiff, if unsuccessful in this proceeding, Progenics may also have liability for Court fees and fees and disbursements of defendant’s and intervenor’s counsel, such fees and disbursements to be at least partially covered by the aforementioned cash security deposited with the Court. Because the outcome of litigation is uncertain, no assurance can be given as to how or when this German proceeding will ultimately be resolved.

Litigation Related to the Merger

Nine purported stockholders of Progenics filed ten lawsuits alleging, among other things, that Progenics and the members of the Progenics Board of Directors violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and 17 C.F.R. § 244.100 and Rule 14a-9 promulgated under the Exchange Act, by misstating or omitting certain allegedly material information in the S-4 Registration Statement filed with the Securities and Exchange Commission (“SEC”) on November 12, 2019, the amended S-4 Registration Statement filed with the SEC on March 16, 2020, and/or the Schedule 14A proxy statement filed with the SEC on March 19, 2020 related to the Merger. Two of the actions alleged that the Company and Plato Merger Sub, Inc. (“Merger Sub”) violated Section 14(a) and/or Section 20(a) of the Exchange Act. One of the actions further alleged that the members of the Progenics Board breached their fiduciary duties of care, loyalty and good faith to the stockholders of Progenics related to the Merger, that Progenics, the Company and Merger Sub aided and abetted such breaches of fiduciary duty, and that the Company and Merger Sub violated Section 14(a) of the Exchange Act. All such lawsuits have been voluntarily dismissed, with the last of the cases dismissed on June 23, 2020.

Whistleblower Complaint

In July 2019, Progenics received notification of a complaint submitted by Dr. Syed Mahmood, the former Vice President of Medical Affairs for Progenics, to the Occupational Safety and Health Administration of the United States Department of Labor (“DOL”), alleging that the termination of his employment by Progenics was in violation of Section 806 of the Sarbanes-Oxley Act of 2002 (“SOX”). Dr. Mahmood sought reinstatement to his former position of Vice President of Medical Affairs, back pay, front pay in lieu of reinstatement, interest, attorneys’ fees and costs incurred, ~~during~~and special damages. In March 2020, Dr. Mahmood filed a complaint in the ~~period under which investment funds affiliated~~U.S. District Court for the Southern District of New York (as permitted by SOX because the DOL had not issued a decision within 180 days). Dr. Mahmood’s federal complaint asserts claims of violation of Section 806 of SOX. The DOL action has been dismissed and the matter will proceed in federal district court. Progenics’ Answer to the Complaint is presently due by August 26, 2020.

The Company believes the claims in this matter are without merit, and the Company has meritorious defenses to the claims. The Company intends to vigorously defend against the claims.

The Company is unable to estimate the potential liability with ~~Avista held an investment~~respect to the legal matters noted above. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at the various stages of the legal proceedings noted above, including the significant number of legal and factual issues still to be resolved in ~~INC.~~those various legal proceedings.

~~Amounts billed and unbilled for related parties included in accounts payable and accrued expenses are immaterial at December 31, 2016.~~

~~14.~~

Table of Contents

18. Segment Information

The Company reports ~~two~~2 operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s segments derive revenues through the manufacture, marketing, selling and distribution of ~~medical imaging products, focused primarily on cardiovascular~~innovative diagnostic ~~imaging.~~and therapeutic agents and products. All goodwill has been allocated to the U.S. operating ~~segment.~~segment, except for the goodwill recognized in connection with the Progenics acquisition which has not yet been assigned to operating segments. The Company does not identify or allocate assets to its segments.

Selected information ~~for each operating segment~~regarding the Company’s segments is provided as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands)	2020		2019		2020		2019
Revenue by product from external customers
U.S.
DEFINITY	$	39,544	$	53,466	$	94,554	$	103,182
TechneLite	15,591		16,865		34,947		36,923
Other nuclear	5,804		9,127		14,866		18,651
Rebates and allowances	(3,540)		(4,268)		(8,223)		(8,132)
Total U.S. Revenues	57,399		75,190		136,144		150,624
International
DEFINITY	821		1,163		2,602		2,558
TechneLite	3,318		3,241		7,060		7,328
Other nuclear	4,473		6,119		10,911		11,715
Rebates and allowances	(1)		(8)		(3)		(10)
Total International Revenues	8,611		10,515		20,570		21,591
Worldwide
DEFINITY	40,365		54,629		97,156		105,740
TechneLite	18,909		20,106		42,007		44,251
Other nuclear	10,277		15,246		25,777		30,366
Rebates and allowances	(3,541)		(4,276)		(8,226)		(8,142)
Total Revenues	$	66,010	$	85,705	$	156,714	$	172,215


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands)	2020		2019		2020		2019




Operating (loss) income
U.S.	$	(6,001)	$	12,689	$	(1,013)	$	27,273
International	456		1,848		2,593		3,433
Total operating (loss) income	(5,545)		14,537		1,580		30,706
Interest expense	1,914		4,543		3,860		9,135
Loss on extinguishment of debt	—		3,196		—		3,196
Other income	(756)		(1,312)		(1,106)		(2,499)
(Loss) income before income taxes	$	(6,703)	$	8,110	$	(1,174)	$	20,874

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017 2016 2017 2016
Revenues from external customers
U.S. $ 69,579
$ 62,621
$ 218,706
$ 192,687
International 10,362
10,442
31,431
34,816
Total revenues from external customers $ 79,941
$ 73,063
$ 250,137
$ 227,503
Operating income
U.S. $ 12,243
$ 11,649
$ 40,306
$ 35,941
International 579
946
2,340
8,506
Total operating income 12,822
12,595
42,646
44,447
Interest expense 4,442
6,792
14,147
20,799
Debt retirement costs —
1,415
—
1,415
Loss on extinguishment of debt —
—
2,161
—
Other (income) expense (908 ) 148
(2,037 ) (317 )
Income before income taxes $ 9,288
$ 4,240
$ 28,375
$ 22,550

~~15. Subsequent Events~~

On October 30, 2017, LMI entered into a binding commercial supply arrangement pursuant to which LMI will supply Cardinal Health with TechneLite generators, Xenon, Neurolite and other products through 2018. The supply arrangement specifies pricing levels and requires Cardinal Health to purchase minimum volumesTable of certain products from LMI during certain periods. The supply arrangement will expire on December 31, 2018 and may be terminated upon the occurrence of specified events, including a material breach by the other party and certain force majeure events.Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

Some of the statements contained in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates are subject to risks and uncertainties. These statements identify prospective information and include words such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “should,” “could,” “predicts,” “hopes” and similar expressions. Examples of forward-looking statements include ~~but are not limited to,~~ statements we make ~~regarding: (i)~~relating to our outlook and expectations including, without limitation, in connection ~~with~~with: (i) the impact of the global COVID-19 pandemic on our business, financial conditions or prospects; (ii) continued market expansion and penetration for our commercial products, particularly DEFINITY, in the face of ~~increased~~segment competition and ~~future~~potential generic competition as a result of patent and regulatory exclusivity expirations; ~~(ii) our outlook and expectations in connection with future performance of Xenon in~~(iii) the ~~face of increased competition; (iii) our outlook and expectations related to our ability to maintain and profitably renew our key customer contracts; and~~global Molybdenum-99 (“Mo-99”) supply; (iv) our ~~outlook and expectations related to~~ products manufactured at Jubilant HollisterStier (“JHS”); (v) our efforts in new product development, including for PyL, the Progenics prostate cancer diagnostic imaging agent, and ~~global isotope supply.~~new clinical applications for our products; (vi) the integration of the Progenics product and product candidate portfolio following the consummation of the Progenics transaction (the “Progenics Transaction”); (vii) our capacity to use in-house manufacturing; and (viii) our ability to commercialize our products in new ex-U.S. markets. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, such statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. ~~Such~~These statements are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this Quarterly Report on Form 10-Q may not in fact occur. We caution you, therefore, against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:

•The impact of the global COVID-19 pandemic on our business, financial condition or prospects, including a decline in the volume of procedures and treatments using our products, potential delays and disruptions to global supply chains, manufacturing activities, logistics, operations, clinical development programs, employees and contractors, the business activities of our suppliers, distributors, customers and other business partners, as well as the effects on worldwide economies, financial markets, social institutions, labor markets and healthcare systems;

•Our ability to continue to ~~increase segment penetration for~~grow the appropriate use of DEFINITY in suboptimal echocardiograms in the face of ~~increased~~ segment competition from other echocardiography contrast agents, including Optison from GE Healthcare Limited (“GE Healthcare”) and Lumason from Bracco Diagnostics Inc. (“Bracco”), and ~~future~~potential generic competition as a result of patent and regulatory exclusivity expirations;

~~Risks associated with revenues~~•The instability of the global Mo-99 supply, including (i) periodic outages at the NTP Radioisotopes (“NTP”) processing facility in South Africa in 2017, 2018 and ~~unit volumes for Xenon~~2019, and (ii) a recently resolved production volume limitations at the Australian Nuclear Science and Technology Organisation’s (“ANSTO”) new Mo-99 processing facility in ~~pulmonary studies and~~Australia, in each case resulting in our inability to fill some or all of the ~~potential competition in this generic segment from Curium (formerly known as Mallinckrodt Nuclear Imaging; purchased by IBA Molecular in January 2017 and renamed Curium in April 2017);~~

~~Our dependence on key customers~~demand for our medical imaging products, and our ability to maintain and profitably renew our contracts with those key customers, including Cardinal Health (“Cardinal”), United Pharmacy Partners (“UPPI”), GE Healthcare and Triad Isotopes (“Triad”);TechneLite generators on certain manufacturing days during the outage periods;

•Our dependence upon third parties for the manufacture and supply of a substantial portion of our products, raw materials and components, including DEFINITY at JHS;

•Risks related to the integration of the Progenics Transaction, including:

•The integration of the Progenics Transaction may involve unexpected costs, liabilities or delays;

•The ability of our combined business to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom we or Progenics do business,

•Unanticipated risks to our integration plan including in connection with timing, talent, and the potential need for additional resources;

•New or previously unidentified manufacturing, regulatory, or research and development issues in the Progenics business;

•Risks that the anticipated benefits of the Progenics Transaction or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected;

•Risks that contractual contingent value rights (“CVRs”) we issued as part of the Progenics Transaction may result in substantial future payments and could divert the attention of our management; and

•The impact of legislative, regulatory, competitive and technological changes on the combined business;

Table of Contents

•Risks related to the commercialization of AZEDRA, including in connection with market acceptance and reimbursement, that may cause the product not to meet revenue or operating income expectations;

•Risks related to RELISTOR, commercialized by Bausch, and that the revenues generated for us thereby may not meet expectations;

•The extensive costs, time and uncertainty associated with the development of new products, such as PyL, including further product development relying on external development partners or developing internally;

•Our ability to identify and acquire or in-license additional products, businesses or technologies to drive our future growth;

•Our ability to protect our intellectual property and the risk of claims that we have infringed on the intellectual property of others;

•Risks associated with the technology transfer programs to secure production of our products at ~~alternate~~additional contract manufacturer sites, including a ~~next generation~~modified formulation of DEFINITY ~~product~~ at Samsung BioLogics (“SBL”) in South Korea;

•Risks associated with our investment in, and construction of, additional specialized manufacturing capabilities at our North Billerica, Massachusetts facility, including our ability to bring the new capabilities online by 2021;

•Our dependence on key customers for certain of our products, and our ability to maintain and profitably renew our contracts with those key customers, including GE Healthcare, Cardinal Health (“Cardinal”), United Pharmacy Partners (“UPPI”), Jubilant Radiopharma formerly known as Triad Isotopes, Inc. (“Jubilant Radiopharma”) and PharmaLogic Holdings Corp (“PharmaLogic”);

•Risks associated with our lead agent in development, PyL, including:

•Our ability to file our New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) later in 2020;

•Our ability to obtain FDA approval of PyL in 2021; and

•Our ability to successfully commercialize PyL in North America and on a global basis (other than Europe, where the agent has been previously out-licensed to Curium, and in Australia and New Zealand, where we do not have commercialization rights).

•Risks associated with flurpiridaz F 18, which in 2017 we out-licensed to GE Healthcare, including:

•GE Healthcare’s ability to successfully complete the Phase 3 development program, including delays in enrollment that have resulted from the COVID-19 pandemic;

•GE Healthcare’s ability to obtain Food and Drug Administration (“FDA”) approval; and

•GE Healthcare’s ability to gain post-approval market acceptance and adequate reimbursement;

•Risks associated with 1095, including delays in enrollment that have resulted from the COVID-19 pandemic and our ability to successfully complete the Phase 2 study in mCRPC;

•Risks associated with the manufacturing and distribution of our products and the regulatory requirements related thereto;

~~The instability of the global Molybdenum-99 (“Moly”) supply;~~

•The dependence of certain of our customers upon third-party healthcare payors and the uncertainty of third-party coverage and reimbursement rates;

•The existence and market success of competitor products;

•Uncertainties regarding the impact of ~~on-going~~ U.S. and state healthcare reform measures and proposals on our business, including measures and proposals related ~~reimbursements~~to reimbursement for our current and potential future ~~products;~~products, controls over drug pricing, drug pricing transparency and generic drug competition;

•Our being subject to extensive government regulation and oversight, our ~~potential inability~~ability to comply with those ~~regulations;~~regulations and the costs of compliance;

•Potential liability associated with our marketing and sales practices;

•The occurrence of any serious or unanticipated side effects with our products;

•Our exposure to potential product liability claims and environmental, health and safety liability;

~~Risks associated with our lead agent in development, flurpiridaz F 18, including:~~


▪	~~The~~•Our ability ~~of GE Healthcare to successfully complete the Phase III development program;~~


▪	~~The ability to obtain Food and Drug Administration (“FDA”) approval; and~~


▪	~~The ability to gain post-approval market acceptance and adequate reimbursement;~~

~~The extensive costs, time and uncertainty associated with new product development, including further product development relying on external development partners or potentially developed internally;~~

~~Our inability~~ to introduce new products and adapt to an evolving technology and ~~diagnostic~~medical practice landscape;

~~Our inability to identify and in-license or acquire additional products to grow our business;~~

~~Our inability to protect our intellectual property and the risk of claims that we have infringed on the intellectual property of others;~~

•Risks associated with prevailing economic or political conditions and events and financial, business and other factors beyond our control;

Table of Contents

•Risks associated with our international ~~operations;~~operations, including potential global disruptions in air transport due to COVID-19, which could adversely affect our international supply chains for radioisotopes and other critical materials as well as international distribution channels for our commercial products;

•Our ~~inability~~ability to adequately qualify, operate, maintain and protect our facilities, equipment and technology infrastructure;

•Our ~~inability~~ability to hire or retain skilled employees and key personnel;

~~Risks related to our outstanding indebtedness and our~~•Our ability ~~to satisfy those obligations;~~

~~Costs and other risks associated with the Sarbanes-Oxley Act and the Dodd-Frank Act;~~

~~Our inability~~ to utilize, or limitations in our ability to utilize, net operating loss carryforwards to reduce our future tax liability;

•Risks related to our outstanding indebtedness and our ability to satisfy those obligations;

•Costs and other risks associated with the Sarbanes-Oxley Act and the Dodd-Frank Act, including in connection with becoming a large accelerated filer as of December 31, 2019;

•Risks related to the ownership of our common stock; and

•Other factors that are described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2016 and~~2019, in Part ~~II—~~II, Item 1A. “Risk Factors” ofin our Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q.

Factors that could cause or contribute to such differences include, but are not limited to, those that are discussed in other documents we file with the SEC. Any forward-looking statement made by us in this Quarterly Report on Form 10-Q speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

~~Investor~~Available Information

Our global Internet site is www.lantheus.com. We routinely make available important information, including copies of our ~~annual, periodic~~Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and ~~current~~amendments to those reports filed or furnished ~~with the SEC under~~pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after those reports are electronically filed with, or furnished to, the SEC, free of charge on our website at ~~http://~~www.investor.lantheus.com. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Quarterly Report on Form 10-Q, and any website references are not intended to be made through active hyperlinks.

Our reports filed with, or furnished to, the SEC are also available on the SEC’s website at www.sec.gov, and for Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, in an iXBRL (Inline Extensible Business Reporting Language) format. iXBRL is an electronic coding language used to create interactive financial statement data over the Internet. The information on our website is neither part of nor incorporated by reference in this Quarterly Report on Form 10-Q.

The following discussion and analysis of our financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of this Quarterly Report on Form 10-Q as well as the other factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2019, and in Part ~~II—~~II, Item ~~1A.~~IA. “Risk Factors” ofin our Quarterly Report on Form 10-Q for the period ended March 31, 2020, and Part II, Item IA. “Risk Factors” in this Quarterly Report on Form 10-Q.

Overview

Our Business

We are a global leader in the development, manufacture and commercialization of innovative diagnostic ~~medical imaging~~and therapeutic agents and products that assist clinicians in the diagnosis and treatment of ~~cardiovascular~~heart disease, cancer and other diseases. ~~Clinicians use~~For our ~~imaging~~diagnostic agents, ~~and products across a range of imaging modalities, including echocardiography and nuclear imaging. We~~we believe that the resulting improved diagnostic information enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs for payers and the entire healthcare system.

Our commercial products are used by cardiologists, nuclear physicians, radiologists, oncologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. We sell our products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices.

We sell our products globally and ~~have operations~~operate our business in two reportable segments, which are further described below:

Table of Contents

•U.S. Segment produces and markets our agents and products throughout the U.S. In the U.S., we primarily sell to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices.

•International Segment operations consist of production and distribution activities in Puerto Rico and ~~Canada~~some direct distribution activities in Canada. Additionally, within our International Segment, we have established and maintain third-party distribution relationships under which different products are marketed and sold in Europe, Canada, Australia, ~~Asia Pacific~~Asia-Pacific and Latin America.

Acquisition of Progenics

On June 19, 2020, pursuant to the Merger Agreement among Holdings, Merger Sub and Progenics, we completed the acquisition of Progenics, by means of a merger of Merger Sub with and into Progenics, with Progenics surviving the merger as a wholly-owned subsidiary of Holdings. Immediately thereafter, Holdings contributed the shares of Progenics to LMI so that Progenics is now a wholly-owned subsidiary of LMI.

Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer. Progenics’ portfolio of products and product candidates includes therapeutic agents designed to target cancer (AZEDRA, 1095 and PSMA TTC), as well as imaging agents designed to target PSMA for prostate cancer (PyL and 1404). Progenics’ current revenue is generated from two principal sources: first AZEDRA sales, and second, royalties, development and commercial milestones from strategic partnerships, in particular royalties from Bausch from sales of RELISTOR.

In accordance with the Merger Agreement, each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the transaction was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one CVR. Former Progenics stockholders received cash in lieu of any fractional shares of Holdings common stock.

In addition, in accordance with the Merger Agreement, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received (i) an option to purchase Holdings common stock (each, a “Lantheus Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested at the time of the transaction. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received a Lantheus Stock Option converted on an exchange ratio determined based on the average of the volume weighted average price per share of common stock of Progenics and Holdings prior to the transaction, which exchange ratio was 0.31.

Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders in connection with the Merger. Holdings also assumed 34,000 in-the-money Progenics stock options and 6,507,342 out-of-the-money Progenics stock options, each converted into Lantheus Stock Options at the exchange ratios noted above.

As a result of the Progenics Transaction, Lantheus added the following products and product candidates to its portfolio:

Table of Contents

Product / Product Candidate

Description

Status

Market

Rights

Ultra-Orphan Theranostic

AZEDRA (iobenguane I 131) 555 MBq/mL injection

Unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma

Approved

U.S

Progenics

Prostate Cancer Theranostics

PyL (18F-DCFPyL)

PSMA-targeted PET/CT imaging agent for prostate cancer

Preparing NDA

Worldwide (ex. EU, AU, & NZ)

Progenics

PyL (18F-DCFPyL)

PSMA-targeted PET/CT imaging agent for prostate cancer

Discussions with European Medicines Agency (EMA)

Europe

Curium

1095 (I 131 1095)

PSMA-targeted small molecule therapeutic for treatment of metastatic prostate cancer

Phase 2

Worldwide

Progenics

PSMA TTC (BAY 2315497)

PSMA-targeted antibody conjugate therapeutic for treatment of metastatic prostate cancer

Phase 1

Worldwide

Bayer

1404

Technetium-99m PSMA-targeted SPECT/CT imaging agent for prostate cancer

Discussions with EMA

Europe

ROTOP

Digital Technology

PSMA AI

Imaging analysis technology that uses artificial intelligence and machine learning to assist readers in the quantification and standardized reporting of PSMA-targeted imaging

Investigational Use Only

Worldwide

Progenics

Automated Bone Scan Index (aBSI)

Automated reading and quantification of bone scans of prostate cancer patients using artificial intelligence and deep learning

Approved in the U.S. and E.U. 510(k) cleared in the U.S. CE marked (E.U. countries)

Worldwide (ex. Japan)

Progenics

Automated Bone Scan Index (BONENAVI)

Automated reading and quantification of bone scans of prostate cancer patients using artificial intelligence and deep learning

Approved

Japan

FUJIFILM

Other Programs

RELISTOR Subcutaneous Injection (methylnaltrexone bromide)

OIC in adults with chronic non-cancer pain or advanced-illness adult patients

Approved

Worldwide

Bausch

RELISTOR Tablets (methylnaltrexone bromide)

OIC in adults with chronic non-cancer pain

Approved

U.S.

Bausch

Leronlimab (PRO 140)

HIV Infection

CytoDyn intends to request Type A meeting with FDA to discuss BLA

U.S.

CytoDyn

See Part I, Item 1A. “Risk Factors” in our Annual Report on form 10-K for the year ended December 31, 2019, and Part II, Item 1A. “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2020 for information regarding certain risks associated with our proposed acquisition of Progenics.

Our ~~Product~~Expanded Portfolio

Our ~~product portfolio includes an ultrasound contrast agent and nuclear imaging products. Our principal~~commercial products now include the following:

•DEFINITY is ~~an ultrasound~~a microbubble contrast agent used in ultrasound exams of the heart, also known as echocardiography exams. DEFINITY contains perflutren-containing lipid microspheres and is indicated in the U.S. for use in patients with suboptimal echocardiograms to assist in imaging the left ventricular chamber and left endocardial border of the heart in ultrasound procedures. We ~~launched DEFINITY in 2001, and~~believe we are currently the leading provider of ultrasound microbubble contrast agents in the U.S., its composition of matter patent will expire in 2019, its manufacturing patent will expire in 2021, and a new method of use patent will expire in 2037. In numerous foreign jurisdictions, patent protection or regulatory exclusivity will currently expire in 2019. We also have an active next generation development program for this agent including pursuing additional indications, new patent protection, and new formulations, but we can give no assurance that the program will be successful or that additional patents will protect the agent.world.

•TechneLite is a ~~technetium~~Technetium (“Tc-99m”) generator ~~which~~that provides the essential nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other ~~technetium-based~~Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures. TechneLite uses ~~Moly~~Mo-99 as its active ingredient.

•Neurolite is an injectable, Tc-99m-labeled imaging agent used with SPECT technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

Table of Contents

•Xenon Xe 133 Gas (“Xenon”) is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also ~~for imaging~~to image cerebral blood flow. Our Xenon is manufactured by a ~~third-party~~third party as a bi-product of Mo-99 production and is processed and finished by us. We believe we are currently the leading provider of Xenon in the U.S.

•FDG is an injectable, fluorine-18-radiolabeled imaging agent used with PET technology to identify and characterize tumors in patients undergoing oncologic diagnostic procedures. We manufacture and distribute FDG from our Puerto Rico radiopharmacy.

•Cardiolite, also known by its generic name sestamibi, is an injectable, Tc-99m-labeled imaging agent used in myocardial perfusion imaging (“MPI”) procedures to assess blood flow to the muscle of the heart using SPECT. Cardiolite was approved by the FDA in 1990 and its market exclusivity expired in July 2008. Included in Cardiolite revenues are branded Cardiolite and generic sestamibi revenues.

•Thallium TI 201 is an injectable radiopharmaceutical imaging agent used in MPI studies to detect cardiovascular disease. We manufacture Thallium using cyclotron technology.

•Gallium (Ga 67) is an injectable radiopharmaceutical imaging agent used to detect certain infections and cancerous tumors, especially lymphoma. We manufacture Gallium using cyclotron technology.

•AZEDRA (iobenguane I 131) is a radiotherapeutic, approved for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. AZEDRA is the first and only FDA-approved therapy for this indication.

•RELISTOR (methylnaltrexone bromide) is a treatment for opioid-induced constipation (“OIC”) that decreases the constipating side effects induced by opioid pain medications such as morphine and codeine without diminishing their ability to relieve pain. RELISTOR is approved in two forms: a subcutaneous injection (12 mg and 8 mg) and an oral tablet (450 mg once daily).

•Quadramet is an injectable radiopharmaceutical used to treat severe bone pain associated with osteoblastic metastatic bone lesions. We serve as the direct manufacturer and supplier of Quadramet in the U.S.

•Automated Bone Scan Index (“aBSI”) calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans and automatically calculating the bone scan index value, representing the disease burden of prostate cancer shown on the bone scan. This quantifiable and reproducible calculation of the bone scan index value is intended to aid in the diagnosis and treatment of men with prostate cancer and may have utility in monitoring the course of the disease. The Japanese rights to the stand-alone aBSI have been transferred and sold to FUJIFILM Toyama Chemical Co. Ltd. (“FUJIFILM”) under the name BONENAVI®. The cloud based aBSI was cleared by the FDA for clinical use in the U.S. on August 5, 2019. In February 2020, Progenics received CE marking for the standalone workstation model of aBSI, meeting the quality standards set by the European Economic Area.

•Cobalt (Co 57) is a non-pharmaceutical radiochemical used in the manufacture of sources for the calibration and maintenance of SPECT imaging cameras.

Sales of our microbubble contrast agent, DEFINITY, are made in the U.S. and Canada through ~~our~~a DEFINITY direct sales ~~team of approximately 80 employees.~~team. In the U.S., our nuclear imaging products, including TechneLite, Xenon, Neurolite and Cardiolite, are primarily distributed through commercial radiopharmacies, the majority of which are controlled by or associated with GE Healthcare, Cardinal, UPPI, ~~GE Healthcare~~Jubilant Radiopharma and ~~Triad.~~PharmaLogic. A small portion of our nuclear imaging product sales in the U.S. are made through our direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities. ~~Outside the U.S., we~~We own one radiopharmacy in Puerto Rico where we sell our own products as well as products of third parties to end-users.

~~In January 2016,~~ AZEDRA is also sold in the U.S. through an AZEDRA direct sales team. RELISTOR was licensed to Bausch, and we ~~sold our Canadian radiopharmacies to Isologic Innovative Radiopharmaceuticals Ltd. (“Isologic”) and entered into a supply agreement under which we supply Isologic with certain of our products~~collect quarterly royalties based on commercial terms, including certain product purchase commitments by Isologic. In August 2016, we sold our Australian radiopharmacy servicing business to Global Medical Solutions (“GMS”), and entered into a supply agreement under which we supply GMS with certain of our products on commercial terms, including certain minimum product purchase commitments by GMS.their sales.

We also maintain our own direct sales force in Canada ~~so that we can control the importation, marketing, distribution and sale~~for certain of our ~~imaging agents in Canada.~~products. In Europe, Australia, ~~Asia Pacific~~Asia-Pacific and Latin America, we generally rely on third-party distributors to market, sell and distribute our nuclear imaging and contrast agent products, either on a country-by-country basis or on a multi-country regional basis. Our headquarters are located in North Billerica, MA with offices in New York, NY, Somerset, NJ, San Juan, PR, Montreal, Canada and Lund, Sweden.

~~The following table sets~~ ~~forth~~Product Candidates

In addition to our ~~revenues derived from our principal products:~~commercial products, we now have an extensive portfolio of product candidates in clinical development, including:

•PyL (also known as 18F-DCFPyL) is a fluorine 18-based PSMA-targeted PET imaging agent that enables visualization of both bone and soft tissue metastases, with potential high clinical utility in the detection of recurrent and/or metastatic prostate

Table of Contents

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017
% of
Revenues
2016
% of
Revenues
2017
% of
Revenues
2016
% of
Revenues
DEFINITY $ 37,729
47.2 % $ 32,604
44.6 % $ 115,569
46.2 % $ 97,499
42.9 %
TechneLite 26,356
33.0 % 24,533
33.6 % 79,900
31.9 % 74,621
32.8 %
Xenon 7,726
9.6 % 6,677
9.1 % 23,713
9.5 % 21,625
9.5 %
Other 8,130
10.2 % 9,249
12.7 % 30,955
12.4 % 33,758
14.8 %
Total revenues $ 79,941
100.0 % $ 73,063
100.0 % $ 250,137
100.0 % $ 227,503
100.0 %
cancer, as well as staging of high risk disease. Progenics has completed a clinical development program that consisted of two pivotal clinical studies, which were designed to provide robust, prospective, well-controlled, and pathology- or composite truth standard-verified data to establish the safety and diagnostic performance of PyL across the disease continuum of prostate cancer. The results from these studies provide data in support of the potential of PyL to reliably detect and localize disease, including in patients with low PSA values, and may help enable appropriate disease management, thus supporting the potential use for detection of recurrent or metastatic prostate cancer. Progenics completed two successful pre-NDA meetings with the FDA in the first quarter of 2020, and we intend to submit the PyL NDA to the FDA later in 2020.

•Flurpiridaz F 18 is a fluorine 18-based PET MPI agent to assess blood flow to the heart. On April 25, 2017, we announced entering into a definitive, exclusive Collaboration and License Agreement with GE Healthcare for the agent’s continued Phase 3 development and worldwide commercialization. The second Phase 3 trial is now underway; however, because of the COVID-19 pandemic, enrollment in the global clinical development program has been delayed. GE Healthcare now expects to complete enrollment by mid-2021 and, assuming regulatory approval, begin commercialization in early 2023.

•LMI 1195 is a fluorine 18-based PET imaging agent for the norepinephrine pathway. We are currently designing two Phase 3 clinical trials for the use of LMI 1195 for the diagnosis and management of neuroendocrine tumors in pediatric and adult populations, respectively. The FDA has granted an Orphan Drug designation for the use of LMI 1195 in the management indication. We have also received notice of eligibility for a rare pediatric disease priority review voucher for a subsequent human drug application so long as LMI 1195 is approved by the FDA for its rare pediatric disease indication prior to September 30, 2022.

•1095 (also known as I-131-1095) is a PSMA-targeted iodine-131 labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. Following the removal of the import alert on Centre for Probe Development & Commercialization (“CPDC”), Progenics initiated eleven clinical sites in the U.S along with the six active sites in Canada to support enrollment in the Company’s multicenter, randomized, controlled, ARROW Phase 2 study in metastatic castration-resistant prostate cancer (“mCRPC”). Because of the COVID-19 pandemic, Progenics paused new enrollment in the Phase 2 trial to minimize the risk to subjects and healthcare providers during the pandemic. For subjects who are active and have been randomized for the study, they continue to receive treatment doses and are being monitored for safety and efficacy in a manner that is permissible by each clinical site.

•PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic. PSMA TTC is designed to deliver a dose of alpha radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. Bayer AG (“Bayer”) has exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology in combination with Bayer’s alpha-emitting radionuclides. Bayer is conducting a Phase 1 trial of PSMA TTC in subjects with mCRPC.

•1404 is a Tc-99m labeled small molecule which binds to PSMA and is used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer as well as soft tissue and bone metastases. ROTOP has exclusive rights to develop, manufacture and commercialize 1404 in Europe.

•PSMA AI is an imaging analysis technology that uses artificial intelligence and machine learning to assist readers in the quantification and standardized reporting of PSMA-targeted imaging. Progenics recently completed a performance study of automated segmentation algorithms with PyL/CT images from the PyL research access initiative. The study demonstrated the efficiency and effectiveness of a fully automated segmentation algorithm of the 49 bones and 12 soft tissue regions of the whole body from PyL-PSMA PET/CT images. This work provides automated generation of lesion quantification, localization and staging, leading to highly contextualized assessments of disease burden.

•Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases. It is owned by CytoDyn Inc. (“CytoDyn”) pursuant to our agreement with CytoDyn, as described below. In May 2020, CytoDyn announced it submitted a Biologics License Application (“BLA”) to the FDA for approval of Leronlimab in combination therapy for HIV infection. On July 13, 2020, CytoDyn announced that it had received a refusal to file letter from the FDA for the BLA and that CytoDyn intends to request a Type A meeting with the FDA to discuss the FDA’s request for additional information.

Strategic Partnerships

In connection with our commercial products and product candidates, we now have a number of strategic partnerships, including:

•Bausch Agreement -- Under its agreement with Salix Pharmaceuticals, Inc., a wholly-owned subsidiary of Bausch, Progenics received a $40 million development milestone upon U.S. marketing approval for subcutaneous RELISTOR in non-cancer pain patients in 2014, a $50 million development milestone for the U.S. marketing approval of an oral formulation of RELISTOR in July 2016, and a $10.0 million sales milestone for RELISTOR achieving U.S. net sales in excess of $100.0 million in 2019. We are also eligible to receive additional one-time sales milestone payments upon achievement of specified U.S. net sales targets, including:

Table of Contents


U.S. Net Sales Levels in any Single Calendar Year						Payment ($)
						(In thousands)
In excess of $150 million						15,000
In excess of $200 million						20,000
In excess of $300 million						30,000
In excess of $750 million						50,000
In excess of $1 billion						75,000

Each sales milestone payment is payable one time only, regardless of the number of times the condition is satisfied, and all six payments could be made within the same calendar year. We are also eligible to receive royalties from Bausch and its affiliates based on the following royalty scale: 15% on worldwide net sales up to $100 million, 17% on the next $400 million in worldwide net sales, and 19% on worldwide net sales over $500 million each calendar year, and 60% of any upfront, milestone, reimbursement or other revenue (net of costs of goods sold, as defined, and territory-specific research and development expense reimbursement) Bausch receives from sublicensees outside the U.S.

•GE Healthcare Agreement – Under our April 2017 Collaboration and License Agreement, GE Healthcare will complete the worldwide development of flurpiridaz F 18, pursue worldwide regulatory approvals, and, if successful, lead a worldwide launch and commercialization of the agent, with us collaborating on both development and commercialization through a joint steering committee. We also have the right to co-promote the agent in the U.S. GE Healthcare’s development plan initially focuses on obtaining regulatory approval in the U.S., Japan, Europe and Canada. Under the agreement, we received an upfront cash payment of $5 million and are eligible to receive up to $60 million in regulatory and sales milestone payments, tiered double-digit royalties on U.S. sales, and mid-single digit royalties on sales outside of the U.S.

•Curium Agreement – Curium has licensed exclusive rights to develop and commercialize PyL in Europe. Under the terms of the collaboration, Curium is responsible for the development, regulatory approvals and commercialization of PyL in Europe, and we are entitled to royalties on net sales of PyL. Curium is in discussions with EMA regarding the development path in Europe.

•Bayer Agreement – Under Progenics’ April 2016 agreement with a subsidiary of Bayer granting Bayer exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology, in combination with Bayer’s alpha-emitting radionuclides, Progenics received an upfront payment of $4.0 million and milestone payments totaling $5.0 million. We could receive up to an additional $44.0 million in potential clinical and development milestones. We are also entitled to single-digit royalties on net sales, and potential net sales milestone payments up to an aggregate of $130.0 million.

•CytoDyn Agreement -- Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases. Progenics sold Leronlimab to CytoDyn in 2012, which sale included milestone and royalty payment obligations to Progenics. Under the 2012 agreement, CytoDyn is responsible for all development, manufacturing and commercialization efforts. Pursuant to such agreement, Progenics received $5.0 million in upfront and milestone payments, and we have the right to receive an additional $5.0 million upon the first U.S. or E.U. approval for the sale of the drug, and a 5% royalty on the net sales of approved products.

•ROTOP Agreement -- In May 2019, Progenics entered into an exclusive license agreement with ROTOP, a Germany-based developer of radiopharmaceuticals for nuclear medicine diagnostics, to develop, manufacture and commercialize 1404 in Europe. Under the terms of the collaboration, ROTOP is responsible for the development, regulatory approvals and commercialization of 1404 in Europe while we are entitled to double-digit, tiered royalties on net sales of 1404 in Europe. ROTOP is in discussions with EMA regarding the development path in Europe.

•FUJIFILM Agreement -- In June 2019, Progenics entered into a transfer agreement with FUJIFILM for the rights to the aBSI product in Japan for use under the name BONENAVI. Under the terms of the transfer agreement, FUJIFILM acquired, by a combination of purchase and license, the Japanese software, source code, supporting data and all Japanese patents associated with the aBSI product from Progenics for use in Japan. In exchange, Progenics received $4.0 million in an upfront payment and FUJIFILM agreed to pay Progenics support and service fees for aBSI and other AI products over the next three years in Japan. BONENAVI has been licensed to FUJIFILM for use in Japan since 2011.

Table of Contents

Key Factors Affecting Our Results

Our business and financial performance have been, and continue to be, affected by the following:

COVID-19 Pandemic

The global COVID-19 pandemic has had, and will continue to have, a material impact on our business. Towards the end of the first quarter of 2020 we began to experience, and through the date of this filing we are continuing to experience, impacts to our business and operations related to the COVID-19 pandemic, including the impact of stay-at-home mandates and advisories, and a decline in the volume of procedures and treatments using our products. We cannot predict the magnitude or duration of the pandemic’s impact on our business.

As a result of the COVID-19 pandemic, we undertook a thorough analysis of all of our discretionary expenses. In the first quarter of 2020 we implemented certain cost reduction initiatives, including, among other things, reducing travel and promotional expenses and implementing a hiring freeze through the balance of 2020. In addition, effective April 13, 2020, we reduced our work week from five days to four days in order to better align manufacturing, supply, distribution and other activities with reduced product demand. We also reduced pay for our personnel, including a 75% reduction for Mary Anne Heino, our President and Chief Executive Officer, a 35% reduction for members of our executive team, a 25% reduction for our vice presidents, and across-the-board reductions of 20% of salaries for our other salaried employees and 20% of hours for our hourly employees for that same time period. In addition, our Board of Directors has also reduced director and committee member compensation by 35% for the second half of the year and has elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units that will vest on the first anniversary of the grant date, rather than in cash. In the latter half of June 2020, we restored our work week back to five days and restored most salaries back to 100% (other than executive team members whose salaries were restored in early July and directors whose compensation will remain at reduced levels for the balance of the calendar year).

We can give no assurances that we will not have to take additional cost reduction measures if the pandemic continues to adversely affect the volume of procedures and treatments using our products.

During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives, including reducing promotional spending and furloughing a portion of its field-based AZEDRA commercial operations and medical employees. Progenics also furloughed several of its clinical employees. The commercial and medical employees were returned to full service with Progenics as of June 22, 2020. In addition, Progenics paused new enrollment in the Phase 2 trial of 1095 in mCRPC patients to minimize the risk to subjects and healthcare providers during the pandemic.

GE Healthcare, our development and commercialization partner for flurpiridaz F 18, also delayed enrollment in the second Phase 3 clinical trial because of the pandemic and has informed us that it now intends to resume enrollment in the third quarter of 2020.

While we are currently unable to estimate the impact of COVID-19 on our overall 2020 operations and financial results, we ended the second quarter of 2020 with $90.3 million of cash and cash equivalents. With our available liquidity and prudent expense management, we believe we will be able to maintain a state of preparedness to resume full business activities to support our customers as external conditions allow, although we can give no assurances that we will have sufficient liquidity if the pandemic continues to adversely affect the volume of procedures and treatments using our products for an extended period of time.

Anticipated Continued Growth of DEFINITY and Expansion of Our Ultrasound Microbubble Franchise

We believe the market opportunity for our ultrasound microbubble contrast agent, DEFINITY, ~~remains~~continues to be significant. DEFINITY is ~~currently~~ our fastest growing and highest margin commercial product. We ~~believe that~~anticipate DEFINITY sales will continue to grow ~~and that DEFINITY will constitute a greater share of our overall product mix.~~over the longer term. As we ~~better~~continue to educate the physician and healthcare provider community about the benefits and risks of ~~this product,~~DEFINITY, we believe we will ~~experience further penetration of suboptimal echocardiograms.~~

~~The future~~ ~~growth of our DEFINITY sales will~~ be ~~dependent on our ability~~able to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms and, as discussed below in “—Inventory Supply,” on the ability of JHS to continue to manufacture and release DEFINITY on a timely and consistent basis. See “Part II—Item 1A. Risk Factors—The growth of our business is substantially dependent on increased market penetration forgrow the appropriate use of DEFINITY in suboptimal echocardiograms.”

~~There are~~ In a U.S. market with three echocardiography contrast agents approved by the FDA, ~~for sale in the U.S.—~~we estimate that DEFINITY ~~which we estimated as having approximately~~had over 80% of the ~~U.S.~~ market ~~for contrast agents in echocardiography procedures~~ as of December 31, ~~2016, Optison from GE Healthcare~~2019.

As we continue to pursue expanding our microbubble franchise, our activities include:

•Patents - We continue to actively pursue additional patents in connection with DEFINITY, both in the U.S. and ~~Lumason from Bracco.~~internationally. In the U.S., three of our recently issued method of use patents covering DEFINITY were listed in the Orange Book. We now have a total of four Orange Book-listed method of use patents, one of which expires in 2035 and three of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2021, 2023 and 2037. Outside of the U.S., while our DEFINITY patent protection and regulatory exclusivity have generally expired, we are currently prosecuting additional patents to try to obtain similar method of use and manufacturing patent protection as granted in the U.S.

~~Competition~~

Table of Contents

Hatch-Waxman Act - Even though our longest duration Orange Book-listed DEFINITY patent extends until March 2037, because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers in the near to intermediate term. Under the Hatch-Waxman Act, the FDA can approve Abbreviated New Drug Applications (“ANDAs”) for ~~Xenon~~

~~Xenon gas for lung ventilation diagnosis~~generic versions of drugs if the ANDA applicant demonstrates, among other things, that (i) its generic candidate is ~~our third largest~~the same as the innovator product by ~~revenues.~~establishing bioequivalence and providing relevant chemistry, manufacturing and product data, and (ii) the marketing of that generic candidate does not infringe an Orange Book-listed patent. With respect to any Orange Book-listed patent covering the innovator product, the ANDA applicant must give a notice to the innovator (a “Notice”) that the ANDA applicant certifies that its generic candidate will not infringe the innovator’s Orange Book-listed patent or that the Orange Book-listed patent is invalid. The innovator can then challenge the ANDA applicant in court within 45 days of receiving that Notice, and FDA approval to commercialize the generic candidate will be stayed (that is, delayed) for up to 30 months (measured from the date on which a Notice is received) while the patent dispute between the innovator and the ANDA applicant is resolved in court. The 30 month stay could potentially expire sooner if the courts determine that no infringement had occurred or that the challenged Orange Book-listed patent is invalid or if the parties otherwise settle their dispute.

As of the date of filing of this Quarterly Report on Form 10-Q, we have not received any Notice from an ANDA applicant. If we were to (i) receive any such Notice in the future, (ii) bring a patent infringement suit against the ANDA applicant within 45 days of receiving that Notice, and (iii) successfully obtain the full 30 month stay, then the ANDA applicant would be precluded from commercializing a generic version of DEFINITY prior to the expiration of that 30 month stay period and, potentially, thereafter, depending on how the patent dispute is resolved. Solely by way of example and not based on any knowledge we currently have, if we received a Notice from an ANDA applicant in August 2020 and the full 30 month stay was obtained, then the ANDA applicant would be precluded from commercialization until at least January 2023. If we received a Notice some number of months in the future and the full 30 month stay was obtained, the commercialization date would roll forward in the future by the same calculation.

•Modified Formulation - We are developing at SBL a modified formulation of DEFINITY. We believe this modified formulation will provide an enhanced product profile enabling storage as well as shipment at room temperature (DEFINITY’s current formulation requires refrigerated storage), will give clinicians additional choice, and will allow for greater utility of this formulation in broader clinical settings. We have a composition of matter patent on the modified formulation which runs through 2035. If the modified formulation is approved by the FDA, then this patent would be eligible to be listed in the Orange Book. We currently believe that, if approved by the FDA, the modified formulation could become commercially available in early 2021, although that timing cannot be assured. Given its physical characteristics, the modified formulation may also be well suited for inclusion in kits requiring microbubbles for other indications and applications (including in kits developed by third parties of the type described in the next paragraph).

•New Clinical Applications - As we continue to look for other opportunities to expand our microbubble franchise, we are evaluating new indications and clinical applications beyond echocardiography and contrast imaging generally. For example, in April 2019, we announced a strategic development and commercial collaboration with Cerevast Medical, Inc. (“Cerevast”) in which our microbubble will be used in connection with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Retinal vein occlusion is one of the most common causes of vision loss worldwide. In ~~order to increase~~December 2019, we announced a strategic commercial supply agreement with CarThera for the ~~predictability~~use of our ~~Xenon business,~~microbubbles in combination with SonoCloud, a proprietary implantable device in development for the treatment of recurrent glioblastoma. Glioblastoma is a lethal and devastating form of brain cancer with median survival of 15 months after diagnosis.

•In-House Manufacturing - We have completed construction of specialized, in-house manufacturing capabilities at our North Billerica, Massachusetts facility for DEFINITY and, potentially, other sterile vial products. We believe the investment in these efforts will allow us to better control DEFINITY manufacturing and inventory, reduce our costs in a potentially more price competitive environment, and provide us with supply chain redundancy. We currently expect to be in a position to use this in-house manufacturing capability in 2021, although that timing cannot be assured.

•DEFINITY in China - On March 19, 2020 in connection with our Chinese development and distribution arrangement with Double Crane Pharmaceutical Company, we filed an Import Drug License application with the National Medical Products Administration, or the NMPA, for the use of DEFINITY for the echocardiography indication. We believe this is an important milestone in our efforts to commercialize DEFINITY in China. Double Crane is also in the process of analyzing the clinical results relating to the liver and kidney indications and will also work with us to prepare an Import Drug License application for those indications.

Global Mo-99 Supply

We currently have ~~entered into Xenon~~Mo-99 supply agreements with ~~customers at committed volumes~~Institute for Radioelements (“IRE”), running through December 31, 2022, and ~~reduced prices. These steps~~renewable by us on a year-to-year basis thereafter, and with NTP and ANSTO, running through December 31, 2021. We also have a Xenon supply agreement with IRE which runs through June 30, 2022, and which is subject to further extension.

Table of Contents

Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. The NTP processing facility had periodic outages in 2017, 2018 and 2019. When NTP was not producing, we relied on Mo-99 supply from both IRE and ANSTO to limit the impact of the NTP outages. In the second quarter of 2019, ANSTO experienced technical issues in its existing Mo-99 processing facility which resulted in ~~more predictable Xenon unit volumes. Historically, several companies, including Mallinckrodt Nuclear Imaging (now known~~a decrease in Mo-99 available to us. In addition, as ~~Curium), sold packaged Xenon as a pulmonary imaging agent~~ANSTO transitioned from its existing Mo-99 processing facility to its new Mo-99 processing facility in the ~~U.S., but from 2010 through the first~~second quarter of ~~2016,~~2019, ANSTO experienced start-up and transition challenges, which also resulted in a decrease in Mo-99 available to us. Further, starting in late June 2019 until April 2020, ANSTO’s new Mo-99 processing facility had production volume limitations imposed on it by the Australian Radiation Protection and Nuclear Safety Agency which limited our ability to receive Mo-99 from ANSTO. During that time we ~~were~~relied on IRE and NTP to limit the ~~only supplier~~impact of those ANSTO outages and volume limitations. As ANSTO increases its production volume over the course of 2020, we expect to receive increasing supply from ANSTO. Because of the COVID-19 pandemic, in the second quarter of 2020 we experienced challenges receiving regularly scheduled orders of Mo-99 from our global suppliers due to the partial or complete delay or cancellation of international flights by our airfreight carriers. As of the filing of this ~~imaging agent in~~report, these COVID-19-related transportation challenges have been largely eliminated. Because of these various supply chain constraints, depending on reactor and processor schedules and operations, we have not been able to fill some or all of the ~~U.S.~~demand for our TechneLite generators on certain manufacturing days.

ANSTO’s new Mo-99 processing facility could eventually increase ANSTO’s Mo-99 production capacity from approximately 2,000 curies per week to 3,500 curies per week with additional committed financial and operational resources. At full ramp-up capacity, ANSTO’s new facility could provide incremental supply to our globally diversified Mo-99 supply chain and therefore mitigate some risk among our Mo-99 suppliers, although we can give no assurances to that effect. In March 2016, Mallinckrodt Nuclear Imaging received regulatory approval from the FDA to again sell packaged Xenon in the U.S. Depending upon the pricing, extent of availability and market penetration of such offering,addition, we ~~believe we are at risk for volume loss and price erosion for those customers which are not subject to price or volume commitments~~also have a strategic arrangement with ~~us. See Part I, Item 1A. “Risk Factors —We face potential supply and demand challenges for Xenon” of our Annual Report on Form 10-K~~SHINE Medical Technologies, Inc. (“SHINE”), a Wisconsin-based company, for the ~~year ended December 31, 2016.~~future supply of Mo-99. Under the terms of that agreement, SHINE will provide us Mo-99 once SHINE’s facility becomes operational and receives all necessary approvals, which SHINE now estimates will occur in 2022.

Inventory Supply

We obtain a substantial portion of our imaging agents from a third-party ~~suppliers.~~supplier. JHS is currently our sole source manufacturer of DEFINITY, Neurolite, Cardiolite and evacuation vials, the latter being an ancillary component for our TechneLite generators. We are currently seeking approval from certain foreign regulatory authorities for JHS to manufacture certain of our products. Until we receive these approvals, we will face continued limitations on where we can sell those products outside of the U.S.

In addition to JHS, we are also currently working to secure additional alternative suppliers for our key products as part of our ongoing supply chain diversification strategy. We have ~~on-going~~ongoing development and technology transfer activities for a ~~next generation~~modified formulation of DEFINITY ~~product~~ with SBL, which is located in South ~~Korea, but we~~Korea. We currently believe that if approved by the FDA, the modified formulation could be commercially available in 2021, although that timing cannot be assured. We have also completed construction of specialized, in-house manufacturing capabilities at our North Billerica, Massachusetts facility, as part of a larger strategy to create a competitive advantage in specialized manufacturing, which will also allow us to optimize our costs and reduce our supply chain risk. We can give ~~any assurances~~no assurance as to when or if ~~and when those technology transfer activities~~we will be ~~completed and when~~successful in these efforts or that we will ~~begin~~be able to ~~receive supply of a next generation DEFINITY product from SBL. See Part I, Item 1A. “Risk Factors—Our dependence upon third parties for the~~successfully manufacture ~~and supply of a substantial portion of~~any additional commercial products at our products could prevent us from delivering our products to our customers in the required quantities, within the required timeframes, or at all, which could result in order cancellations and decreased revenues” of our Annual Report on Form 10-K for the year ended December 31, 2016.North Billerica, Massachusetts facility.

Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. These products cannot be kept in inventory because of their limited shelf lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at our North Billerica, Massachusetts facility.

~~Global Isotope Supply~~

We currently have Moly supply agreements with NTP Radioisotopes (“NTP”) of South Africa and ANSTO of Australia, and with Institute for Radioelements (“IRE”) of Belgium, each running through December 31, 2017, and a Xenon supply agreement with IRE which runs through June 30, 2019, subject to extensions.

We believe we are well-positioned with ANSTO, IRE and NTP to have a secure supply of Moly, including low-enriched uranium-based Moly produced from targets containing less than 20% of Uranium-235 (“LEU Moly”). From November 2016, the NRU reactor transitioned from providing regular supply of medical isotopes to providing only emergency back-up supply of highly-enriched uranium-based Moly through March 2018. ANSTO has already significantly increased its Moly production capacity from its existing facility in August 2016 and has under construction, in cooperation with NTP, a new Moly processing facility that ANSTO believes will expand its production capacity, which is expected to be in commercial operation in the first half of 2018. In addition, IRE received approval from its regulator to expand its production capability by up to 50% of its former capacity. The new ANSTO and IRE production capacity is expected to replace and exceed what was the NRU’s most recent routine production.

~~We are receiving bulk unprocessed Xenon from IRE, which we are processing and finishing for our customers. We believe we are well-positioned to supply Xenon to our customers. See Part I, Item 1A. “Risk Factors —We face potential supply and demand challenges for Xenon” of our Annual Report on Form 10-K for the year ended December 31, 2016.~~

~~Demand for TechneLite~~

We believe that due to industry-wide cost containment initiatives that have resulted in a transition of where imaging procedures are performed, from free-standing imaging centers to the hospital setting, the total MPI market has been essentially flat since 2011. Our 2016 sales of TechneLite generators exceeded our expectations because of opportunistic sales when customers could not obtain sufficient generators from other suppliers. We can give no assurances that such opportunistic sales will be replicated in 2017.

In November 2016, CMS announced the 2017 final Medicare payment rules for hospital outpatient settings. Under the final rules, each technetium dose produced from a generator for a diagnostic procedure in a hospital outpatient setting is reimbursed by Medicare at a higher rate if that technetium dose is produced from a generator containing at least 95% LEU Moly. In January 2013, we began to offer a TechneLite generator which contains at least 95% LEU Moly and which satisfies the requirements for reimbursement under this incentive program. Although demand for LEU generators appears to be growing, we do not know when, or if, this incremental reimbursement for LEU Moly generators will result in a material increase in our generator sales.

Research and Development Expenses

To remain a leader in the marketplace, we have historically made substantial investments in new product development. ~~As a result,~~In addition to our flurpiridaz F 18 clinical development program, the ~~positive contributions~~expenses of those internally funded research and development programs have been a key factor in our historical results and success. On April 25, 2017, we announced entering into a definitive, exclusive Collaboration and License Agreement withwhich are now being borne by GE Healthcare, and our proposed LMI 1195 Phase 3 clinical program for the ~~continued~~diagnosis and management of neuroendocrine tumors in pediatric and adult populations, the final plans for which are still being developed, the Progenics Transaction brings additional and substantial clinical development expense. Progenics completed two successful pre-NDA meetings with the FDA in the first quarter of 2020, and we intend to submit the PyL NDA to the FDA later in 2020. For 1095, the ARROW Phase ~~III~~2 study in mCRPC patients has been paused to minimize risk to subjects and healthcare providers during the pandemic. In addition, the Company’s development activities for PSMA AI are on-going. Our investments in these additional clinical activities will increase our operating expenses and ~~worldwide commercialization~~impact our results of ~~flurpiridaz F 18. In the future, we may also seek to engage strategic partners for our 18F LMI 1195~~operations and ~~LMI 1174 programs, or we may choose to partially or fully fund one or more development programs ourselves. See Part I, Item 1. “Business—Research~~cash flow, and Development—Proposed GE Healthcare Transaction” and Part I, Item 1A. “Risk Factors—We may not be able to further develop or commercialize our agents in development without successful strategic partners” of our Annual Report on Form 10-K for the year ended December 31, 2016.

~~Hurricane Maria in Puerto Rico~~

In September 2017, Hurricane Maria devastated Puerto Rico, interrupting power and telecommunications services for most of the island and limiting ground and air transportation. We operate a radiopharmacy in San Juan, Puerto Rico; the building that houses our radiopharmacy sustained minimal external physical damage as a result of the hurricane. From and after September 20, 2017, the number of diagnostic imaging procedures performed on the island has severely declined. While we currently believe that the number of diagnostic imaging procedures performed in Puerto Rico will slowly return to prior levels, we can give no assurances as to whether any of ~~that,~~these clinical development candidates will be approved.

New Initiatives

Table of Contents

In addition to integrating the new assets and ~~failure~~programs resulting from the Progenics Transaction, we continue to seek ways to further expand our portfolio of products and product candidates, evaluating a number of different opportunities to acquire or in-license additional products, product candidates, businesses and technologies to drive our ~~radiopharmacy to return to such prior levels could have a negative effect on~~future growth. As the ~~revenue and cash flow of our business. See Part II, Item 1A. “Risk Factors—In the U.S.,~~Progenics Transaction indicates, we are ~~heavily dependent on a few large customers and group purchasing organization arrangements to generate a majority of~~particularly interested in expanding our ~~revenues for our medical imaging products. Outside of the U.S., we rely primarily on distributors to generate a substantial portion of our revenue.”~~

~~Segments~~

~~We report our results of operations~~presence in ~~two operating segments: U.S. and International. We generate a greater proportion of our revenues and net income~~oncology, in ~~the U.S. segment, which consists of all regions of the U.S. with the exception of Puerto Rico.~~

~~Executive Overview~~

~~Our results for the three and nine months ended September 30, 2017 as compared to the corresponding periods in 2016 reflect the following:~~

~~increased revenues and segment penetration for DEFINITY in the suboptimal echocardiogram segment as a result of our continued focused sales efforts;~~

~~increased revenues for TechneLite, mainly the result of higher contracted volumes from certain customers;~~

~~increased revenues of $5.0 million from GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18;~~

~~lower international revenues and cost of goods sold as a result of the sales of our Canadian and Australian radiopharmacies in 2016;~~

~~increased depreciation expense as a result of the scheduled decommissioning of certain long-lived assets;~~

~~general and administrative expense of $1.7 million incurred in connection with the refinancing of our debt~~radiotherapeutics as well as diagnostics. In May 2019 we entered into a ~~related $2.2 million loss~~strategic collaboration and license agreement with NanoMab Technology Limited, a privately-held biopharmaceutical company focusing on the ~~extinguishment~~development of ~~debt;~~next generation radiopharmaceuticals for cancer precision medicine. We believe this collaboration will provide the first broadly-available imaging biomarker research tool to pharmaceutical companies and academic centers conducting research and development on PD-L1 immuno-oncology treatments, including combination therapies. We can give no assurance as to when or if this collaboration will be successful or accretive to earnings.

~~decreased interest expense due to the refinancing of long-term debt and a lower principal balance on our long-term debt.~~

Results of Operations

The following is a summary of our consolidated results of operations:


	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands)	2020		2019		2020		2019
Revenues	$	66,010	$	85,705	$	156,714	$	172,215
Cost of goods sold	40,162		41,132		92,864		83,558
Gross profit	25,848		44,573		63,850		88,657
Operating expenses
Sales and marketing	6,305		10,948		16,435		21,345
General and administrative	20,670		13,293		37,369		25,882
Research and development	4,418		5,795		8,466		10,724
Total operating expenses	31,393		30,036		62,270		57,951
Operating (loss) income	(5,545)		14,537		1,580		30,706
Interest expense	1,914		4,543		3,860		9,135
Loss on extinguishment of debt	—		3,196		—		3,196
Other income	(756)		(1,312)		(1,106)		(2,499)
(Loss) income before income taxes	(6,703)		8,110		(1,174)		20,874
Income tax expense	309		1,698		2,501		4,513
Net (loss) income	$	(7,012)	$	6,412	$	(3,675)	$	16,361

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017 2016 2017 2016
Revenues $ 79,941
$ 73,063
$ 250,137
$ 227,503
Cost of goods sold 41,414
39,382
125,901
124,370
Gross profit 38,527
33,681
124,236
103,133
Operating expenses
Sales and marketing 10,075
8,706
31,892
27,856
General and administrative 12,076
10,091
35,549
28,842
Research and development 3,554
2,849
14,149
8,493
Total operating expenses 25,705
21,646
81,590
65,191
Gain on sales of assets —
(560 ) —
(6,505 )
Operating income 12,822
12,595
42,646
44,447
Interest expense 4,442
6,792
14,147
20,799
Debt retirement costs —
1,415
—
1,415
Loss on extinguishment of debt —
—
2,161
—
Other (income) expense (908 ) 148
(2,037 ) (317 )
Income before income taxes 9,288
4,240
28,375
22,550
Provision for income taxes 762
20
2,116
657
Net income $ 8,526
$ 4,220
$ 26,259
$ 21,893

Table of Contents

Comparison of the Periods Ended ~~September~~June 30, ~~2017~~2020 and ~~2016~~2019

Revenues

Segment revenues are summarized by product as follows:


	Three Months Ended September 30,									Nine Months Ended September 30,										Three Months Ended June 30,														Six Months Ended June 30,
(in thousands)	2017		2016		Change $			Change %		2017		2016		Change $			Change %		(in thousands)	2020		2019		Change $		Change %		2020		2019		Change $		Change %
U.S.																			U.S.
DEFINITY	$	36,901	$	32,007	$	4,894		15.3	%	$	113,035	$	95,497	$	17,538		18.4	%	DEFINITY	$	39,544	$	53,466	$	(13,922)	(26.0)	%	$	94,554	$	103,182	$	(8,628)	(8.4)	%
TechneLite	22,621		20,906		1,715			8.2	%	69,150		64,282		4,868			7.6	%	TechneLite	15,591		16,865		(1,274)		(7.6)	%	34,947		36,923		(1,976)		(5.4)	%
Xenon	7,726		6,675		1,051			15.7	%	23,709		21,620		2,089			9.7	%
Other	2,331		3,033		(702		)	(23.1	)%	12,812		11,288		1,524			13.5	%

Other nuclear																			Other nuclear	5,804		9,127		(3,323)		(36.4)	%	14,866		18,651		(3,785)		(20.3)	%
Rebates and allowances																			Rebates and allowances	(3,540)		(4,268)		728		(17.1)	%	(8,223)		(8,132)		(91)		1.1	%
Total U.S. revenues	69,579		62,621		6,958			11.1	%	218,706		192,687		26,019			13.5	%	Total U.S. revenues	57,399		75,190		(17,791)		(23.7)	%	136,144		150,624		(14,480)		(9.6)	%
International																			International
DEFINITY	828		597		231			38.7	%	2,534		2,002		532			26.6	%	DEFINITY	821		1,163		(342)		(29.4)	%	2,602		2,558		44		1.7	%
TechneLite	3,735		3,627		108			3.0	%	10,750		10,339		411			4.0	%	TechneLite	3,318		3,241		77		2.4	%	7,060		7,328		(268)		(3.7)	%
Xenon	—		2		(2		)	(100.0	)%	4		5		(1		)	(20.0	)%
Other	5,799		6,216		(417		)	(6.7	)%	18,143		22,470		(4,327		)	(19.3	)%

Other nuclear																			Other nuclear	4,473		6,119		(1,646)		(26.9)	%	10,911		11,715		(804)		(6.9)	%
Rebates and allowances																			Rebates and allowances	(1)		(8)		7		(87.5)	%	(3)		(10)		7		(70.0)	%
Total International revenues	10,362		10,442		(80		)	(0.8	)%	31,431		34,816		(3,385		)	(9.7	)%	Total International revenues	8,611		10,515		(1,904)		(18.1)	%	20,570		21,591		(1,021)		(4.7)	%
Worldwide																			Worldwide
DEFINITY																			DEFINITY	40,365		54,629		(14,264)		(26.1)	%	97,156		105,740		(8,584)		(8.1)	%
TechneLite																			TechneLite	18,909		20,106		(1,197)		(6.0)	%	42,007		44,251		(2,244)		(5.1)	%

Other nuclear																			Other nuclear	10,277		15,246		(4,969)		(32.6)	%	25,777		30,366		(4,589)		(15.1)	%
Rebates and allowances																			Rebates and allowances	(3,541)		(4,276)		735		(17.2)	%	(8,226)		(8,142)		(84)		1.0	%
Total revenues	$	79,941	$	73,063	$	6,878		9.4	%	$	250,137	$	227,503	$	22,634		9.9	%	Total revenues	$	66,010	$	85,705	$	(19,695)	(23.0)	%	$	156,714	$	172,215	$	(15,501)	(9.0)	%

The ~~increase~~decrease in the U.S. segment revenues for the three months ended ~~September~~June 30, ~~2017,~~2020, as compared to the prior year period is primarily due to a ~~$4.9~~$13.9 million ~~increase~~decrease in DEFINITY ~~revenues~~revenue as a result of ~~higher~~lower unit volumes ~~a $1.7 million increase in TechneLite revenues primarily~~ as a result of ~~increased unit volumes and a $1.1~~COVID-19. TechneLite revenue was $1.3 million ~~increase~~lower driven by COVID-19 impact, partially offset by supplier disruptions in 2019. Other Nuclear revenue was lower than the prior year primarily associated with lower Xenon ~~revenues~~volume as a result of ~~higher unit volumes. Offsetting these increases~~COVID-19, which was ~~a $0.7 million decrease due to~~offset, in part, by reduced rebate and allowance ~~provisions.~~provisions of $0.7 million.

The ~~increase~~decrease in the U.S. segment revenues for the ~~nine~~six months ended ~~September~~June 30, ~~2017,~~2020, as compared to the prior year period is primarily due to ~~a $17.5~~an $8.6 million ~~increase~~decrease in DEFINITY ~~revenues~~revenue as a result of ~~higher~~lower unit volumes ~~a $4.9 million increase in TechneLite revenues primarily~~ as a result of ~~increased unit volumes and a $2.1~~COVID-19 that was concentrated in the second quarter, offset by first quarter performance. TechneLite revenue was $2.0 million ~~increase~~lower driven by COVID-19 impact, partially offset by supplier disruptions in 2019. Other Nuclear revenue was lower than the prior year primarily associated with $4.1 million lower Xenon revenue with lower volume as a result of ~~higher unit volumes. In addition, there was an increase~~COVID-19.

The Progenics business contributed approximately $1.0 million of ~~$5.0 million in other~~ revenue ~~associated with the up-front license fee recognized related~~ to the License Agreement with GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18. Offsetting these increases was a $1.9 million decrease due to rebate and allowance provisions, as well as a $1.6 million decrease in Ablavar revenues as the product is no longer sold.

~~The International~~U.S. segment ~~revenues~~ for the three and six months ended ~~September~~June 30, ~~2017, were consistent compared to the prior year period.~~ 2020.

The decrease in the International segment revenues for the ~~nine~~three months ended ~~September~~June 30, ~~2017,~~2020, as compared to the prior year period is primarily ~~the~~due to lower volume as a result of COVID-19.

The decrease in the ~~sale~~International segment revenues for the six months ended June 30, 2020, as compared to the prior year period is primarily due to lower volume as a result of COVID-19 as well as opportunistic incremental demand of TechneLite in the ~~Australian radiopharmacy business during 2016.~~prior year period.

Table of Contents

Rebates and Allowances

Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for our products, administrative fees of group purchasing organizations ~~royalties~~ and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s buying patterns and the resulting applicable contractual rebate ~~or commission rate(s)~~ to be earned over a contractual period.

An analysis of the amount of, and change in, reserves is summarized as follows:


(in thousands)	Rebates and Allowances
Balance, January 1, 2020	$	6,985
Provision related to current period revenues	8,216
Adjustments relating to prior period revenues	10
Payments or credits made during the period	(8,266)
Balance, June 30, 2020	$	6,945

Gross Profit

(in thousands) Rebates and
Allowances
Balance, as of January 1, 2017 $ 2,297
Current provisions relating to revenues in current year 6,864
Adjustments relating to prior years’ estimate (154 )
Payments/credits relating to revenues in current year (4,658 )
Payments/credits relating to revenues in prior years (1,474 )
Balance, as of September 30, 2017 $ 2,875

~~Costs of Goods Sold~~

~~Cost of goods sold consists of manufacturing, distribution, intangible asset amortization, write-offs of excess and obsolete inventory and other costs related to our commercial products.~~

~~Cost of goods sold~~Gross profit is summarized by segment as follows:


	Three Months Ended September 30,								Nine Months Ended September 30,										Three Months Ended June 30,														Six Months Ended June 30,
(in thousands)	2017		2016		Change $		Change %		2017		2016		Change $			Change %		(in thousands)	2020		2019		Change $		Change %		2020		2019		Change $		Change %
U.S.	$	32,759	$	31,133	$	1,626	5.2	%	$	100,225	$	96,791	$	3,434		3.5	%	U.S.	$	24,697	$	42,033	$	(17,336)	(41.2)	%	$	59,760	$	83,584	$	(23,824)	(28.5)	%
International	8,655		8,249		406		4.9	%	25,676		27,579		(1,903		)	(6.9	)%	International	1,151		2,540		(1,389)		(54.7)	%	4,090		5,073		(983)		(19.4)	%
Total cost of goods sold	$	41,414	$	39,382	$	2,032	5.2	%	$	125,901	$	124,370	$	1,531		1.2	%
Total gross profit																		Total gross profit	$	25,848	$	44,573	$	(18,725)	(42.0)	%	$	63,850	$	88,657	$	(24,807)	(28.0)	%

The ~~increases~~decrease in the U.S. segment cost of goods sold for the three and nine months ended September 30, 2017 as compared to the prior year periods are primarily due to costs associated with the increase in sales volume as noted above. We also incurred, increases in technology transfer expense, partially offset by lower amortization expense as a result of a fully amortized intangible asset.

~~The increase in the International segment cost of goods sold~~gross profit for the three months ended ~~September~~June 30, 2017 as compared to the prior year period is primarily due to higher manufacturing costs for certain products due to higher sales volume, partially offset by lower manufacturing costs as a result of the sale of our Australian radiopharmacy business.

~~The decrease in the International segment cost of goods sold for the nine months ended September 30, 2017~~2020, as compared to the prior year period is primarily due to lower ~~manufacturing costs as a result of the sale of our Australian radiopharmacy business, partially~~DEFINITY, TechneLite, Xenon and other nuclear product unit volumes due to COVID-19. This was offset by ~~higher manufacturing costs for certain products due to higher sales volume~~a decrease in rebate and ~~higher material costs for certain products.~~

~~Gross Profit~~

~~Gross profit is summarized by segment as follows:~~

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017 2016
Change
$

Change
%
2017 2016
Change
$

Change
%
U.S. $ 36,820
$ 31,488
$ 5,332
16.9 % $ 118,481
$ 95,896
$ 22,585
23.6 %
International 1,707
2,193
(486 ) (22.2 )% 5,755
7,237
(1,482 ) (20.5 )%
Total gross profit $ 38,527
$ 33,681
$ 4,846
14.4 % $ 124,236
$ 103,133
$ 21,103
20.5 %
allowance provisions.

The ~~increase~~decrease in the U.S. segment gross profit for the ~~three~~six months ended ~~September~~June 30, ~~2017 over~~2020, as compared to the prior year period is primarily due to ~~higher~~lower DEFINITY, ~~unit volumes~~TechneLite, and ~~higher Xenon unit volumes.~~

~~The increase in the U.S. segment gross profit for the nine months ended September 30, 2017 over the prior year period is primarily due to higher DEFINITY unit volumes, higher~~ Xenon unit volumes due to COVID-19 and ~~the recognition of $5.0 million in~~an asset impairment loss on other ~~revenue associated with the License Agreement with GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18 without any associated cost of goods sold.~~nuclear products.

The ~~decreases~~decrease in the International segment gross profit for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 over~~2020, as compared to the prior year ~~periods are~~period is primarily due to ~~higher manufacturing~~lower DEFINITY and ~~material costs for certain products.~~other nuclear product unit volumes due to COVID-19.

Sales and Marketing

Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing ~~business development~~ and customer service functions. Other costs in sales and marketing expenses include the development and printing of advertising and promotional material, professional services, market research and sales meetings.

Sales and marketing expense is summarized by segment as follows:


	Three Months Ended June 30,														Six Months Ended June 30,
(in thousands)	2020		2019		Change $		Change %		2020		2019		Change $		Change %
U.S.	$	5,830	$	10,369	$	(4,539)	(43.8)	%	$	15,437	$	20,338	$	(4,901)	(24.1)	%
International	475		579		(104)		(18.0)	%	998		1,007		(9)		(0.9)	%
Total sales and marketing	$	6,305	$	10,948	$	(4,643)	(42.4)	%	$	16,435	$	21,345	$	(4,910)	(23.0)	%

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017 2016
Change
$

Change
%
2017 2016
Change
$

Change
%
U.S. $ 9,480
$ 8,021
$ 1,459
18.2 % $ 29,854
$ 24,902
$ 4,952
19.9 %
International 595
685
(90 ) (13.1 )% 2,038
2,954
(916 ) (31.0 )%
Total sales and marketing $ 10,075
$ 8,706
$ 1,369
15.7 % $ 31,892
$ 27,856
$ 4,036
14.5 %

Table of Contents

The ~~increases~~decrease in the U.S. segment sales and marketing expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 over~~2020, as compared to the prior year ~~periods are~~period is primarily due to reduced marketing promotional programs and travel due to COVID-19 impact, as well as lower employee-related ~~expenses, market research~~costs. The Progenics business contributed approximately $0.3 million of expense to the U.S. segment for the three and ~~promotional program expenses.~~six months ended June 30, 2020.

The ~~decreases~~decrease in the International segment sales and marketing expenses for the three ~~and nine~~ months ended ~~September~~June 30, ~~2017 over~~2020, as compared to the prior year ~~periods are~~period is primarily due to lower ~~headcount.~~employee-related costs.

The International segment sales and marketing expenses for the six months ended June 30, 2020 is flat as compared to the prior year.

General and Administrative

General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.

General and administrative expense is summarized by segment as follows:


	Three Months Ended September 30,									Nine Months Ended September 30,										Three Months Ended June 30,														Six Months Ended June 30,
(in thousands)	2017		2016		Change $			Change %		2017		2016		Change $			Change %		(in thousands)	2020		2019		Change $		Change %		2020		2019		Change $		Change %
U.S.	$	11,901	$	9,693	$	2,208		22.8	%	$	35,055	$	27,629	$	7,426		26.9	%	U.S.	$	20,522	$	13,323	$	7,199	54.0	%	$	37,077	$	25,671	$	11,406	44.4	%
International	175		398		(223		)	(56.0	)%	494		1,213		(719		)	(59.3	)%	International	148		(30)		178		(593.3)	%	292		211		81		38.4	%
Total general and administrative	$	12,076	$	10,091	$	1,985		19.7	%	$	35,549	$	28,842	$	6,707		23.3	%	Total general and administrative	$	20,670	$	13,293	$	7,377	55.5	%	$	37,369	$	25,882	$	11,487	44.4	%

The ~~increase in the~~ U.S. segment general and administrative expenses increased for the three and six months ended ~~September~~June 30, ~~2017 over~~2020 as compared to the prior year ~~period are primarily due to higher employee-related expenses and campus consolidation costs.~~

period. The primary driver was an increase in acquisition-related costs associated with the acquisition of Progenics offset by lower employee-related costs driven by COVID related measures. In addition, the Progenics business contributed approximately $2.9 million of expense to the U.S. segment ~~general and administrative expenses~~ for the ~~nine~~three and six months ended ~~September~~June 30, ~~2017 over the prior year period are primarily due to $1.7 million of debt refinancing costs, higher employee-related expenses and campus consolidation costs.~~2020.

The ~~decreases in the~~ International segment general and administrative expenses increased for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 over~~2020 as compared to the prior year ~~periods are~~period driven primarily ~~due to~~by an insurance benefit received in 2019 which was partly offset by lower employee ~~headcount and~~ related ~~expenses.~~costs in 2020.

Research and Development

Research and development expenses relate primarily to the development of new products to add to our portfolio and costs related to ~~its~~our medical affairs, medical information and regulatory functions. We do not allocate research and development expenses incurred in the ~~United States~~U.S. to our International segment.

Research and development expense is summarized by segment as follows:


	Three Months Ended September 30,								Nine Months Ended September 30,									Three Months Ended June 30,														Six Months Ended June 30,
(in thousands)	2017		2016		Change $		Change %		2017		2016		Change $		Change %		(in thousands)	2020		2019		Change $		Change %		2020		2019		Change $		Change %
U.S.	$	3,196	$	2,685	$	511	19.0	%	$	13,265	$	7,985	$	5,280	66.1	%	U.S.	$	4,345	$	5,652	$	(1,307)	(23.1)	%	$	8,258	$	10,302	$	(2,044)	(19.8)	%
International	358		164		194		118.3	%	884		508		376		74.0	%	International	73		143		(70)		(49.0)	%	208		422		(214)		(50.7)	%
Total research and development	$	3,554	$	2,849	$	705	24.7	%	$	14,149	$	8,493	$	5,656	66.6	%	Total research and development	$	4,418	$	5,795	$	(1,377)	(23.8)	%	$	8,466	$	10,724	$	(2,258)	21.1	%

The ~~increase~~decrease in the U.S. segment research and development expenses for the three and six months ended ~~September~~June 30, ~~2017 over~~2020, as compared to the prior year ~~period~~ is primarily ~~due~~driven by clinical research expenses related to ~~an increase in higher employee-related~~DEFINITY studies completing and lower employee related expenses.

The ~~increase in~~Progenics business contributed approximately $1.2 million of expense to the U.S. segment ~~research and development expenses~~ for the ~~nine~~three and six months ended ~~September~~June 30, ~~2017 over the prior year period is primarily due to an increase in depreciation expense and other charges as a result~~2020.

Table of the scheduled decommissioning of certain long-lived assets associated with research and development operations as well as higher employee-related expenses, partially offset by lower pharmacovigilance expenses due to the transition to a new vendor in the prior year.Contents

The ~~increases~~decrease in the International segment research and development expenses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2017 over~~2020, as compared to the prior year ~~periods were~~period is primarily driven by ~~a European Phase IV study for one of our products.~~regulatory costs related to Brexit matters.

~~Gain on Sales of Assets~~

Effective January 7, 2016, our Canadian subsidiary entered into an asset purchase agreement, pursuant to which it would sell substantially all of the assets of our Canadian radiopharmacies and Gludef manufacturing and distribution business to one of our existing Canadian radiopharmacy customers. The purchase price for the asset sale was $9.0 million in cash and also included a working capital adjustment of $0.5 million, resulting in a pre-tax gain of $5.9 million recorded within operating income during the nine months ended September 30, 2016.

Effective August 11, 2016, we entered into a share purchase agreement, pursuant to which we sold 100% of the stock of our Australian subsidiary to one of our existing radiopharmacy customers. This sale included the radiopharmacy business as well as all the direct/bulk business. The sale price for the share sale was AUD$2.0 million (approximately $1.5 million U.S. Dollars) in cash and also included a working capital receivable adjustment of approximately AUD$2.0 million (approximately $1.5 million U.S. Dollars), resulting in a pre-tax book gain of $0.6 million, which was recorded within operating income for the nine months ended September 30, 2016.

Interest Expense

Interest expense decreased by approximately ~~$2.4 million and $6.7~~$5.3 million for the ~~three and nine~~six months ended ~~September~~June 30, ~~2017, respectively,~~2020 as compared to the prior year ~~periods,~~period due to the March 2017 refinancing of our long-term debt and reductions in the principal balance of our long-term debt related to the 2017 refinancing and the voluntary principal prepayments we made during September and November 2016.

~~Loss on Extinguishment of Debt~~

~~For the nine months ended September 30, 2017, we incurred a $2.2 million loss on extinguishment of debt in connection with~~ the refinancing of our existing indebtedness ~~with~~in the ~~new term loan~~second quarter of 2019 which reduced our underlying principal amount and ~~revolving credit facilities, see Note 8, “Financing Arrangements” to~~decreased interest rates on our ~~condensed consolidated financial statements.~~long-term debt.

~~Provision for~~ Income ~~Taxes~~Tax Expense

~~Provision for~~Income tax expense is summarized as follows:


	Three Months Ended June 30,														Six Months Ended June 30,
(in thousands)	2020		2019		Change $		Change %		2020		2019		Change $		Change %
Income tax expense	$	309	$	1,698	$	(1,389)	(81.8)	%	$	2,501	$	4,513	$	(2,012)	(44.6)	%

The income ~~taxes~~tax expense for the ~~periods presented is as follows:~~

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands) 2017 2016
Change
$

Change
%
2017 2016
Change
$

Change
%
Provision for income taxes $ 762
$ 20
$ 742
>1,000% $ 2,116
$ 657
$ 1,459
222.1 %

~~Our provision for income taxes results~~three and six months ended June 30, 2020 was primarily ~~from~~due to the recording of non-deductible transaction costs and the accrual of interest ~~and penalties~~ associated with uncertain tax positions, offset by reversals of those positions as statutes lapse or such positions are settled during the year, as well as taxes due in certain foreign jurisdictions where we generate taxable income. The $0.7 million and $1.5 million increases in the tax provision for the three and nine months ended September 30, 2017, as compared to the same periods in 2016 primarily reflect a reduced amount of statute lapses and consequent liability releases in the current period, when compared with the prior year period.positions.

We regularly assess our ability to realize our deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether our deferred tax assets are ~~more likely than not~~more-likely-than-not realizable, we ~~evaluated~~evaluate all available positive and negative evidence, and ~~weighed~~weigh the objective evidence and expected impact. ~~Evidence considered included our history~~As of ~~net operating losses, which resulted in our recording~~June 30, 2020, we recorded valuation allowances of ~~a full valuation allowance~~$3.0 million against ~~our domestic~~the net deferred tax assets ~~beginning in 2011, and in each year thereafter. We were profitable on~~of certain foreign subsidiaries, as well as a ~~cumulative basis for the three-year period ended September 30, 2017, but substantially all of that profitability was achieved during 2016 and the nine months ended September 30, 2017.~~

We continue to evaluate other negative evidence, including customer concentration and contractual risk, the risk of Moly supply availability and cost, DEFINITY supplier risk, and certain product development risks, all of which provide for uncertainties around our future level of profitability. Based on our review of all available evidence, we determined that we have not yet attained a sustained level of profitability sufficient to outweigh the objectively verifiable negative evidence, and have recorded a full valuation allowance of $0.7 million against ~~our domestic~~ net state deferred tax assets ~~at September 30, 2017. We will continue~~due to ~~assess~~ the ~~level~~potential expiration of certain state tax losses and tax credits prior to utilization.

On June 19, 2020, we acquired the stock of Progenics Pharmaceuticals, Inc. in a transaction that is expected to qualify as a tax-deferred reorganization under Section 368 of the ~~valuation allowance required. If~~Internal Revenue Code of 1986, as amended. The transaction resulted in an ownership change of Progenics under Section 382 and a ~~sufficient weight~~limitation on the utilization of ~~positive evidence exists in future periods to support a release of some or all~~Progenics’ pre-transaction tax attributes. All pre-transaction research credits and Orphan drug credits have been removed from the balance sheet, and the gross carrying value of the ~~valuation allowance recorded against domestic~~tax loss carryforwards reduced to their realizable value on the opening balance sheet, in accordance with the Section 382 limitation. Significant deferred tax ~~assets, such~~liabilities arising from the purchase accounting basis step-up in identified intangibles were also recorded as part of the purchase accounting, resulting in a ~~release would likely have a material impact on our results~~small net overall deferred tax liability for Progenics after the application of ~~operations in that future period.~~purchase accounting.

Our effective tax rate for ~~the periods~~each reporting period is presented ~~are~~ as follows:


	Six Months Ended June 30,
	2020	2019
Effective tax rate	(213.0)%	21.6%

Our effective tax rate in fiscal 2020 differs from the U.S. statutory rate of 21% principally due to the impact of U.S. state taxes, non-deductible transaction costs, and the accrual of interest on uncertain tax positions.

The decrease in the effective income tax rate for the six months ended June 30, 2020 as compared to the prior year period is primarily due to the lower amount of pre-tax income driving an increased tax rate impact from the accrual of interest on uncertain tax positions in the current period and non-deductible transaction costs.

Nine Months Ended September 30,
2017 2016
Effective tax rate 7.5% 2.9%

Table of Contents

Liquidity and Capital Resources

Cash Flows

The following table provides information regarding our cash flows:


	Nine Months Ended September 30,							Six Months Ended June 30,
(in thousands)	2017			2016			(in thousands)	2020		2019
Net cash provided by operating activities	$	41,691		$	36,861		Net cash provided by operating activities	$	7,252	$	31,521
Net cash (used in) provided by investing activities	$	(10,355	)	$	5,639
Net cash provided by (used in) investing activities							Net cash provided by (used in) investing activities	$	2,609	$	(13,984)
Net cash used in financing activities	$	(14,600	)	$	(17,958	)	Net cash used in financing activities	$	(10,218)	$	(74,158)

Net Cash Provided by Operating Activities

~~Cash~~Net cash provided by operating activities of ~~$41.7~~$7.3 million in the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 was driven primarily by ~~net income of $26.3 million plus $15.0~~$7.8 million of depreciation, amortization and accretion expense, ~~$3.8~~impairment of long-lived assets of $7.3 million, of stock-based compensation expense of $6.5 million, and ~~a $2.2 million loss on debt extinguishment.~~changes in deferred taxes of $1.1 million. These net sources of cash were offset by a net loss of $3.7 million and a net decrease of ~~$8.9~~$14.4 million related to movements in our working capital accounts during the period. The overall decreases in cash from our working capital accounts were primarily driven by ~~higher accounts receivable~~the payment of prior year annual bonuses as well as change in inventory related to ~~increases in revenues to certain major customers~~COVID-19 impact on products and the timing of ~~inventory purchases during the period.~~batch processes.

~~Cash~~Net cash provided by operating activities of ~~$36.9~~$31.5 million in the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2019 was driven primarily by net income of ~~$21.9~~$16.4 million plus ~~$12.7~~$6.6 million of depreciation, amortization and accretion expense, ~~$1.9~~debt extinguishment expense of $3.2 million, of stock-based compensation expense of $6.1 million and ~~$1.4 million~~changes in deferred taxes of ~~debt retirement costs.~~$2.4 million. These net sources of cash were offset by ~~the gain on sales~~a net decrease of ~~assets of $6.5 million. In addition, we had a $3.6~~$5.2 million ~~net increase~~ related to movements in our working capital accounts during the period. The overall ~~increases~~decreases in cash from our working capital accounts were primarily driven by the ~~timing~~payment of payment runs, timing of payroll and accrued bonuses, and improved collections, which were offset by an increase in inventory due to the timing of production and receipt of inventory and an increase in prepaid expenses due to insurance renewals.prior year annual bonuses.

Net Cash ~~(Used in)~~ Provided by Investing Activities

Net cash used in investing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 reflected ~~$11.6~~$17.6 million of acquired cash related to the non-cash acquisition of Progenics offset by $10.0 million in lending on a note receivable to Progenics prior to the acquisition and $5.0 million in capital ~~expenditures offset by the cash proceeds of $1.2 million received from the sale of assets from our Australian radiopharmacy business during the third quarter of 2016.~~expenditures.

Net cash ~~provided by~~used in investing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2016 was primarily due to cash proceeds of $10.5 million received from the sale of assets from our Canadian and Australian radiopharmacy businesses, which was offset by $5.0~~2019 reflected $14.0 million in capital expenditures.

Net Cash Used in Financing Activities

Net cash used in financing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2017~~2020 is primarily attributable to the payments on long-term debt and other borrowings of $7.0 million related to the 2019 Term Facility and Royalty-Backed Loan and payments for minimum statutory tax withholding related to net ~~outflow~~share settlement of ~~$11.9 million in connection with our refinancing~~equity awards of ~~our previous $365.0 million seven-year term loan agreement with a new five-year $275.0 million term loan facility.~~$2.0 million.

Net cash used in financing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2016 was~~2019 is primarily ~~used~~attributable to ~~repay $55.0~~the net cash outflow of approximately $73 million ofin connection with the ~~principal balance~~refinancing of our ~~$365.0 million Term~~previous 2017 Facility ~~with~~and payments for minimum statutory tax withholding related to net ~~proceeds~~share settlement of ~~$39.9 million, which were raised upon completion~~equity awards of ~~a follow-on underwritten primary offering, and $15.1 million~~$2.1 million. Starting in 2019, we require certain senior executives to cover tax liabilities resulting from ~~cash on hand.~~the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans.

External Sources of Liquidity

OnIn June 30, 2015, we completed our initial public offering, entered into a $365.0 million seven-year term facility (the “2015 Term Facility”) and amended and restated our revolving facility (the “2015 Revolving Facility”) that had a borrowing capacity of $50.0 million.

In September 2016, we completed a follow-on underwritten offering of 5,200,000 shares of common stock and utilized the net proceeds to us from this offering, combined with cash on hand, to prepay $55.0 million of the principal balance of our 2015 Term Facility. In November 2016, we completed a second follow-on underwritten offering that included 1,000,000 shares of common stock

offered by us and utilized the net proceeds to us from this offering, combined with cash on hand, to prepay $20.0 million of the principal balance of our 2015 Term Facility. As of December 31, 2016, the principal balance outstanding on our 2015 Term Facility was $284.5 million.

~~In March 2017,~~2019, we refinanced ~~the 2015 Term Facility with a new~~our 2017 $275 million five-year ~~$275.0 million~~ term loan facility ~~(the “2017~~with the 2019 Term ~~Facility” and the loans thereunder, the “Term Loans”).~~Facility. In addition, we replaced our ~~2015 Revolving Facility with a new $75.0~~$75 million ~~five-year~~ revolving ~~credit~~ facility ~~(the “2017 Revolving Facility” and, together~~ with the ~~2017 Term Facility, the “2017 Facility”, the~~2019 Revolving Facility. The terms of ~~which~~the 2019 Facility are set forth in the Credit ~~Agreement). The 2017 Term Facility was issued net~~Agreement, dated as of ~~a $0.7 million discount.~~June 27, 2019, by and among us, the lenders from time to time party thereto and Wells Fargo Bank, N.A., as administrative agent and collateral agent (the “2019 Credit Agreement”). We have the right to request an increase to the ~~2017~~2019 Term Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to ~~$75.0~~$100 million, plus additional amounts, in certain circumstances.

We used the net proceeds of the 2017 Term Facility, together with approximately $15.3 million of cash on hand, to refinance in full the aggregate remaining principal amount of the loans outstanding under the 2015 Term Facility and pay related interest, transaction fees and expenses. No amounts were outstanding under the 2015 Revolving Facility at that time.

The Term Loans under the 2017 Term Facility bear interest, with pricing based from time to time at our election at (i) LIBOR plus a spread of 4.50% or (ii) the Base Rate (as defined in the Credit Agreement) plus a spread of 3.50%. Interest is payable (i) with respect to LIBOR Term Loans, at the end of each Interest Period (as defined in the Credit Agreement) and (ii) with respect to Base Rate Term Loans, at the end of each quarter. At September 30, 2017, our interest rate under the 2017 Term Facility was 5.7%.

We are permitted to voluntarily prepay the 2019 Term Loans, in whole or in ~~part.~~part, without premium or penalty. The ~~2017~~2019 Term Facility requires us to make mandatory prepayments of the outstanding 2019 Term Loans in certain circumstances. The ~~2017~~2019 Term Facility amortizes at ~~1.00%~~5.00% per year through September 30, 2022 and 7.5% thereafter, until its June ~~30, 2022~~27, 2024 maturity date.

Under the terms of the ~~2017~~2019 Revolving Facility, the lenders thereunder agreed to extend credit to us from time to time until ~~March 30, 2022 (the “Revolving Termination Date”)~~June 27, 2024 consisting of revolving loans ~~(the “Revolving Loans” and, together with the Term Loans, the “Loans”)~~ in an aggregate principal amount not to exceed ~~$75.0~~$200 million ~~(the “Revolving Commitment”)~~ at any time outstanding. The ~~2017~~2019 Revolving Facility includes a ~~$20.0~~$20 million sub-facility for the issuance of ~~letters~~Letters of ~~credit (the “Letters~~Credit. The 2019 Revolving Facility includes

Table of ~~Credit”).~~Contents

a $10 million sub-facility for Swingline Loans. The Letters of Credit, Swingline Loans and the borrowings under the ~~2017~~2019 Revolving Facility are expected to be used for working capital and other general corporate purposes.

~~The Revolving Loans~~Please refer to our Form 10-K for fiscal year ended December 31, 2019 for further details on the 2019 Facility.

On April 6, 2020, the Company drew down $100.0 million under ~~the 2017~~its 2019 Revolving Facility, ~~bear interest, with pricing based~~and subsequently repaid such amounts on June 9, 2020.

On June 19, 2020, we amended our 2019 Credit Agreement (“the Amendment”) as a result of the impact of the COVID-19 pandemic on our business and operations and the near-term higher level of indebtedness resulting from ~~time~~our decision not to ~~time at~~immediately repay the Progenics debt secured by the RELISTOR royalties following our ~~election at (i) LIBOR plus a spread~~acquisition of ~~3.50% or (ii) the Base Rate~~Progenics.

The Amendment provides for, among other things, modifications to our financial maintenance covenants. The covenant related to Total Net Leverage Ratio (as defined in the Amended Credit Agreement) ~~plus a spread~~has been waived from the date of ~~2.50%.~~the Amendment through December 31, 2020. The ~~2017 Revolving Facility also includes an unused line fee, which is set at 0.375% while our secured~~maximum total net leverage ratio ~~(as defined in the Credit Agreement) is greater than 3.00 to 1.00~~ and ~~0.25% when our secured leverage ratio is less than or equal to 3.00 to 1.00.~~

We are permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans and Letters of Credit exceeds the total Revolving Commitment, we must prepay the Revolving Loans in an amount equal to such excess. The 2017 Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The 2017 Facility requires us to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum consolidated leverageinterest coverage ratio permitted by the financial covenant is displayed in the table below:

~~2017 Facility Financial Covenant~~


2020 Amended Credit Agreement
Period		Total Net Leverage Ratio
Q1 2021		5.50 to 1.00
Q2 2021		3.75 to 1.00
Thereafter		3.50 to 1.00

Period		Interest Coverage Ratio
Q2 2020 to Q1 2021		2.00 to 1.00
Thereafter		3.00 to 1.00

~~Period~~	~~Consolidated~~ ~~Leverage Ratio~~
~~Q3 2017 through Q1 2018~~	~~5.00 to 1.00~~
~~Q2 2018 through Q1 2019~~	~~4.75 to 1.00~~
~~Thereafter~~	~~4.50 to 1.00~~

The ~~2017 Facility contains usual~~Amendment also introduces a new financial covenant requiring Consolidated Liquidity (as defined in the Amended Credit Agreement) to be no less than $150.0 million. The Consolidated Liquidity covenant is tested on a continuing basis beginning on the date of the Amendment and ~~customary restrictions~~ending on the date on which we deliver a compliance certificate for the fiscal quarter ending March 31, 2021.

The commitment fee applicable to the Revolving Facility is 0.50% until the Adjustment Date for the fiscal quarter ending March 31, 2021. On and ~~that~~after the Adjustment Date for the fiscal quarter ending on March 31, 2021, the commitment fee ranges from 0.15% to 0.40% based on our Total Net Leverage Ratio.

On June 19, 2020, as a result of ~~our subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell~~the Progenics Transaction, we assumed Progenics outstanding debt as of such date in the amount of $40.2 million. Progenics, through a wholly-owned subsidiary MNTX Royalties Sub LLC (“MNTX Royalties”), entered into a $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. (“HCRP”) on November 4, 2016. Under the terms of the Royalty-Backed Loan, the lenders have no recourse to Progenics or ~~otherwise dispose of all or substantially all~~any of its ~~assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make~~assets other ~~restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.~~

~~Upon an event of default, the administrative agent under the Credit Agreement will have~~than the right to ~~declare~~receive royalty payments from the ~~Loans~~commercial sales of RELISTOR products owed under Progenics’ license agreement with Salix Pharmaceuticals, Inc., a wholly-owned subsidiary of Bausch. The RELISTOR royalty payments will be used to repay the principal and ~~other obligations outstanding immediately due~~interest on the loan. The Royalty-Backed Loan bears interest at a per annum rate of 9.5% and ~~payable~~matures on June 30, 2025. On June 22, 2020, HCRP waived the automatic acceleration of the Royalty-Backed Loan that otherwise would have been triggered by the consummation of the Progenics Transaction and ~~all commitments immediately terminated or reduced.~~MNTX Royalties agreed not to prepay the loan until after December 31, 2020.

~~The 2017 Facility is guaranteed~~Under the terms of the loan agreement, payments of interest and principal, if any, are made on the last day of each calendar quarter out of RELISTOR royalty payments received since the immediately-preceding payment date. On each payment date, 50% of RELISTOR royalty payments received since the immediately-preceding payment date in excess of accrued interest on the loan are used to repay the principal of the loan, with the balance retained by ~~Holdings and Lantheus MI Real Estate, LLC (“LMI-RE”), and obligations under the 2017 Facility are generally secured by first priority liens over substantially~~us. Starting on September 30, 2021, all of the ~~assets~~RELISTOR royalties

Table of ~~each of LMI, Holdings~~Contents

received since the immediately-preceding payment date will be used to repay the interest and ~~LMI-RE (subject to customary exclusions set forth in~~outstanding principal balance until the ~~transaction documents) owned as of March 30, 2017 or thereafter acquired.~~balance is fully repaid.

Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets or other sources of funding, as well as the capacity and terms of our financing arrangements.

We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include prepayments of our term loans or other retirements or refinancing of outstanding debt, privately ~~negotiat~~ednegotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and will depend on market conditions, our cash position and other considerations.

Funding Requirements

Our future capital requirements will depend on many factors, including:

~~Our ability to have product manufactured and released from JHS and other manufacturing sites in a timely manner in the future;~~

•The ~~pricing environment and the~~ level of product sales and the pricing environment of our currently marketed products, particularly DEFINITY and any additional products that we may market in the ~~future;~~future, including decreased product sales resulting from the COVID-19 pandemic;

•Revenue mix shifts and associated volume and selling price changes that could result from contractual status changes with key customers and additional competition;

•The costs of acquiring or in-licensing, developing, obtaining regulatory approval for, and commercializing, new products, businesses or technologies, together with the costs of pursuing opportunities that are not eventually consummated;

•Our investment in the further clinical development and commercialization of products and development candidates, including the newly acquired Progenics assets AZEDRA, PyL, 1095 and PSMA AI;

•The costs of investing in our facilities, equipment and technology infrastructure;

•The costs and timing of establishing manufacturing and supply arrangements for commercial supplies of our products and raw materials and components;

•Our ability to have product manufactured and released from JHS and other manufacturing sites in a timely manner in the future;

•The costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;

~~The costs of investing in our facilities, equipment and technology infrastructure;~~

~~The costs and timing of establishing manufacturing and supply arrangements for commercial supplies of our products;~~

~~The extent to which we acquire or invest in (i) new products, businesses and technologies, or (ii) the further clinical development or commercialization of existing development candidates or products;~~

•The extent to which we choose to establish collaboration, co-promotion, distribution or other similar arrangements for our marketed products;

•The legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance or other claims; and

•The cost of interest on any additional borrowings which we may incur under our financing arrangements.

Until we ~~successfully~~successfully become dual sourced for our principal products, we are vulnerable to future supply shortages. Disruption in ~~the financial~~our financial performance could also occur if we experience significant adverse changes in product or customer mix, broad economic downturns, adverse industry or company conditions or catastrophic external events, including pandemics such as COVID-19, natural disasters and political or military conflict. If we experience one or more of these events in the future, we may be required to implement ~~additional~~further expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through public or private equity offerings, debt financings, assets securitizations, ~~debt financings,~~ sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of ~~the agreements governing~~ our ~~senior secured credit facilities.~~Credit Agreement. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in ~~the agreements governing~~ our ~~senior secured credit facilities,~~Credit Agreement, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such a waiver to remain in compliance with those covenants. However, we cannot be assured that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.

Table of Contents

At ~~September~~June 30, ~~2017,~~2020, our only current committed external source of funds is our borrowing availability under our ~~2017~~2019 Revolving Facility. We had ~~$68.1~~$90.3 million of cash and cash equivalents at ~~September~~June 30, ~~2017.~~2020. Our ~~2017~~2019 Facility, as amended, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the ~~2017~~2019 Revolving Facility, as amended, may affect our ability to comply with the covenants in the ~~2017~~2019 Facility, as amended, including the financial ~~covenant~~covenants restricting ~~total~~consolidated net ~~leverage.~~leverage and interest coverage. Accordingly, we may be limited in utilizing the full amount of our ~~2017~~2019 Revolving Facility, as amended, as a source of liquidity.

In addition, in connection with the Progenics Transaction, which we closed in June 2020, we incurred legal, accounting, financial advisory, consulting and printing fees, and transition, integration and other costs which we funded from our available cash and the available cash of Progenics. The CVRs we issued in the Progenics Transaction entitle holders thereof to future cash payments of 40% of PyL net sales over (i) $100 million in 2022 and (ii) $150 million in 2023, which, if payable, we currently intend to fund from our then-available cash. In no event will our aggregate payments under the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Transaction, exceed 19.9% (which we estimate could be approximately $100 million) of the total consideration we pay in the Progenics Transaction. Refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities.

Based on our current operating plans, including our prudent expense management in response to the COVID-19 pandemic, we believe that our existing cash and cash equivalents, results of operations and availability under our ~~2017~~2019 Revolving Facility, as amended, will be sufficient to continue to fund our liquidity requirements for the foreseeable future.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial ~~position~~condition and results of operations isare based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements ~~in accordance with U.S. GAAP requires~~require us to make estimates and judgments that ~~may~~ affect ~~the~~our reported ~~amounts of~~ assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition and related allowances, inventory, impairments of long-lived assets including intangible assets, impairments of goodwill, income taxes including the valuation allowance for deferred tax assets.other financial information. Actual results may differ materially from these estimates under different assumptions and conditions. In addition, our reported financial condition and results of operations could vary due to a change in the application of a particular accounting standard.

There have been no ~~material~~other significant changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies in the ~~nine~~six months ended ~~September~~June 30, ~~2017.~~2020, except as set forth below. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, ~~2016.~~2019.

Business Combinations

We account for business combinations using the acquisition method of accounting. We recognize the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. We assess the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.

The fair values assigned to tangible and intangible assets acquired and liabilities assumed are based on our estimates and assumptions, as well as other information we have compiled, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and assumptions used in these estimates, it could result in a possible impairment of the intangible assets and goodwill, a required acceleration of the amortization expense of finite-lived intangible assets or the recognition of additional consideration, which would be expensed.

During the measurement period, which extends no later than one year from the acquisition date, we may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the condensed consolidated statements of operations as operating expenses or income.

Intangible and Long-Lived Assets

Table of Contents

We test intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. We measure the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. Long-lived assets, other than goodwill and other intangible assets, that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.

Intangible assets, consisting of trademarks, customer relationships, currently marketed products, licenses and developed technology are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.

Our IPR&D represents intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is whether we have obtained regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. We classify IPR&D acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset. We test our IPR&D assets at least annually or when a triggering event occurs that could indicate a potential impairment and we recognize any impairment loss in our condensed consolidated statements of operations.

Off-Balance Sheet Arrangements

We are required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating our ability to fund the decommissioning of our North Billerica, Massachusetts production facility upon closure, though we do not intend to close the facility. We have provided this financial assurance in the form of a $28.2 million surety bond.

Since inception, we have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, except as set forth below, see Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2019. Our exposures to market risk have not changed materially since December 31, ~~2016.~~2019.

Interest Rate Risk

The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. As of June 30, 2020, the Company had entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps as of June 30, 2020 was approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. Please refer to Note 12, “Derivative Instruments”, for further details on the interest rate swaps.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer ~~(its~~(“CFO”), its principal executive officer and principal financial officer, ~~respectively),~~respectively, has evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange ~~Act as of September 30, 2017.~~Act. Based on that evaluation, the Company’s ~~Chief Executive Officer~~CEO and ~~Chief Financial Officer~~CFO concluded that the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective as of ~~September 30, 2017.~~the period covered by this report.

Changes in Internal Controls Over Financial Reporting

As of June 30, 2020, management is in the process of evaluating and integrating the internal controls of the acquired Progenics business into the Company's existing operations. During the quarter, the Company implemented controls over the accounting and disclosures related to the business combination and integration of the Progenics business. There were no other material changes in ~~our~~the

Table of Contents

Company's internal control over financial reporting during the quarter ended ~~September~~June 30, ~~2017,~~2020, that ~~have~~has materially affected, or ~~are~~is reasonably likely to materially affect, the Company's internal control over financial reporting. Additionally, as a result of the COVID-19 pandemic, certain employees began working remotely in March. Notwithstanding these changes to the working environment, we have not identified any material changes in our internal control over financial reporting due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

As of ~~September~~June 30, ~~2017,~~2020, the Company ~~has no~~had the following material ongoing litigation into which the Company was a ~~party~~party:

RELISTOR Subcutaneous Injection

Between November 19, 2015 and September 18, 2017, Progenics, Salix, Valeant (now Bausch) and Wyeth filed multiple lawsuits against Mylan Pharmaceuticals and certain of its affiliates (collectively, “Mylan”) in the United States District Court for the District of New Jersey for infringement of certain U.S. patents based upon Mylan’s filing of multiple ANDAs seeking to obtain approval to market a generic version of RELISTOR subcutaneous injection before some or ~~any material ongoing regulatory~~all of those patents expire. These actions were later consolidated into two separate actions in the District of New Jersey.

On May 1, 2018, in the lead action, the Court granted Plaintiffs’ motion for partial summary judgment as to the validity of a particular claim that Mylan had admitted it infringed. On May 23, 2018, the Court entered an order for final judgment in favor of Plaintiffs and against Mylan on that particular claim. As a result, trial on the merits in the lead action was adjourned, allowing trial, if necessary, to be consolidated with the lagging, second action. Fact discovery has concluded in the lagging case, but deadlines for expert discovery have not yet been set.

RELISTOR Tablets - Actavis

Between December 6, 2016 and December 8, 2017, Progenics, Salix, Bausch, and Wyeth filed suit against Actavis, Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. (collectively, “Actavis”) in the United States District Court for the District of New Jersey for infringement of certain U.S. patents based upon Actavis’s filing of an ANDA seeking to obtain approval to market a generic version of RELISTOR tablets before some or ~~other proceedings~~all of those patents expire. The actions were later consolidated into a single action in the District of New Jersey.

On May 6-9, 2019, a bench trial was held, and ~~had no knowledge~~on July 17, 2019, the Court issued an Order finding the asserted claims of a certain U.S. patent valid and infringed. The Court additionally ordered that the effective date of any ~~investigations~~approval of Actavis’s ANDA may not be earlier than the expiration date of that patent. Actavis filed an appeal of the Court’s decision with the CAFC on August 13, 2019. The matter is currently pending on appeal at the CAFC and merits briefing is underway. Actavis’s opening brief was filed February 6, 2020. The deadline for Plaintiffs to file their responsive brief is currently September 15, 2020.

On June 13, 2019, Progenics, Salix, Bausch, and Wyeth filed another suit against Actavis in the United States District Court for the District of New Jersey for infringement of a separate, and at that time, recently granted U.S. patent based upon Actavis’s filing of an ANDA seeking to obtain approval to market a generic version of RELISTOR tablets before this patent expires. Litigation in this action is underway, and fact discovery has not yet begun.

RELISTOR European Opposition Proceedings

In addition to the above described ANDA notifications, in October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone. Notices of opposition were filed separately by ~~government~~each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the opposition division provided notice that the three European patents would be revoked. Each of these matters are on appeal with the European Patent Office. Oral proceedings are set to occur on September 22, 2020, November 17, 2020 and November 18, 2020. For each of the above-described RELISTOR proceedings, Progenics and Bausch continue to cooperate closely to vigorously defend and enforce RELISTOR intellectual property rights. Pursuant to the RELISTOR license agreement between Progenics and Bausch, Bausch has the first right to enforce the intellectual property rights at issue and is responsible for the costs of such enforcement. Because the outcome of litigation is uncertain

Table of Contents

and in these RELISTOR proceedings the Company does not control the enforcement of the intellectual property rights at issue, no assurance can be given as to how or ~~regulatory authorities~~when any of these RELISTOR proceedings will ultimately be resolved.

German PSMA-617 Litigation

Litigation Related to the Merger

Whistleblower Complaint

In July 2019, Progenics received notification of a complaint submitted by Dr. Syed Mahmood, the former Vice President of Medical Affairs for Progenics, to the Occupational Safety and Health Administration of the United States Department of Labor (“DOL”), alleging that the termination of his employment by Progenics was in violation of Section 806 of the Sarbanes-Oxley Act of 2002 (“SOX”). Dr. Mahmood sought reinstatement to his former position of Vice President of Medical Affairs, back pay, front pay in lieu of reinstatement, interest, attorneys’ fees and costs incurred, and special damages. In March 2020, Dr. Mahmood filed a complaint in the U.S. District Court for the Southern District of New York (as permitted by SOX because the DOL had not issued a decision within 180 days). Dr. Mahmood’s federal complaint asserts claims of violation of Section 806 of SOX. The DOL action has been dismissed and the matter will proceed in federal district court. Progenics’ Answer to the Complaint is ~~a target that could have a material adverse effect on its current business.~~presently due by August 26, 2020.

The Company believes the claims in this matter are without merit, and the Company has meritorious defenses to the claims. The Company intends to vigorously defend against the claims.

Table of Contents

Item 1A. Risk Factors

There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, ~~2016,~~2019 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, except as set forth ~~below. For~~below which generally relate to the COVID-19 pandemic and the Progenics business and assets we have recently acquired:

The COVID-19 pandemic could have a material impact on our business, results of operation and financial condition, operating results, cash flows and prospects.

In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan China. Less than four months later, in March 2020, the World Health Organization declared COVID-19 a pandemic. While the outbreak initially was largely concentrated in China and caused significant disruptions in its economy, the virus has now spread to many other countries and regions, and every state within the United States, including Massachusetts, where our primary offices and manufacturing facility are located, as well as New York, New Jersey, Puerto Rico, Canada and Sweden, where our other offices and manufacturing facilities are located.

Towards the end of the first quarter of 2020 we began to experience, and through the date of this filing we are continuing to experience, impacts to our business and operations related to the COVID-19 pandemic, including the impact of stay-at-home mandates and advisories, and a decline in the volume of procedures using our products. In response to the pandemic, healthcare providers have, and may need to further, ~~information, refer~~reallocate resources, such as physicians, staff and facilities, as they prioritize limited resources and personnel capacity to ~~Part I, Item 1A. “Risk Factors”~~focus on the treatment of patients with COVID-19 and implement limitations on access to hospitals and other medical institutions due to concerns about the potential spread of COVID-19 in such settings. These actions have significantly delayed the provision of other medical care including procedures involving our products, having an adverse effect on our revenue. These measures and challenges may continue for the duration of the COVID-19 pandemic, and such duration is uncertain and may significantly reduce our revenue and cash flows while the pandemic continues and thereafter until we and our customers are able to resume normal business operations. We cannot predict the magnitude or duration of the pandemic’s impact on our business.

In connection with the COVID-19 pandemic, the following risks could have a material effect on our business, financial condition, results of operations and prospects:

•The delay or cancellation by hospitals and clinics of the procedures in which our products are used as a result of their COVID-19 response efforts and the duration of such effects, thereby reducing sales of our products for an unknown period of time;

•The inability or unwillingness of some patients to visit hospitals or clinics in order to undergo procedures in which our products are used, thereby reducing sales of our products for an unknown period of time;

•The inability of some patients to pay for procedures and/or the co-pay associated with those procedures in which our products are used due to job loss or lack of insurance, thereby reducing sales of our products for an unknown period of time;

•The inability of our distributors, radiopharmacy customers, hospitals, clinics and other customers to conduct their normal operations, including supplying or conducting procedures in which our products are used, because of their COVID-19 response efforts, or the reduced capacity or productivity of their employees and contractors as a result of possible illness, quarantine or other inability to work, thereby reducing sales of our products for an unknown period of time;

•The reduction in pulmonary ventilation studies in which our Xenon-133 gas is used because of institutional concerns about a hospital’s ability to adequately decontaminate equipment used to administer those studies during the COVID-19 pandemic, thereby reducing Xenon-133 sales for an unknown period of time;

•The inability of global suppliers of raw materials or components used in the manufacture of our products, or contract manufacturers of our products, to supply and/or transport those raw materials, components and products to us in a timely and cost effective manner due to shutdowns, interruptions or delays, limiting and potentially precluding the production of our finished products, impacting our ability to supply customers, reducing our sales, increasing our costs of goods sold, and reducing our absorption of overhead;

•The partial or complete delay or cancellation of international or domestic flights by our airfreight carriers, resulting in our ~~Annual Report on Form 10-K for the year ended December 31, 2016.~~inability to receive raw materials, components and products from our global suppliers or to ship and deliver our finished products to our domestic and international customers in a timely or cost effective manner, thereby potentially increasing our freight costs as we seek alternate, potentially more expensive, methods to ship raw materials, components or products, and negatively impacting our sales;

Table of Contents

•The ~~growth~~reduced capacity or productivity of our ~~business is substantially dependent on increased market penetration for the appropriate use~~complex, on-campus operations as a result of ~~DEFINITY in suboptimal echocardiograms.~~

~~The growth~~possible illness, quarantine or other inability of our business is substantially dependent on increased market penetration for the appropriate use of DEFINITY in suboptimal echocardiograms. Of the total number of echocardiograms performed each year in the U.S., over 31.8 million in 2016, based on medical literature, a third-party source estimates that 20%, or approximately 6.4 million echocardiograms in 2016, produced suboptimal images. We estimate that DEFINITY had an approximately 80% shareemployees and contractors to work, despite all of the ~~U.S. market~~preventative measures we continue to undertake to protect the health and safety of our workforce;

•The illiquidity or insolvency of our suppliers, contract manufacturers or freight carriers whose business activities could be shut down, interrupted or delayed;

•The illiquidity or insolvency of our distributors or customers, or their inability to pay our invoices in full or in a timely manner, due to the reduction in their revenues caused by the cancellation or delay of procedures and other factors, which could potentially reduce our cash flow, reduce our liquidity and increase our bad debt reserves;

•A portion of our raw materials or finished product inventory may expire due to reduced demand for ~~contrast agents~~our drugs;

•Delays in ~~echocardiography procedures~~our ability, and the ability of our development partners to conduct, enroll and complete clinical development programs such as our ARROW Phase 2 study in mCRPC, the flurpiridaz F 18 Phase 3 clinical development program currently being conducted by GE Healthcare, or the Phase 1 trial of ~~December 2016. We launched DEFINITY in 2001,~~PSMA TTC being conducted by Bayer AG;

•Delays of regulatory reviews and inapprovals, including with respect to our product candidates, by the U.S., its composition of matter patent will expire in 2019, its manufacturing patent will expire in 2021, and a new method of use patent will expire in 2037. In numerous foreign jurisdictions, patent protectionFDA or other health or regulatory ~~exclusivity will currently expire~~authorities;

•Decreased sales of those of our products that are promotionally sensitive, like DEFINITY, due to the reduction of in-person sales and marketing activities and training caused by travel restrictions, quarantines, other similar social distancing measures and more restrictive hospital access policies;

•Our ability to maintain employee morale and motivate and retain management personnel and other key employees as a result of our previous work week and salary reductions;

•A disruption or delay in ~~2019. We have an active next generation development program~~regulatory approval for, ~~this agent, including pursuing additional indications,~~and operation of, our new, ~~patent protection,~~on-campus manufacturing facility, which would delay implementation of our supply diversification strategy for certain of our key products and ~~new formulations, but~~impact our ability to benefit from a lower cost of goods for those products;

•A reduction in revenue with continued incurrence of high fixed costs relating to our already-existing, complex and expensive radiopharmaceutical manufacturing facility could adversely affect our cash flows, liquidity and ability to comply with the financial covenants in our 2019 Facility, and there can be no assurance that ~~this program~~any required waiver or consent related to any such failure to comply would be granted by our current lenders similar to the waiver of total net leverage ratio in exchange for a consolidated liquidity covenant recently included in the Amendment;

•The increased reliance on our personnel working from home, which may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business;

•A delay in achieving, or inability to achieve, successful integration of Lantheus and Progenics, or the synergies, cost savings, innovation and other anticipated benefits of the acquisition due to impact of the COVID-19 pandemic on the operations, financial condition and prospects of our Company;

•The instability to worldwide economies, financial markets, social institutions, labor markets and the healthcare systems as a result of the COVID-19 pandemic, which could result in an economic downturn that could adversely impact our business, results of operations and financial condition, as well as that of our suppliers, distributors, customers or other business partners; and

•A recurrence of the COVID-19 pandemic after social distancing and other similar measures have been relaxed.

The extent to which the COVID-19 pandemic impacts our business and our results of operations and financial condition will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge in connection with the severity of the virus, the ability to treat and ultimately prevent it, its potential recurrence, and actions that may be taken to contain its impact.

We rely on Bausch to develop and commercialize RELISTOR, exposing us to significant risks.

We rely on Bausch to pursue and complete further development and obtain regulatory approvals for RELISTOR worldwide and to effectively commercialize the product and manage pricing, sales and marketing practices and inventory levels in the distribution channel. The revenue derived from royalty and milestone payments from our RELISTOR collaboration with Bausch can fluctuate significantly from period to period, and our past revenue is therefore not necessarily indicative of our future revenue. We are and will be ~~successful~~dependent upon Bausch and any other business partners with which we may collaborate in the future to perform and fund development, including clinical testing of RELISTOR, making related regulatory filings and manufacturing and marketing products, including for new indications and in new formulations, in their respective territories. Revenue from the sale of RELISTOR depends entirely upon the efforts of Bausch and its sublicensees, which have significant discretion in determining the

Table of Contents

efforts and resources they apply to sales of RELISTOR. Bausch may not be effective in obtaining approvals for new indications or formulations, marketing existing or future products or arranging for necessary sublicense or distribution relationships. Our business relationships with Bausch and other partners may not be scientifically, clinically or commercially successful. For example, Bausch has a variety of marketed products and its own corporate objectives, which may not be consistent with our best interests, and may change its strategic focus or pursue alternative technologies in a manner that ~~new patents will protect~~results in reduced or delayed revenue to us. Bausch may also have commercial and financial interests that are not fully aligned with ours in a given territory or territories - which may make it more difficult for us to fully realize the ~~agent.~~

value of RELISTOR. We may have ~~on-going development~~future disagreements with Bausch, which has significantly greater financial and ~~technology transfer activities for a next generation DEFINITY product with SBL located~~managerial resources which it could draw upon in ~~Songdo, South Korea, approximately 20 miles southwest of Seoul, but can give no assurances as to when those technology transfer activities will be completed and when we will begin to receive a supply~~the event of a ~~next generation DEFINITY product from SBL. In addition, those activities~~dispute. Such disagreements could ~~be adversely affected by on-going political~~lead to lengthy and ~~military tensions on the Korean peninsula.~~

~~If we are not able~~expensive litigation or other dispute-resolution proceedings as well as extensive financial and operational consequences to ~~continue to grow DEFINITY sales through increased market penetration, we will not be able to grow the revenue~~us and ~~cash flow of the business or leverage the substantial overhead of the balance of our business, which could~~ have ~~a negative effect on our prospects.~~

In the U.S., we are heavily dependent on a few large customers and group purchasing organization arrangements to generate a majority of our revenues for our nuclear medical imaging products and our other products. Outside of the U.S., we rely primarily on distributors to generate a substantial portion of our revenue.

In the U.S., we have historically relied on a limited number of radiopharmacy customers, primarily Cardinal, UPPI, GE Healthcare and Triad, to distribute our current largest volume nuclear imaging products and generate a majority of our revenues. Three customers accounted for approximately 30% of our revenues in the year ended December 31, 2016, with UPPI, Cardinal, and GE Healthcare accounting for approximately 11%, 10% and 9%, respectively. Among the existing radiopharmacies in the U.S., continued consolidations, divestitures and reorganizations may have a negativean adverse effect on our business, results of operations and financial ~~condition or cash flows.~~ condition. In addition, independent actions may be taken by Bausch concerning product development, marketing strategies, manufacturing and supply issues, and rights relating to intellectual property.

We ~~generally have distribution arrangements~~are also dependent on Bausch for compliance with ~~our major radiopharmacy customers pursuant~~regulatory requirements as they apply to ~~multi-year contracts, each of which is~~RELISTOR.

The RELISTOR commercialization program continues to be subject to ~~renewal. If these contracts are terminated prior~~risk.

Future developments in the commercialization of RELISTOR may result in Bausch or any other business partner with which we may collaborate in the future taking independent actions concerning product development, marketing strategies or other matters, including termination of its efforts to ~~expiration~~develop and commercialize the drug.

Under our license agreement with Bausch, Bausch is responsible for obtaining supplies of ~~their term, or are~~RELISTOR, including contracting with contract manufacturing organizations (“CMOs”) for supply of RELISTOR active pharmaceutical ingredient and subcutaneous and oral finished drug product. These arrangements may not ~~renewed, or are renewed~~be on terms that are ~~less~~advantageous and, as a result of our royalty and other interests in RELISTOR’s commercial success, will subject us to risks that the counterparties may not perform optimally in terms of quality or reliability.

Bausch’s ability to optimally commercialize either oral or subcutaneous RELISTOR in a given jurisdiction may be impacted by applicable labeling and other regulatory requirements. If clinical trials indicate, or regulatory bodies are concerned about, actual or possible serious problems with the safety or efficacy of RELISTOR, Bausch may stop or significantly slow further development or commercialization of RELISTOR. In such an event, we could be faced with either further developing and commercializing the drug on our own or with one or more substitute collaborators, either of which paths would subject us to the development, commercialization, collaboration and/or financing risks.

We are also aware of other approved and marketed products, as well as product candidates in pre-clinical or clinical development that are intended to target the side effects of opioid pain therapy and are direct competitors to RELISTOR. For instance, there are three approved products that target opioid-induced constipation: MOVANTIK® (naloxegol), AMITIZA® (lubiprostone), and Symproic® (naldemedine) which could compete with RELISTOR. The competitors who have developed these products and product candidates may have superior resources that allow them to implement more effective approaches to sales and marketing. There is no guarantee that RELISTOR will be able to compete commercially with these products. Additionally, there has been growing public concern regarding the use of opioid drugs. Any efforts by the FDA or other governmental authorities to restrict or limit the use of opioids may negatively impact the market for RELISTOR. In addition, there is a substantial risk that the revenue targets for receiving additional RELISTOR milestone payments will not be met. As a result, there is no assurance that we will realize the potential revenue represented by future RELISTOR milestone payments.

Any such significant action adverse to the further development and commercialization of RELISTOR could have an adverse impact on our business.

Our patents are subject to generic challenge, and the validity, enforceability and commercial value of these patents are highly uncertain.

Our ability to obtain and defend our patents impacts the commercial value of our products and product candidates. Third parties have challenged and are likely to continue challenging the patents that have been issued or licensed to us. Patent protection involves complex legal and factual questions and, therefore, enforceability is uncertain. Our patents may be challenged, invalidated, held to be unenforceable, or circumvented, which could negatively impact their commercial value. For example, Progenics (along with Bausch and Wyeth LLC) received notifications of a Paragraph IV certification for RELISTOR (methylnaltrexone bromide) subcutaneous injection and for RELISTOR (methylnaltrexone bromide) Tablets, for certain patents that are listed in the FDA Orange Book. The certifications resulted from filings by entities such as Mylan Pharmaceuticals Inc., Actavis LLC and Par Sterile Products, LLC of ANDAs with the FDA, challenging such patents for RELISTOR subcutaneous injection and seeking to obtain approval to market a generic version of RELISTOR subcutaneous injection and filings by Actavis

Table of Contents

Laboratories FL, Inc. seeking to obtain approval to market a generic version of RELISTOR Tablets before some or all of these patents expire. Furthermore, patent applications filed outside the United States may be challenged by other parties, for example, by filing third-party observations that argue against patentability or an opposition. Such opposition proceedings are increasingly common in the EU and are costly to defend. For example, we received notices of opposition to three European patents relating to methylnaltrexone.

Although we and Bausch are cooperating to defend against both the ANDA challenges and the European oppositions and intend to continue to vigorously enforce RELISTOR intellectual property rights, such litigation is inherently subject to significant risks and uncertainties, and there can be no assurance that the outcome of these litigations will be favorable to us ~~then~~or Bausch. An unfavorable outcome in these cases could result in the rapid genericization of RELISTOR products or could result in the shortening of available patent life. Any such outcome could have an adverse impact on our financial performance and stock price.

Pursuant to the RELISTOR license agreement between us and Bausch, Bausch has the first right to enforce the intellectual property rights at issue and is responsible for the costs of such enforcement. At the same time, we may incur substantial further costs in supporting the effort to uphold the validity of patents or to prevent infringement. Patent disputes are frequent, costly and can preclude, delay or increase the cost of commercialization of products. Progenics has previously been and is currently involved in patent litigation, and we expect to be subject to patent litigation in the future.

Our AZEDRA commercialization program is subject to significant risk.

It is very difficult to estimate the commercial potential of recently approved products, due to factors such as safety and efficacy compared to other available treatments (including potential generic drug alternatives with similar efficacy profiles), changing standards of care, third party payer reimbursement, patient and physician preferences, readiness of a clinical site to administer a new product and the availability of competitive alternatives that may emerge either during the approval process or after commercial introduction. Frequently, products that have shown promising results in clinical trials suffer significant setbacks even after they are approved for commercial sale.

On July 30, 2018, Progenics received FDA approval of our NDA for AZEDRA. There is no guarantee that AZEDRA will be a commercial success. Further, future uses of AZEDRA commercially may reveal that AZEDRA is ineffective, unacceptably toxic, has other undesirable side effects, is difficult to manufacture on a commercial scale, is not cost-effective or economically viable, infringes on proprietary rights of another party or is otherwise not fit for further use.

AZEDRA, designated as an Orphan Drug is intended to treat a rare disease with a small patient population. While we have received FDA approval, we are still in discussions with payors regarding pricing for AZEDRA. If pricing for AZEDRA is not accepted in the market at an appropriate level it may not generate enough revenue to make it economically viable. There have been recent examples of the market reacting poorly to the high cost of certain drugs. If the market reacts similarly to AZEDRA, it could result in negative publicity and reputational harm to us. Further, the Legislative and Executive branches of our federal government have indicated support for possible new measures related to drug pricing, which could increase the pricing pressures related to AZEDRA and further limit its economic viability.

If AZEDRA is determined to be unsafe or ineffective in humans, not economically viable or we are unable to successfully commercialize it, our business could be adversely affected.

We may not be able to maintain Orphan Drug exclusivity for AZEDRA and, even if we do, that exclusivity may not prevent the FDA, from approving competing products.

Under the Orphan Drug Act, the FDA may designate a product as an Orphan Drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. AZEDRA currently has the Orphan Drug designation in the United States.

In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has Orphan Drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity.

Table of Contents

We may not be able to maintain Orphan Drug exclusivity for AZEDRA. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Even after an Orphan Drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. A loss of the Orphan Drug exclusivity for AZEDRA may have an adverse impact on our ability to adequately commercialize AZEDRA.

Failure to obtain marketing approval in foreign jurisdictions would prevent AZEDRA from being marketed abroad.

Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. In order to market and sell AZEDRA in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval process varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or our potential third-party collaborators may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize AZEDRA in any market outside of the United States.

Manufacturing resources could limit or adversely affect our ability to commercialize products.

We or our partners may engage third parties to manufacture our product candidates. We or our partners may not be able to obtain adequate supplies from third-party manufacturers in a timely fashion for development or commercialization purposes, and commercial quantities of products may not be available from CMOs at acceptable costs. For example, until December 2019, the CPDC was subject to an Import Alert by the FDA, which restricted the CPDC’s ability to ship products to the U.S. Although the CPDC has since been cleared by the FDA to ship products to the U.S., there can be no guarantee that the CPDC, or any other third-party manufacturer that we may partner with in the future, will not be subject to similar restrictions in the future.

In order to commercialize our product candidates successfully, we need to be able to manufacture or arrange for the manufacture of products in commercial quantities, in compliance with regulatory requirements, at acceptable costs and in a timely manner. Manufacture of our product candidates, can be complex, difficult to accomplish even in small quantities, difficult to scale-up for large-scale production and subject to delays, inefficiencies and low yields of quality products. The manufacture of radiopharmaceuticals is relatively complex and requires significant capital expenditures. Although Progenics recently acquired the assets comprising the AZEDRA radiopharmaceutical manufacturing facility, we continue to rely on CMOs for our product candidates. The cost of manufacturing our product candidates may make them prohibitively expensive. If adequate supplies of any of our product candidates or related materials are not available on a timely basis or at all, our clinical trials or commercialization of our product candidates could be seriously delayed, since these materials are time consuming to manufacture and cannot be readily obtained from third-party sources. We continue to rely on a limited number of highly specialized manufacturing and development partners, including single source manufacturers for certain of our product candidates. If we were to lose one or more of these key relationships, it could materially adversely affect our business. Establishing new manufacturing relationships, or creating our own manufacturing capability, would require significant time, capital and management effort, and the transfer of product-related technology and know-how from one manufacturer to another is an inherently complex and uncertain process.

Patents have a limited life and expire by law.

In addition to uncertainties as to scope, validity, enforceability and changes in law, patents by law have limited lives. Upon expiration of patent protection, our drug candidates and/or products may be subject to generic competition, which could adversely affect pricing and sales volumes of the affected products.

With regard to our RELISTOR-related intellectual property, the composition-of-matter patent for the active ingredient of RELISTOR, methylnaltrexone, has expired. University of Chicago, as well as we and our collaborators, have extended the methylnaltrexone patent estate with additional patents and pending patent applications covering various inventions relating to the product. Bausch has listed in the Orange Book eight U.S. patents relating to subcutaneous RELISTOR, which have expiration dates ranging from 2024 to 2030, and nine U.S. patents relating to RELISTOR tablet, which have expiration dates ranging from 2029 to 2031. In May 2018, Progenics entered into settlement agreements that granted non-exclusive limited licenses with respect to certain RELISTOR subcutaneous injection applications, effective on the earlier of January 1, 2028 and September 30, 2030 or

Table of Contents

other circumstances described in the settlement agreements, including in connection with future ANDA filers. Four Canadian patents (two expiring in 2024, one in 2027 and one in 2029) have been listed with Health Canada relating to subcutaneous RELISTOR.

The original patents surrounding the AZEDRA program were licensed from the University of Western Ontario (“UWO”). The patent family directed to processes for making polymer precursors, as well as processes for making the final product, expired in 2018 in the U.S. and Canada. Other licensed patent families from UWO relate to alternative approaches for preparing AZEDRA, which if implemented would expire in 2024, worldwide. Progenics owns pending applications worldwide directed to manufacturing improvements and the resulting compositions which, if issued, would expire in 2035.

Patent protection for the composition-of-matter patent on the PyL compound, radiolabeled form of the compound, as well as methods of use expire in 2030 in the United States. Corresponding patent family members are pending or issued worldwide, all with expirations of 2029. Process improvement patent applications are pending worldwide which, if issued, would expire in 2037.

Company-owned patents relating to 1095 have expiration ranges of 2027 to 2031 in the U.S. We view as most significant the composition-of-matter patent on this compound, as well as radiolabeled forms, which expires in 2027 in the U.S., as well as Europe. Additional U.S. patents are directed to stable compositions and radiolabeling processes which expire in 2030 and 2031, respectively.

We own patents relating to automated detection of bone cancer metastases. The patents on this technology expire in 2028 outside of the United States. The U.S. patent under reexamination was reissued with an expiration of 2032. Applications are pending relating to automated medical image analysis.

Owned and in-licensed patents relating to the 1404 product candidate have expiration ranges of 2020 to 2029; we view as most significant the composition-of-matter patent on the compound, as well as technetium-99 labeled forms, which expires in 2029 worldwide.

With respect to PSMA antibody, currently issued composition-of-matter patents comprising co-owned and in-licensed patents have expirations of 2022 and 2023 in the U.S. Corresponding foreign counterpart patents will expire in 2022. We view all of these patents as significant.

We depend on intellectual property licensed from third parties and unpatented technology, trade secrets and confidential information. If we lose any of these rights, including by failing to achieve milestone requirements or to satisfy other conditions, our business, results of operations and financial condition could be harmed.

Many of our product candidates incorporate intellectual property licensed from third parties. For example, PyL utilizes technology licensed to us from Johns Hopkins University. We could lose the right to patents and other intellectual property licensed to us if the related license agreement is terminated due to a breach by us or otherwise. Our ability to commercialize products incorporating licensed intellectual property would be impaired if the related license agreements were terminated. In addition, we are required to make substantial cash payments, achieve milestones and satisfy other conditions, including filing for and obtaining marketing approvals and introducing products, to maintain rights under our intellectual property licenses. Due to the nature of these agreements and the uncertainties of development, we may not be able to achieve milestones or satisfy conditions to which we have contractually committed, and as a result may be unable to maintain our rights under these licenses. If we do not comply with our license agreements, the licensors may terminate them, which could result in our losing our rights to, and therefore being unable to commercialize, related products.

We also rely on unpatented technology, trade secrets and confidential information. Third parties may independently develop substantially equivalent information and techniques or otherwise gain access to our technology or disclose our technology, and we may be unable to effectively protect our rights in unpatented technology, trade secrets and confidential information. We require each of our employees, consultants and advisors to execute a confidentiality agreement at the commencement of an employment or consulting relationship with us. These agreements may, however, not provide effective protection in the event of unauthorized use or disclosure of confidential information. Any loss of trade secret protection or other unpatented technology rights could harm our business, results of operations and financial condition.

If we do not achieve milestones or satisfy conditions regarding some of our product candidates, we may not maintain our rights under related licenses.

We are required to make substantial cash payments, achieve milestones and satisfy other conditions, including filing for and obtaining marketing approvals and introducing products, to maintain rights under certain intellectual property licenses. Due to the nature of these agreements and the uncertainties of research and development, we may not be able to achieve milestones or satisfy

Table of Contents

conditions to which we have contractually committed, and as a result may be unable to maintain our rights under these licenses. If we do not comply with our license agreements, the licensors may terminate them, which could result in our losing our rights to, and therefore being unable to commercialize, related products.

If we infringe third-party patent or other intellectual property rights, we may need to alter or terminate a product development program.

There may be patent or other intellectual property rights belonging to others that require us to alter our products, pay licensing fees or cease certain activities. If our products infringe patent or other intellectual property rights of others, the owners of those rights could bring legal actions against us claiming damages and seeking to enjoin manufacturing and marketing of the affected products. If these legal actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected products. We may not prevail in any action brought against us, and any license required under any rights that we infringe may not be available on acceptable terms or at all. We are aware of intellectual property rights held by third parties that relate to products or technologies we are developing. For example, we are aware of other groups investigating PSMA or related compounds and monoclonal antibodies directed at PSMA, PSMA-targeted imaging agents and therapeutics, and methylnaltrexone and other peripheral opioid antagonists, and of patents held, and patent applications filed, by these groups in those areas. While the validity of these issued patents, the patentability of these pending patent applications and the applicability of any of them to our products and programs are uncertain, if asserted against us, any related patent or other intellectual property rights could adversely affect our ability to commercialize our products.

Research, development and commercialization of a biopharmaceutical product often require choosing between alternative development and optimization routes at various stages in the development process. Preferred routes may depend on subsequent discoveries and test results and cannot be predicted with certainty at the outset. There are numerous third-party patents in our field, and we may need to obtain a license under a patent in order to pursue the preferred development route of one or more of our products or product candidates. The need to obtain a license would decrease the ultimate profitability of the applicable product. If we cannot negotiate a license, we might have to pursue a less desirable development route or terminate the program altogether.

We have been and expect to continue to be dependent on collaborators for the development, manufacturing and sales of certain products and product candidates, which expose us to the risk of reliance on these collaborators.

In conducting our operations, we currently depend, and expect to continue to depend, on numerous collaborators. Key among these collaborations, are those with Bayer to develop and commercialize products using our PSMA antibody technology and with Fuji for the development and commercialization of 1404 and bone BSI in Japan. In addition, certain clinical trials for our product candidates may be conducted by government-sponsored agencies, and consequently will be dependent on governmental participation and funding. These arrangements expose us to the same considerations we face when contracting with third parties for our own trials.

If any of our collaborators breach or terminate its agreement with us or otherwise fail to conduct successfully and in a timely manner the collaborative activities for which they are responsible, the preclinical or clinical development or commercialization of the affected product candidate or research program could be delayed or terminated. We generally do not control the amount and timing of resources that our collaborators devote to our programs or product candidates. We also do not know whether current or future collaboration partners, if any, might pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing treatments for the diseases or conditions targeted by our collaborative arrangements. Our collaborators are also subject to similar development, regulatory, manufacturing, cyber-security and competitive risks as us, which may further impede their ability to successfully perform the collaborative activities for which they are responsible. Setbacks of these types to our collaborators could have a material adverse effect on our business, results of operations and financial condition.

We are involved in various legal proceedings that are uncertain, costly and time-consuming and could have a material adverse impact on our business, financial condition and ~~cash flows.~~results of operations.

~~In Puerto Rico,~~From time to time we ~~own~~are involved in legal proceedings and ~~operate one of two radiopharmacies on~~disputes and may be involved in litigation in the ~~island~~future. These proceedings are complex and ~~sell our own products as well as products of third parties to end users. In September 2017, Hurricane Maria devastated~~extended and occupy the ~~island, interrupting power and telecommunications services for most of the island and limiting ground and air transportation. The building that houses our radiopharmacy sustained~~

minimal external physical damage as a result of the hurricane. From and after September 20, 2017, the number of diagnostic imaging procedures performed on the island has severely declined. While we currently believe that the number of diagnostic imaging procedures performed in Puerto Rico will slowly return to prior levels, we can give no assurances of that, and failureresources of our ~~radiopharmacy~~management and employees. These proceedings are also costly to ~~return~~prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor. We may also be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such ~~prior levels could have a negative effect on the revenue and cash flow of our business.~~

~~For all of our medical imaging products, we continue to experience significant pricing pressures from our competitors, large customers and group purchasing organizations,~~proceedings. Defending against or settling such claims and any ~~significant, additional pricing pressures could lead to a reduction in revenue which~~unfavorable legal decisions, settlements or orders could have a material adverse effect on our business, financial condition and results of operations ~~financial condition~~ and ~~cash flows.~~could cause the market value of our common stock to decline.

~~Outside~~

Table of Contents

In particular, the ~~U.S., Canada~~pharmaceutical and ~~Puerto Rico,~~medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products and we ~~have no sales force and, consequently, rely on third-party distributors, either on a country-by-country basis or on a multi-country, regional basis,~~expect this litigation activity to market, sell and distribute our products. This is the case in both Canada and Australia, where we formerly owned or operated radiopharmacies and are now distributing products under the Isologic Agreement and the GMS Agreement, respectively. Distributors accounted for approximately 34%, 15% and 17% of International segment revenues for the years ended December 31, 2016, 2015 and 2014, respectively. In certain circumstances, distributors may also sell competing products to our own or products for competing diagnostic modalities and may have incentives to shift sales towards those competing products.continue. As a result, we ~~cannot assure you tha~~texpect that patents related to our ~~international distributors~~products will ~~increase~~routinely be challenged, and our patents may not be upheld. In order to protect or ~~maintain current levels~~enforce patent rights, we may initiate litigation against third parties. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of ~~unit~~our products still under patent protection, we could lose a significant portion of sales orin a very short period. We may also become subject to infringement claims by third parties and may have to defend against charges that we ~~will~~violated patents or the proprietary rights of third parties. If we infringe the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, or could be ~~able~~required to ~~increase~~pay monetary damages or ~~maintain our current unit pricing, which,~~royalties to license proprietary rights from third parties.

In addition, in ~~turn,~~the U.S., it has become increasingly common for patent infringement actions to prompt claims that antitrust laws have been violated during the prosecution of the patent or during litigation involving the defense of that patent. Such claims by direct and indirect purchasers and other payers are typically filed as class actions. The relief sought may include treble damages and restitution claims. Similarly, antitrust claims may be brought by government entities or private parties following settlement of patent litigation, alleging that such settlements are anti-competitive and in violation of antitrust laws. In the U.S. and Europe, regulatory authorities have continued to challenge as anti-competitive so-called “reverse payment” settlements between branded and generic drug manufacturers. We may also be subject to other antitrust litigation involving competition claims unrelated to patent infringement and prosecution. A successful antitrust claim by a private party or government entity against us could have a material adverse effect on our business, financial condition and results of operations ~~financial condition~~ and ~~cash flows.~~

~~Our business is subject to international economic, political and other risks that~~ could ~~negatively affect our results of operations or financial position.~~

~~For~~cause the ~~years ended December 31, 2016, 2015 and 2014, we derived approximately 15%, 20% and 22%~~market value of our ~~revenues from outside the fifty United States, respectively. Accordingly,~~common stock to decline.

Marketplace acceptance depends in part on competition in our ~~business~~industry, which is ~~subject to risks associated with doing business internationally, including:~~

~~Less stable political~~intense, and ~~economic environments and changes~~competing products in ~~a specific country’s or region’s political or economic conditions, including on-going political and military tensions on the Korean peninsula which could~~development may adversely affect acceptance of our ~~next generation DEFINITY program at SBL;~~products.

~~Entering into~~The extent to which any of our future products achieves market acceptance will depend on competitive factors. Competition in the biopharmaceutical industry is intense and characterized by ongoing research and development and technological change. We face competition from many for-profit companies and major universities and research institutions in the U.S. and abroad. We face competition from companies marketing existing products or ~~renewing commercial agreements~~developing new products for diseases and conditions targeted by our technologies. We are aware of a number of products and product candidates which compete or may potentially compete with ~~international governments~~PSMA-targeted imaging agents and therapeutics, or ~~provincial authorities or entities directly or indirectly controlled by such governments or authorities,~~our other product candidates. We are aware of several competitors, such as ~~our Chinese partner Double-Crane Pharmaceutical Company;~~

~~International customers~~Johnson & Johnson subsidiary Janssen Biotech, Inc.; Novartis AG; Pfizer, Inc. in collaboration with Astellas Pharma US, Inc.; Aytu Bioscience, Inc.; Bracco Diagnostics, Inc.; Bayer HealthCare Pharmaceuticals Inc. and Telix Pharmaceuticals, which have received approval for or are ~~agencies~~developing treatments or ~~institutions~~diagnostics for prostate cancer. Any of ~~foreign governments;~~

~~Local business practices~~these competing approved products or product candidates, or others which may be developed in ~~conflict with~~ the ~~U.S. Foreign Corrupt Practices Act and U.K. Bribery Act;~~future, may achieve a significant competitive advantage relative to AZEDRA, PyL, 1095, 1404 or other product candidates.

~~Currency fluctuations;~~

~~Potential negative consequences from changes in tax laws affecting our ability to repatriate profits;~~

~~Unfavorable labor regulations;~~

~~Greater difficulties in relying on non-U.S. courts to enforce either local or U.S. laws, particularly~~Competition with respect to ~~intellectual property;~~

~~Greater potential for intellectual property piracy;~~

~~Greater difficulties in managing~~our technologies and ~~staffing non-U.S. operations;~~

~~The need~~product candidates is based on, among other things, product efficacy, safety, reliability, method of administration, availability, price and clinical benefit relative to ~~ensure compliance with the numerous in-country~~cost; timing and ~~international~~scope of regulatory approval; sales, marketing and ~~legal requirements applicable to our business in each of these jurisdictions and to maintain an effective compliance program to ensure compliance with these requirements;~~

~~Changes in public attitudes about the perceived safety of nuclear facilities;~~

~~Changes in trade policies, regulatory requirements~~manufacturing capabilities; collaborator capabilities; insurance and other ~~barriers;~~

~~Civil unrest or other catastrophic events, including Hurricane Maria~~reimbursement coverage; and patent protection. Competitive disadvantages in ~~Puerto Rico; and~~

~~Longer payment cycles of non-U.S. customers and difficulty collecting receivables in non-U.S. jurisdictions.~~

~~These factors are beyond our control. The realization of~~ any of these ~~or other risks associated with operating outside the fifty United States~~factors could ~~have a material adverse effect on~~materially harm our business and financial condition. Many of our competitors have substantially greater research and development capabilities and experience and greater manufacturing, marketing, financial and managerial resources than we do. These competitors may develop products that are superior to those we are developing and render our products or technologies non-competitive or obsolete. Our product candidates under development may not compete successfully with existing products or product candidates under development by other companies, universities and other institutions. Drug manufacturers that are first in the market with a therapeutic for a specific indication generally obtain and maintain a significant competitive advantage over later entrants and therefore, the speed with which industry participants move to develop products, complete clinical trials, approve processes and commercialize products is an important competitive factor. If our product candidates receive marketing approval but cannot compete effectively in the marketplace, our operating results and financial position would suffer.

Table of ~~operations, financial condition and cash flows. As our international exposure increases and as we execute our strategy of international expansion, these risks may intensify.~~Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Repurchases

The following table presents information with respect to purchases of common stock we made during the quarter ~~ending September~~ended June 30, ~~2017.~~2020. The Company does not currently have a share repurchase program in effect. The 2015 Equity Incentive Plan, adopted by the Company on June 24, 2015, ~~and~~as amended on April 26, 2016 and as further amended on April 27, 2017 and April 24, 2019 (the “2015 Plan”), provides for the withholding of shares ~~held by employees~~ to satisfy minimum statutory tax withholding obligations. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy minimum tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this ~~Item.~~Item 2. These shares are then sold in compliance with Rule 10b5-1 into the market to allow the Company to satisfy the tax withholding requirements in cash.

Period

Total Number of
Shares Purchased

Average Price Paid
per Share

Total Number of
Shares Purchased as
Part of Publicly
Announced Programs

Approximate Dollar
Value of Shares that
May Yet Be Purchased Under
the Program

April 2020**

29,792

13.43

May 2020**

4,907

12.57

June 2020**

1,600

13.59

Total

36,299

Period
Total Number of
Shares Purchased

Average Price Paid
per Share

Total Number of
Shares Purchased as
Part of Publicly
Announced Programs

Approximate Dollar
Value of Shares that
May Yet Be Purchased Under
the Program
July 2017** —
$ —
* *
August 2017** 27,918
$ 17.48
* *
September 2017** 37,860
$ 16.80
* *
Total 65,778
*
________________________________

* These amounts are not applicable as the Company does not have a share repurchase program in effect.

** Reflects shares withheld to satisfy minimum statutory tax withholding amounts due from employees related to the receipt of stock which resulted from the exercise or vesting of equity awards.

~~restricted shares from equity-based awards.~~

Dividend Policy

We did not declare or pay any dividends, and we do not currently intend to pay dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the foreseeable future, to ~~repay indebtedness and to~~ finance the growth and development of our ~~business.~~business and to repay indebtedness. Our ability to pay dividends ~~are~~is restricted by our financing arrangements. See Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources-External Sources of Liquidity” for further information.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

On October 30, 2017, we entered into a binding commercial supply arrangement pursuant to which we will supply Cardinal Health with TechneLite generators, Xenon, Neurolite and other products through 2018. The supply arrangement specifies pricing levels and requires Cardinal Health to purchase minimum volumesNone.

Table of certain products from us during certain periods. The supply arrangement will expire on December 31, 2018 and may be terminated upon the occurrence of specified events, including a material breach by the other party and certain force majeure events.Contents

Item 6. Exhibits

INCORPORATED BY REFERENCE

EXHIBIT
NUMBER

DESCRIPTION OF EXHIBITS

FORM

FILE
NUMBER

EXHIBIT

FILING
DATE

10.1

Support Agreement, dated as of April 14, 2020, among Lantheus Holdings, Inc., Velan Capital, L.P., Altiva Management Inc., Velan Capital Partners LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Velan Principals GP LLC, Velan Capital Management LLC, Balaji Venkataraman, Deepak Sarpangal and Kevin McNeill

8-K

001-36569

10.1

April 14, 2020

10.2*

Amendment No. 1 to Credit Agreement, dated as of June 19, 2020, among Lantheus Medical Imaging, Inc., as borrower, Lantheus Holdings, Inc. and Wells Fargo Bank, N.A., as administrative agent and collateral agent*

10.3

Contingent Value Rights Agreement, dated as of June 19, 2020, by and between Lantheus Holdings, Inc. and Computershare Trust Company, N.A., as rights agent.

8-K

001-36569

10.1

June 22, 2020

10.4

Lantheus Holdings, Inc. 2005 Stock Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc. 2005 Stock Incentive Plan).

S-8

333-239491

4.4

June 26, 2020

10.5

Lantheus Holdings, Inc. 2018 Performance Incentive Plan (f/k/a Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan).

S-8

333-239491

4.5

June 26, 2020

10.6†

License Agreement, dated February 3, 2011, by and between Salix Pharmaceuticals, Inc., the Registrant, Progenics Pharmaceuticals Nevada, Inc. and Excelsior Life Sciences Ireland Limited.

10-Q

000-23143

10.37(16)

May 10, 2011

10.7†

Lease, dated December 31, 2015, between the Registrant and WTC TOWER 1 LLC.

8-K

000-23143

10.46 (21)

January 5, 2016

10.8†

Loan Agreement, dated November 4, 2016, between the Registrant through its wholly-owned subsidiary MNTX Royalties Sub LLC and Healthcare Royalty Partners III, L.P.

8-K

000-23143

10.53(24)

November 7, 2016

31.1*

Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).

31.2*

Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).

32.1**

Certification pursuant to 18 U.S.C. Section 1350.

101.INS*

Inline XBRL Instance Document

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*

Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~INCORPORATED BY REFERENCE~~

~~EXHIBIT~~

~~NUMBER~~

~~DESCRIPTION OF EXHIBITS~~

~~FORM~~

~~FILE~~

~~NUMBER~~

~~EXHIBIT~~

~~FILING~~

~~DATE~~

31.1*

~~Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~

31.2*

~~Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~

32.1*

~~Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~

101.INS*

~~XBRL Instance Document~~

101.SCH*

~~XBRL Taxonomy Extension Schema Document~~

101.CAL*

~~XBRL Taxonomy Extension Calculation Linkbase Document~~

101.DEF*

~~XBRL Taxonomy Extension Definition Linkbase Document~~

101.LAB*

~~XBRL Taxonomy Extension Label Linkbase Document~~

101.PRE*

~~XBRL Taxonomy Extension Presentation Linkbase Document~~

* Filed herewith.

** Furnished herewith.

† Confidential treatment granted as to certain portions omitted and filed separately with the Commission.

+ Indicates management contract or compensatory plan or arrangement.


*	~~Filed herewith~~

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LANTHEUS HOLDINGS, INC.

By:

/s/ MARY ANNE HEINO

Name:

Mary Anne Heino

Title:

President and Chief Executive Officer

(Principal Executive Officer)

Date:

~~November 2, 2017~~July 31, 2020

LANTHEUS HOLDINGS, INC.

By:

/s/ ~~JOHN W. CROWLEY~~ROBERT J. MARSHALL, JR.

Name:

~~John W. Crowley~~Robert J. Marshall, Jr.

Title:

Chief Financial Officer and Treasurer ~~(Principal~~
(Principal Financial Officer and Principal Accounting Officer)

Date:

~~November 2, 2017~~July 31, 2020



(in thousands)	Amount
Balance at January 1, 2017	$	9,370
Accretion expense	781
Balance at September 30, 2017	$	10,151



(in thousands)	Amount
Remainder of 2017	$	688
2018	2,750
2019	2,750
2020	2,750
2021	2,750
2022	261,937
Total principal outstanding	273,625
Unamortized debt discount	(2,273		)
Unamortized debt issuance costs	(3,079		)
Total	268,273
Less: current portion	(2,750		)
Total long-term debt	$	265,523



(in thousands)	Rebates and Allowances
Balance, as of January 1, 2017	$	2,297
Current provisions relating to revenues in current year	6,864
Adjustments relating to prior years’ estimate	(154		)
Payments/credits relating to revenues in current year	(4,658		)
Payments/credits relating to revenues in prior years	(1,474		)
Balance, as of September 30, 2017	$	2,875



	Nine Months Ended September 30,
	2017	2016
Effective tax rate	7.5%	2.9%